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Preface 
This dissertation describes the use of contrast agents in magnetic resonance 
imaging (MRI) studies to differentiate compartments, to study dose dependence of 
relaxation times, and to characterize tumors using signal amplifying enzymes in the brain. 
The work described in this dissertation was carried out at the University of Massachusetts 
Medical School. I completed all aspects of the works presented in Chapters III-V under 
the supervision of Dr. Christopher Sotak, which included performing animal MRI 
experiments, data analysis, and writing of the manuscripts. These works are in the 
process of being submitted for publications. The work presented in Chapter VI has been 
submitted to Cancer Research (2010) and is currently in review. This work was done 
under the supervision of Dr. Alexei Bogdanov, Jr. My responsibilities in this study 
included collecting all the MRI data, performing the data analysis, and principal 
authorship in writing the manuscript. The synthesis of contrast agents, histological and 
immunofluorescence work, and in vitro cell experiments were completed by Dr. 
Bogdanov. The methods section of the manuscript describing these techniques and the 
corresponding figures were prepared by Dr. Bogdanov. 
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Abstract 
Magnetic resonance imaging (MRI) has increasingly become the preferred 
imaging modality in modern day research to study disease. MRI presents an imaging 
technique that is practically non-invasive and without any ionizing radiation. This 
dissertation presents the use of contrast agents in MRI studies to differentiate 
compartments, to study dose dependence of relaxation times, and to characterize tumors 
using signal amplifying enzymes in the brain.  
Differentiating compartments in the brain can be useful in diffusion studies to 
detect stroke at an early stage. Diffusion-weighted NMR techniques have established that 
the apparent diffusion coefficient (ADC) of cerebral tissue water decreases during 
ischemia. However, it is unclear whether the ADC change occurs due to changes in the 
intracellular (IC) space, extracellular (EC) space, or both. To better understand the 
mechanism of water ADC changes in response to ischemic injury, making IC and EC 
compartment specific measurements of water diffusion is essential. The first study was 
done where manganese (Mn
2+
) was used as an IC contrast agent. Mn
2+
 uptake by cells 
causes shortening of the T1 relaxation time of IC water. The relative difference in T1 
relaxation times between the IC and EC compartments can be used to discriminate 
between the MR signals arising from water in the respective compartments. 
Mn
2+
 is also widely used in manganese-enhanced MRI (MEMRI) studies to 
visualize functional neural tracts and anatomy in the brain in vivo. In animal studies, the 
goal is to use a dose of Mn
2+
 that will maximize the contrast while minimizing its toxic 
effects. The goal of dose study was to investigate the MRI dose response of Mn
2+
 in rat 
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brain following SC administration of Mn
2+
. The dose dependence and temporal dynamics 
of Mn
2+
 after SC injection can prove useful for longitudinal in vivo studies that require 
brain enhancement to persist for a long period of time to visualize neuroarchitecture like 
in neurodegenerative disease studies. 
Contrast agents, in addition to their use in compartmental differentiation and dose 
studies, can be used for imaging tumors. The last study in this dissertation focuses on 
imaging EGF receptors in brain tumors. We tested a novel pretargeting imaging approach 
that includes the administration of humanized monoclonal antibody (anti-EGFR mAb, 
EMD72000) linked to enzymes with complementing activities that use a low-molecular 
weight paramagnetic molecule (diTyr-GdDTPA) as a reducing substrate administered 
following the mAb conjugates. We analyzed the differential MR tumor signal decay in 
vivo using orthotopic models of human glioma. The patterns of MR signal change 
following substrate administration revealed differences in elimination patterns that 
allowed distinguishing between non-specific and specific modes of MR signal decay.  
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1.1. Introduction 
Principles of nuclear magnetic resonance (NMR) will be discussed in this 
chapter. In brief, MR utilizes a strong external magnetic field, magnetic field 
gradients, and radio frequency (RF) waves tuned to a specific frequency to 
selectively excite nuclei in a region of interest in a biological sample. Once the 
RF waves are turned off, the nuclei relax back to the equilibrium state dissipating 
energy and inducing an electrical signal, which can be detected, amplified and 
processed to obtain MR images. Several sources of information were used as 
references for the preparation of this chapter (1-7). 
 
1.1.1. Magnetic Resonance Imaging: Its Advent and Beyond 
NMR is a powerful noninvasive technique that allows investigation of 
physical and chemical properties of biological entities at the molecular level. 
Even though the existence of nuclear spins, the entity essential to NMR, was first 
proposed by Wolfgang Pauli in 1924, the first NMR experiments were not done 
until 1946 by Felix Bloch and co-workers at Stanford University (8) and 
independently by Edward Purcell‟s group at Harvard University (9). Jasper 
Jackson extended the idea of MR to studies on humans. In 1967, he produced 
what are believed to be the first MR signals from a live animal (10). In 1971, 
Damadian (11) demonstrated that NMR can be useful to diagnose cancer based 
on differences in NMR measurements between malignant tumors and normal 
tissue. It was not until 1973, with Lauterber‟s (12) generation of the first two-
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dimensional proton MR image of a water sample at Stony Brook, New York, that 
NMR began to evolve as a valuable biomedical imaging modality due to the 
abundance of protons in the human body. Since then, magnetic resonance 
imaging (MRI) has evolved and transformed into a non-invasive diagnostic tool 
with applications expanding to all fields of research in physics, chemistry, 
biology, and engineering. 
 
1.2. Basic Physical Principles of NMR 
Understanding the NMR phenomenon requires a review of the basic 
principles of nuclear behavior in an electromagnetic (EM) environment. NMR 
principles are presented herein in both classical physics and quantum mechanics 
approach to describe the nuclear response to a static, external magnetic field, 
and RF radiation. 
 
1.2.1. Electromagnetic Wave Theory 
1.2.1.1. Wave Concept 
EM radiation propagates through space in the form of waves. By 
Maxwell‟s wave theory, the waves are composed of a magnetic field component, 
B, and an electric field component, E, which are perpendicular to each other and 
have the same frequency. Both travel at the speed of light in a direction, C, which 
is perpendicular to both the electrical and magnetic field components (Fig. 1.1).  
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Using the classical wave equation, the waves can be characterized as 
follows: 
      c           [1.1] 
where c is the speed of light (3 × 108 m∙s-1), λ is the wavelength (m), and υ is the 
frequency (s-1). Only the magnetic field component, B, is relevant for the NMR 
discussion. 
 
1.2.1.2. Particle Concept 
EM radiation with short wavelengths, like x-rays, reacts with matter as if 
they were particles rather than waves. These particles are discrete bundles of 
energy called a quantum or photon and are characterized by a specific frequency 
Figure 1.1 – Vector representation of the components of electromagnetic radiation: 
electric field component (E), magnetic field component (B), and direction of propagation 
(C). 
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of radiation. Using this frequency, the actual amount of energy of the photon can 
be calculated as follows: 
                  hE                   [1.2] 
where E is the energy (keV), h is the Planck‟s constant (4.13 × 10-18 keV∙s), and 
υ is the frequency (s-1). 
 
 
 
 
 
 
1.2.1.3. Electromagnetic Spectrum 
EM radiation covers a wide range of wavelengths and frequencies (Fig. 
1.2). Biologic tissue is relatively transparent to x-rays and opaque to radiation 
Figure 1.2 – The electromagnetic (EM) spectrum. Various types of EM radiation are 
noted ranging from high-frequency γ rays to the low-frequency radiowaves. The 
approximate frequency and wavelength window for type of EM radiation is depicted. The 
range shaded in grey represents the typical range of radiofrequency (RF) pulses that 
are used in MR imaging. 
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with intermediate wavelengths. This holds true for ultraviolet, visible light, and to 
some extent infrared and microwaves. MR study is associated with absorption of 
frequency components in the radiowave band (radio frequency (RF)) of the EM 
spectrum which typically ranges from 5–200 MHz. 
 
1.2.2. Nuclear Spin 
1.2.2.1. Nuclear Angular Momentum 
NMR signal is generated as a result of the nuclear angular momentum. 
The nuclear angular momentum (composed of orbital and spin angular 
momentum) arises as a result of orbital and spin rotational motions of the 
nucleons (protons and neutrons). For a nucleus the orbital motion of the 
nucleons is caused by the spinning motion of the entire nucleus rather than the 
orbital motion of individual nucleons while the spin rotational is an intrinsic 
property of the nucleons. The magnitude of the spin angular momentum is 
quantized as follows: 
        
   2/11 II        [1.3] 
where ρ is the spin angular momentum (J∙s), ħ is Planck‟s constant (4.13 × 10-18 
keV∙s) divided by 2π, and I is the spin quantum number (unitless). Depending on 
the combination of protons and neutrons in the nucleus, the value of I is either an 
integer or a half-integer. Each individual proton and neutron in the nucleus has a 
spin quantum number I = ½ which results in the protons and neutrons having a 
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spin-up (+½) and spin-down (–½) state. The protons pair with protons and the 
neutrons pair with neutrons. This pairing with their anti-aligned counterpart yields 
a net spin of zero for the pair. The protons and neutrons that remain unpaired 
determine the total spin angular momentum of the nucleus. Thus, nuclei with an 
odd number of protons and/or neutrons are NMR observable because I is a non-
zero integer (e.g. 1H, 13C, 19F, and 31P have spin-½ nuclei). With an even number 
of both protons and neutrons, I is zero and therefore not NMR observable (e.g. 
12C and 16O). 
 
1.2.2.2. Nuclear Magnetic Dipole Moment 
The nucleus that has a net non-zero spin angular momentum will generate 
a local magnetic field around the nucleus due to the spin and orbital rotational 
motions. The direction and magnitude of this magnetic field is called the nuclear 
magnetic dipole moment and has the following relationship with the nuclear 
angular momentum: 
               [1.4] 
where µ is the nuclear magnetic dipole moment (J∙T-1), γ is the gyromagnetic 
ratio ((Hz∙T-1), a nucleus-specific parameter), and ρ is the spin angular 
momentum (J∙s). Notice that when the nuclear angular momentum is zero (i.e., I 
= 0), then the nucleus has no magnetic moment and hence will not produce an 
NMR signal. 
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1.2.2.3. Quantum Mechanical Constraints 
The nuclear angular momentum and magnetic moment vectors are 
restricted to a finite number of possible orientations that are described by the set 
of magnetic quantum numbers, m, determined from I and given by the following 
series: 
    IIIImI  ),...,2(),1(,           [1.5] 
For example, nuclei with spin quantum number I = ½, two possible spin quantum 
numbers exist: +½ and –½. For I = 1, there are three possible states: +1, 0, and 
–1. In general, there are (2∙I + 1) possible states for a given I value. 
In addition to the magnitude, the nuclear spin angular momentum has a 
directional component. If the external magnetic field (B0) is taken to be oriented 
along the z-axis, ρz will the component of the nuclear angular momentum along 
the z-axis specifying the orientation of ρ as follows: 
   Iz m          [1.6] 
Similarly, the magnetic dipole moment, µ, is also quantized where combining 
Eqs. [1.3] and [1.4] for the magnitude, we get: 
       
   2/11 II        [1.7] 
The orientation of µ is also constrained to discrete values as determined by µz 
where 
       Izz
m         [1.8] 
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To illustrate with an example for a spin-½ nucleus like 1H, I = ½. Therefore, mI 
can only be +½ or –½ giving only two possible orientations of ρz and µz. Fig. 1.3 
illustrates the two orientations for a spin-½ nucleus: spin-up and spin-down. 
 
 
 
 
 
 
 
1.2.2.4. Nuclear Energy State Quantization 
Interaction between µ and B0 field gives rise to potential energy E, 
according to the relation 
   0BE z              [1.9] 
Figure 1.3 – Quantum mechanical view of the nuclear spin angular momentum, ρ, and 
the nuclear magnetic dipole moment, µ, for a spin-½ nucleus. The B0 field is oriented in 
the positive z-axis direction. The magnitudes of the vectors, ρ and µ, are their 
projections on the z-axis, ρz and µz, are shown. 
P a g e  | 10 
 
where µz is the component of nuclear magnetic dipole moment along the 
direction of the external magnetic field, B0. Thus, for a spin-½ nucleus there are 
two possible energy states corresponding to two possible orientations of the 
nuclear magnetic dipole moment. The parallel orientation has a lower energy 
state, E1, and the anti-parallel orientation has a higher energy state, E2: 
2
0
1
B
E



     [1.10] 
2
0
2
B
E



     [1.11] 
 
The lower energy state is termed spin-up and the higher energy state is termed 
spin-down (Fig. 1.4(b)). In the absence of the B0 field the energies of all spins are 
degenerate (Fig. 1.4(a)), meaning all spins have the same energy value. 
Transitions between the two energy levels can occur when EM radiation is 
absorbed or emitted (Fig. 1.4(c)), depending on whether the spins are 
transitioning from the lower-to-upper or upper-to-lower energy states. In either 
case, a characteristic frequency defines the quantum of radiation required for a 
single transition between the two energy states. From conservation of energy, 
this frequency can be redefined as: 
   


2
0
0
B
       [1.12] 
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where υ0 is the frequency of absorbed or emitted radiation (rad∙s
-1), γ is the 
gyromagnetic ratio (Hz∙T-1), and B0 is the external magnetic field strength (T). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 – Quantization of the nuclear energy states for spin-½ nuclei in the presence 
and absence of an external magnetic field (B0) and/or RF pulse radiation (B1). The B0 
field is oriented in the positive z-axis direction and the B1 field is oriented orthogonal to 
the B0 field. (a) In the absence of both fields, the nucleic spins are in a degenerate state 
where the energy is equal in all the spins. (b) In the presence of only a B0 field, without 
any RF radiation, the degeneracy between the energy levels is removed and the spins 
orient themselves to a spin-up (lower energy) or a spin-down (higher energy) orientation. 
The lower energy state contains more nuclei than the higher energy state, being 
distributed according to Boltzmann equilibrium and ΔE is the difference between the 
energy levels. (c) With the application of an appropriate B1 field, some of the spin-up 
nuclei change their orientation to a spin-down state so that both energy levels are 
occupied by an equal number of spins. Once the B1 field is turned off, the spins will 
return to the orientation in (b). When both fields (B0 and B1) are turned off, the spins will 
return to a degenerate state as shown in (a). 
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1.2.2.5. The Boltzmann Equilibrium 
As described earlier, the presence of B0 field causes the spins to orient 
into a lower and higher energy state (Eqs. [1.10] and [1.11]). The equilibrium 
distribution of nuclei in a particular energy state is described by the Boltzmann 
Law: 
      
 kTE
I
IeN
/         [1.13] 
where NI is the number of nuclei in spin state I, T is the temperature (°K), and k 
is the Boltzmann constant (1.38 × 10-23 J∙K-1) (see Fig. 1.4b). The NMR signal is 
proportional to the population between the lower and higher states, which is 
given by: 
             kT
BN
n T
2
0

      [1.14] 
where Δn is the population difference between the energy states, NT is the total 
number of nuclei being considered, γ is the gyromagnetic ratio (Hz∙T-1), and ħ is 
Planck‟s constant (4.13 × 10-18 keV∙s) divided by 2π. This population difference 
can also relate to the total magnetic dipole moment of the system, or net 
magnetization Mz, which is the sum of all the z-components of the individual 
magnetic moments: 
        



I
Im
mzmz NM ,      [1.15] 
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where Nm is the total population of nuclei in state m and µz,m is the z-component 
of each individual nuclear magnetic moment in state m (J∙T-1). In a spin-½ 
system, the total magnetization at the Boltzmann equilibrium, M0, is given by: 
2
0
n
M



      [1.16] 
(shown in Fig. 1.5) which when combined with Eq. [1.14] gives: 
     KT
BN
M T
4
0
22
0



     [1.17] 
 
1.2.3. Classical Description of NMR 
In NMR experiments, placing nuclei in an external magnetic field B0, 
exerts a torque L on the magnetic dipole moment µ. Since the magnetic dipole 
moment is inclined at an angle with respect to B0, the interaction of µ and B0 will 
result in a precessional motion of µ around B0. In classical physics this 
precessional motion is described as the cross product of µ and B0 as follows: 
0B
dt
d
L  

     [1.18] 
where the torque L is the rate of change of the angular momentum. Using the 
relationship between the nuclear magnetic dipole moment and the nuclear 
angular momentum, Eq. [1.18] can be rewritten as: 
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0B
dt
d
dt
d
 



     [1.19] 
where the rate of change of the nuclear magnetic dipole moment is equal to the 
product of the rate of change of the nuclear angular momentum and the 
gyromagnetic ratio. The frequency of precession of the nuclei about B0 is 
expressed by the Larmor equation: 
    00 B         [1.20] 
where ω0 is the Larmor frequency (Hz), γ is the gyromagnetic ratio (Hz∙T
-1) and 
B0 is the external magnetic field strength (T). Resonant absorption of energy will 
take place when the frequency of the applied radiation matches the natural 
precessional frequency (Larmor frequency) of the system. Once this resonance 
condition is satisfied, the system will be perturbed away from the Boltzmann 
equilibrium distribution where energy will be absorbed and spins in the ground 
state will be promoted to the first excited state. 
Without applied RF energy, the magnetic moment only responds to the B0 
field and precesses at the Larmor frequency. In the presence of an RF field, B1, 
the motion of the magnetic moment will be the result of an interaction with both 
the fields, B0 and B1: 
 
 10 BB
dt
d
dt
d
 



     [1.21] 
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1.2.4. The Bloch Equations 
The Bloch equations can be used to explain the interactions between 
nuclei (8). For a collection of spins, the vector sum of all individual magnetic 
moments yields a net magnetization, M.  In the absence of B0 field, the net 
magnetization is equal to zero. In the presence of B0 field, each magnetic 
moment precesses around the B0 field at the Larmor frequency, ω0. As per the 
Boltzmann distribution, more nuclei populate the parallel orientation or the lower 
energy state, which results in a net longitudinal or z-axis magnetization, Mz. The 
vector sum of the transverse or xy-components of M results in phase 
cancellation of the individual contributions to the net magnetization of the nuclei 
which results in no coherent transverse magnetization, Mxy, at the Boltzmann 
equilibrium. Thus, the net magnetization results in a longitudinal component with 
magnetization Mz (also termed M0) (Fig. 1.5). 
From Eq. [1.19], the motion of the net magnetization can be described as 
follows: 
        
)( 0BM
dt
dM
       [1.22] 
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To include the effect of both B0 and B1, Eq. [1.22] becomes: 
                        )( BMdt
dM
         [1.23] 
where B consists of static field, B0, and the RF field, B1. The components of B 
are described as follows: 
Figure 1.5 – Precession of spin-½ nuclei in the presence of an external magnetic field 
(B0) using the laboratory frame of reference. (a) Individual magnetic dipole moments are 
indicated in the spin-up and spin-down states with the arrows rotating at the Larmor 
frequency (ω0). (b) Due to the presence of excess nuclei in the spin-up state (lower 
energy), the spin-down arrows get cancelled out leaving an excess population of spins in 
the spin-up state. (c) A vector sum of all the individual magnetic dipole moments of the 
nuclei results in a net magnetization vector, M, which precesses at the same Larmor 
frequency, ω0, like the individual magnetic moments. The z-component of this net 
magnetization (Mz) is called the longitudinal magnetization and is represented by M0. 
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            )cos(1 tBBx        [1.24]  
        
)sin(1 tBBy         [1.25] 
        0
BBz         [1.26] 
The net magnetization responds dynamically to the presence of B0, B1, 
and the effects of nuclear relaxation processes. The Bloch differential equations 
describe the behavior of the constituent components {Mx, My, and Mz} as 
follows: 
    
2
10 )sin(
T
M
MtBMB
dt
dM y
zy
x  
   [1.27] 
   
2
10 )cos(
T
M
MtBMB
dt
dM
x
zx
y
 
   [1.28] 
             
  
1
0
1 )cos(sin
T
MM
tMtMB
dt
dM z
yx
z  
  [1.29] 
where T1 and T2 are longitudinal and transverse time constants, respectively, 
associated with the equilibrium of the net magnetization. Eqs. [1.27], [1.28], and 
[1.29] are in the laboratory frame of reference. For convenience the net 
magnetization M can be described in the rotating frame reference where the x- 
and y-axes rotate at the Larmor frequency, ω0. When describing the motion of 
nuclei in the following sections, M0 will be discussed in the rotating frame of 
reference with the rotational axis parallel to B0.  
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1.2.5. Free Induction Decay 
In NMR experiments, an RF resonant circuit surrounds the sample of 
interest and is placed such that the generated RF magnetic field (B1) is 
perpendicular to the static B0 field. At equilibrium, M0 is parallel to the B0 field 
which is oriented along the positive z-axis (Fig. 1.6). When the B1 field is applied 
at the Larmor frequency in the transverse (x-y) plane, M0 tips to the transverse 
plane. The angle of rotation is given by: 
  1B       [1.30] 
where θ is the tip angle and τ is the duration of the B1 field application.  
RF pulses are typically applied to tip the magnetization either completely 
onto the transverse plane (90° pulse) or onto the negative z-axis (180° pulse). 
Upon RF pulse application, perturbation of the net magnetization yields a 
transverse component, Mxy, which is detectable by the RF receive coil. The 
transverse component arises due to the RF pulse imparting phase coherence to 
the spins that form the net magnetization in the transverse plane. When the RF 
pulse is switched off, the net magnetization will precess about the z-axis and the 
spin system will return to the Boltzmann equilibrium by T1 relaxation, while the 
transverse magnetization will decay to zero by T2* relaxation due to loss of 
phase coherence (see Section 1.2.6 for discussion of relaxation mechanisms). 
The measured evolution of the transverse signal is an exponentially decaying 
sinusoid called free induction decay (FID) (Fig. 1.10). The signal decays by T2* 
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relaxation which is a combination of intrinsic T2 relaxation of the nuclei, and 
contributions from magnetic susceptibility, B0-field inhomogeneities, and 
molecular diffusion (discussed in Section 1.2.6.3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 – Precession of spin-½ nuclei in the presence of a B0 and a B1 field using 
the rotating frame of reference. Notice the axes are labeled x‟, y‟, and z‟ representing 
the axes rotating at the Larmor frequency. The B1 field that satisfies the resonance 
condition of the nuclei is applied orthogonal to the B0 field. This causes the net 
magnetization, M0, to precess around B1 which tips M0 towards the transverse plane at 
an angle θ. The transverse component of M0, Mxy, arises due to the RF pulse imparting 
phase coherence to the spins which comprise of the net magnetization in the transverse 
plane. This net transverse component is detected by the RF receive coil giving rise to 
the NMR signal. 
P a g e  | 20 
 
1.2.6. Relaxation Mechanisms 
Spin-lattice (T1) relaxation and spin-spin (T2) relaxation are the two main 
relaxation mechanisms in NMR. Once the RF field (B1) is turned off, thus 
perturbing the net magnetization of the nuclei, the nuclei will return to the 
Boltzmann equilibrium in an exponential manner. The exponential process by 
which the longitudinal magnetization, Mz, returns to its equilibrium state is 
measured by the time constant T1. T2 is the time constant that measures the 
exponential decay of the transverse magnetization, Mxy. Nuclei in various tissues 
and tissue states (normal, diseased, etc.) have intrinsically different values for T1 
and T2, thus allowing their manipulation to generate tissue contrast in MR 
images. 
 
1.2.6.1. Spin-Lattice (T1) Relaxation 
T1 is called the longitudinal or the spin-lattice relaxation time. When RF 
pulse is switched off after exciting the spins onto the transverse plane, the spins 
in the transverse plane continue to precess around the z-axis, seeking to return 
to the lower energy state according to the Boltzmann equilibrium. The spins 
recover by transferring energy to the surrounding “lattice” (the atomic 
environment) and the Mz component of the net magnetization slowly recovers 
along the longitudinal z-axis. This recovery component can be derived from the 
Bloch equations which give: 
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       1
0
T
MM
dt
dM zz 
       [1.31] 
Solving this differential equation gives the following equation which describes the 
growth of the longitudinal magnetization: 
         












11)( 0
T
t
z ebMtM
      [1.32] 
where Mz is the change in longitudinal magnetization, M0 is the value of net 
magnetization prior to the application of the RF pulse, b is equal to 1 or 2 
depending on whether a 90° or 180° RF pulse is used, T1 is the time required for 
the longitudinal component to return to 63% of its original value, and t is the time 
following the RF pulse. 
 
1.2.6.2. Measuring T1 Relaxation time 
T1 relaxation time can be measured using a progressive saturation 
method or an inversion recovery method. For a progressive saturation method 
two 90° RF pulses can be used separated by an interval called the repetition time 
(TR). Once the first 90° RF pulse is applied, the spins have phase coherence in 
the transverse plane with no longitudinal magnetization component, i.e. Mz = 0 
and Mxy is a maximum. When the 90° RF pulse is switched off, the longitudinal 
magnetization begins to recover over time t = TR. The amount of recovery will 
P a g e  | 22 
 
depend on the ratio of TR to the T1 of the sample being measured. At t = TR, 
another 90° RF pulse is applied which tips the recovered longitudinal 
magnetization onto the transverse plane and an FID of this magnetization is 
collected by the RF receive coil. By acquiring several different FIDs at different 
values of TR, the signal amplitude of the FID can be plotted to calculate the T1 of 
the sample using Eq. [1.32] with b = 1 (Fig. 1.7, blue curve). 
When using the inversion recovery method, a 180° and a 90° RF pulse are 
used to calculate the T1 relaxation time. Once the 180° RF pulse is applied, the 
net magnetization is flipped onto the negative z-axis, i.e. Mz = –M0 and Mxy = 0. 
Then, after waiting for one inversion time (TI), a 90° RF pulse is applied. 
Depending on the ratio of TI and T1 of the sample, the longitudinal magnetization 
will begin to recover. When the 90° RF pulse is applied after one TI, the 
remaining longitudinal magnetization will be flipped onto the transverse plane to 
create the FID signal. Thus, several FIDs collected at different TI values can be 
used to plot the inversion recovery of the longitudinal signal and Eq. [1.32] can 
be used to calculate the T1 of the sample using b = 2 (Fig. 1.7, red curve). 
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1.2.6.3. Spin-Spin (T2) Relaxation 
T2 is called the transverse or the spin-spin relaxation time. After the RF 
pulse is switched off, the vector sum of the spins in the transverse plane are 
Figure 1.7 – Methods for measuring T1 relaxation time. Both curves are shown with a T1 
relaxation time of 500 ms. Blue (upper) curve: Progressive saturation method uses two 
90° RF pulses separated by one repetition time (t = TR) to collect FIDs at different TR 
values to plot the saturation recovery curve. T1 relaxation time can be calculated by 
solving Eq. [1.32] with b=1. Red (lower) curve: Inversion recovery method uses one 
180° RF pulse and one 90° RF pulse separated by one inversion time (t = TI) to collect 
FIDs at different TI values to plot the inversion recovery curve. T1 relaxation time can be 
calculated by solving Eq. [1.32] with b=2. 
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spinning in phase at the same frequency. With time, due to spin-spin interactions, 
the transverse component begins to decay as the spins lose their phase 
coherence. In addition to spin-spin interactions, other factors contribute to the 
total transverse relaxation time, T2* as follows:  
           DSI TTTTT
2222
*
2
11111

     [1.33] 
where T2
I
 is the dephasing time due to external magnetic field inhomogeneities, 
T2
S
 is the dephasing time due to differences in magnetic susceptibility, and T2
D
 is 
the dephasing time due to molecular diffusion effects. The change in transverse 
component can be derived from the Bloch equations which give: 
                  
2T
M
dt
dM xyxy
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     [1.34] 
The decay following a 90° RF pulse follows a time constant T2* and the 
exponential decay is given by: 
              
*
2
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T
t
xy eMtM

      [1.35] 
where Mxy is the change in the transverse magnetization, M0 is the value of net 
magnetization prior to the application of the 90°-RF pulse,  t is the time following 
the RF pulse, and T2* is the time required for the transverse component to decay 
by 37% of the original net transverse magnetization prior to switching off the RF 
pulse. 
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1.2.6.4. Measuring T2 Relaxation time 
T2 relaxation time can be measured using a Hahn spin echo method 
which utilizes a 90° RF pulse followed by a 180° RF pulse separated by a time 
period of t = TE/2, where TE is called the echo time. After the 90° RF pulse is 
applied, the spins have phase coherence in the transverse plane with no net 
longitudinal magnetization component, i.e. Mz = 0 and Mxy is a maximum. When 
the 90° RF pulse is switched off spin dephasing will begin to occur by T2
*
 
relaxation processes as shown in Eq. [1.33]. The application of 180° RF pulse at 
t = TE/2 reverses the phases of the individual spins relative to the Larmor 
frequency resulting in the transverse magnetization being again in phase by t = 
TE. This magnetization is called the spin echo and is measured by the RF 
receive coil. Several spin echoes, collected at different TE values, generate a 
decay curve from which the T2 relaxation time can be calculated using Eq. [1.35] 
(Fig. 1.8). Notice that the effects of T2
*
 relaxation processes caused by external 
magnetic field inhomogeneities and differences in magnetic susceptibility are 
eliminated using this method due to the formation of the spin echo by the 180° 
RF pulse (see Section 1.3.5.1). 
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1.2.6.5. Generation of Tissue Contrast 
In the body, different tissues have different T1 and T2 relaxation times at a 
particular magnetic field strength. In general, the T2 relaxation time is much 
shorter than the T1 relaxation time. Thus, the signal in the transverse plane will 
decay more quickly than the recovery of the longitudinal signal to its equilibrium 
state. If the second 90° RF pulse is applied when the signal in the transverse 
Figure 1.8 – Method for measuring T2 relaxation time. The curve is shown with a T2 
relaxation time of 100 ms. Hahn spin echo method uses a 90° RF pulse followed by a 
180° RF pulse separated by one half the echo time (t = TE/2) to collect spin echoes at 
different TE values to plot the transverse decay curve. T2 relaxation time can be 
calculated by solving Eq. [1.35]. Effects of T2
*
 relaxation processes caused by magnetic 
field inhomogeneities and magnetic susceptibilities are eliminated using this method due 
to the formation of the spin echo by the 180° RF pulse. 
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plane is completely decayed and the longitudinal signal has not reached an 
equilibrium state, then the signal collected will be proportional to the T1 relaxation 
time. The image formed from this signal will have high T1 contrast and low T2 
contrast, thereby generating a T1-weighted image. On the other hand, if the 
longitudinal signal reaches the equilibrium state and the echo time is fairly long, 
then the signal collected will be weighted by T2 or T2
*
 depending on whether a 
90° or 180° RF pulse is used as the second RF pulse. A proton-density image is 
formed if the echo is collected at a long TR and short TE, where the image is 
neither T1- nor T2-weighted (Fig. 1.9).  
 
 
 
 
 
Figure 1.9 – Image contrast resulting from different values of repetition time (TR) and 
echo time (TE). A short TR and short TE acquisition results in a T1-weighted image due 
to the high T1 contrast. A long TR and long TE acquisition results in a T2-weighted image 
due to the high T2 contrast. A long TR and short TE acquisition results in low T1 and low 
T2 contrast; this type of image is called a proton-density image. 
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1.2.7. The Fourier Transform 
The Fourier transform (FT) is a mathematical process which mediates the 
interconversion of time (in seconds) and frequency (in Hertz). The FID signal 
received from NMR is in the form of amplitude versus time in the time domain. 
This FID has phase, frequency, and amplitude. FT of this signal transforms the 
FID from the time domain to the frequency domain where the FID will yield a plot 
of signal strength versus frequency. If the FID contains a single frequency of 
oscillation, then there will be a single Lorentzian peak located symmetrically 
about that frequency whose full-width-at-half-maximum (FWHM) height is related 
to the time constant T2
* of exponential decay (Fig. 1.10). If the FID contains 
multiple frequencies of oscillations, then the frequency domain will show as many 
Lorentzian peaks symmetrically disposed about each individual frequency. When 
studying chemical structures, obtaining FIDs would be sufficient; however, when 
performing MRI of biological tissue, NMR signals are composed of varying 
frequencies and amplitudes due to heterogeneity in tissues, e.g. fat, muscle, etc. 
In order to distinguish between the different tissues, spatial encoding is essential 
which is achieved by the application of a linear field gradient. 
 
1.3.  Principles of Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) entails the encoding of spatial 
information into the frequency and phase of the NMR signal using linear 
magnetic field gradients.  
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1.3.1. Slice Selection 
Selective excitation of a slice of the sample of interest is accomplished by 
imposing a linear magnetic field gradient orthogonal to the chosen plane size. 
This linear gradient causes a linear variation of the local magnetic field, thus 
altering the resonance frequencies of the nuclei along the gradient axis. Thus, 
the Larmor frequency depends on the spatial location of the nuclei in addition to 
B0 as follows: 
    
 zGBz z  0)(       [1.36] 
Figure 1.10 – Fourier transform (FT) of a free induction decay (FID) signal. The FID 
signal is an exponentially decaying sinusoidal signal (Left) is in the time domain and a 
Lorentzian waveform in the frequency domain (Right). T2
*
 characterizes both signals 
where the exponential decay in the time domain decays by T2
* 
while the full-width-half-
maximum (FWHM) is characterized by T2
* 
in the frequency domain. 
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where ω(z) is the angular frequency, γ is the gyromagnetic ratio, B0 is the 
external magnetic field, Gz is the linear gradient applied along the z-axis 
direction, and z is the position along the gradient direction. For slice selection, a 
narrow bandwidth of frequencies must be excited which corresponds to a narrow 
spatial distribution of nuclei within the sample. A sinc-pulse (
x
x)sin( ) is used to 
restrict the bandwidth of the RF pulse which yields a rectangular RF power 
spectrum (Fig. 1.11). 
 
 
 
 
 
 
 
 
Figure 1.11 – Fourier transform (FT) of a sinc (
x
x)sin( ) pulse. The sinc pulse in the time 
domain corresponds to a rectangular pulse in the frequency domain. 
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The bandwidth is proportional to the slice thickness as follows: 
  
zG
z


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

       [1.37] 
where Δz is the slice thickness, Δω is the frequency bandwidth, γ is the 
gyromagnetic ratio, and Gz is the linear gradient applied along the z-axis 
direction. The thickness of the slice can be altered by either changing the 
frequency bandwidth of the RF pulse or the amplitude of the gradient. For 
imaging slices away from the isocenter of the magnet, the imaging slice can be 
offset in the slice plane by changing the center frequency of the RF pulse: 
      zGz z   )(       [1.38] 
Thus, for a desired offset of a 0.5 cm (z) in the presence of a 1 G/cm gradient, 
the frequency of the RF pulse must be increased by 2129 Hz (γ = 4258 Hz/G). 
 
1.3.2. Frequency Encoding 
Analogous to the spatial encoding of the slice-selection process, the in-
plane frequency encoding process applies a linear field gradient along the x-axis 
(called the read-out gradient) during the data acquisition process period to 
encode spatial information along the x-direction (x-axis is chosen arbitrarily here 
for the read-out gradient). As in the case of slice selection, the read-out gradient 
results in a linear variation of the precessional frequencies of the nuclei which 
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correspond to the spatial location of the nuclei and is dependent on the gradient 
amplitude. This relationship is equivalent to: 
x
x
G
BW
FOV


       [1.39] 
where FOVx is the field of view (FOV) along the readout or x-direction in this 
case (cm), γ is the gyromagnetic ratio (Hz/G), Gx is the gradient amplitude 
(G/cm) and BW is the signal bandwidth (Hz) specified as: 
    AT
N
BW
f

       [1.40] 
where Nf is the number of data points used to digitize the NMR signal during 
acquisition time, AT. 
 
1.3.3. Phase Encoding 
The second dimension of the image is spatially encoded in the phase of 
NMR signal by applying a gradient, Gy, along the y-direction of the slice plane. 
Gy must be applied before the echo readout either between or after slice-
selective RF pulses (in the case of spin-echo experiment). Upon the application 
of phase-encoding gradient, a phase shift is induced based on the spatial 
location of the nuclei along the direction of the gradient at each voxel. The 
precessional frequencies of the nuclei correspond to the spatial position of the 
nuclei and are dependent on the gradient amplitude: 
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yGy y   )(      [1.41] 
where ω(y) is the frequency of precession experienced along the y-axis, γ is the 
gyromagnetic ratio, y is the direction along the phase-encoding or y-direction in 
this case, and Gy is the gradient applied along the y-axis direction.  
A phase shift is induced in the nuclei when Gy is applied for time t: 
tyGy        [1.42] 
Since the phase information imparted to the nuclei is retained through the 
experiment, the pulse sequence must be repeated a number of times (Np) using 
an equivalent number of phase-encoding gradients (Gy,inc). This increment is 
dependent on the desired FOV in the phase-encoding direction (FOVy) which is 
equal to: 
       
tG
FOV
incy
y


,
1
      [1.43] 
where Gy,inc is the minimum gradient increment required and t is the duration of 
the gradient application. From this relationship and the number of phase-
encoding steps (Np), the minimum and maximum gradient values can be 
determined as: 
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Gy,range is the range of possible values for the gradient amplitude. 
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1.3.4. Fourier Reconstruction in k-space 
The frequency and phase encoding information for each slice is depicted 
in a two-dimensional (2D) k-space (Fig. 1.12). Each line of the k-space is 
collected at a particular phase increment. On the frequency encoding axis, each 
Figure 1.12 – Imaging of the k-space. The phase encoding direction is shown in the 
vertical axis while the frequency encoding direction is shown in the horizontal axis. At 
zero frequency the maximum amplitude appears in all lines of k-space due to the 
collection of spin echoes with the nuclei in phase. Moving away from center frequency 
the nuclei become out of phase resulting in weaker signals at υA and υB. With phase 
encoding the maximum amplitude appears at zero phase since no dephasing is 
experienced by the nuclei. With dephasing the signal amplitude decreases causing the 
lowest signals to occur at φA and φB.  
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increment represents a single sampling point. The total length of the frequency 
axis is equal to the total number of sampling points (Nf ) in Eq. [1.40]. Notice that 
the center of k-space (0,0) contains the maximum amplitude because the phase 
and frequency shifts are near zero. On the other with a phase and frequency shift 
the signal is attenuated due to dephasing of the spin coherence. The center of 
the k-space contains the low-frequency spatial information while the peripheral 
region contains the detail information (high-frequency information). Taking the 
2D-FT of the k-space will result in the formation of a 2D MR image.  
 
1.3.5. Imaging Sequences 
In order to collect a complete 2D image, multiple signal acquisitions are 
required as discussed in the earlier portion of Section 1.3. In summary, a slice 
selective RF pulse is required to tip the magnetization onto the transverse plane. 
As soon as the RF pulse is turned off, a phase encoding gradient needs to be 
applied. Then a readout gradient must be applied during the echo acquisition. 
 
1.3.5.1. Spin Echo Sequence 
The spin echo sequence uses 90° and 180° RF pulses (Fig. 1.13). The 
90° RF pulse is first applied while the slice-select gradient (Gz) is on, rotating the 
magnetization of a particular slice onto the transverse plane. The phase-
encoding gradient (Gy) is applied immediately at the first increment value of Gy,1 
to begin phase encoding. Then a 180° RF pulse is applied to rephase the nuclei 
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that began to dephase as a result of T2
*
 relaxation. This way the collected signal 
will contain information of the intrinsic T2 relaxation (discussed earlier in Section 
1.2.6.4). During the 180° RF pulse the slice-select gradient is turned on to affect 
the nuclei in the same slice as elected earlier. Then, the readout gradient is 
turned on during the spin echo acquisition to encode in the frequency direction. 
Notice the grey lobes in the Gz and Gx gradients. These are rephasing gradients 
that are applied for phase-shift correction due to dephasing of nuclei as a result 
of the application of the Gz and Gx gradients. After the first sequence is complete, 
the sequence repeats with the next Gy increment value (Gy,2) until the end of the 
phase encoding steps. The main disadvantage of this technique is that the echo 
time (TE) cannot be very short due to the presence of the finite 180° RF pulse. 
However, the signal received with this technique will have a higher magnitude, 
compared to the gradient echo technique (discussed in Section 1.3.5.2). 
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Figure 1.13 – A complete spin echo pulse sequence diagram showing two different 
gradient values of Gy, Gy,1 and Gy,2. The repetition time (TR) is the duration between the 
applications of two 90° RF pulses. The echo time (TE) is the time between the center of 
the 90° RF pulse and center of the generated spin echo. A 90° RF pulse is applied at a 
slice-selective gradient. The phase encoding gradient, Gy,1, is then applied immediately 
after which a slice-selective 180° RF pulse is applied. During the signal acquisition time 
the readout gradient is turned on for frequency encoding. The grey lobes represent 
rephasing gradients that apply a phase-shift correction. The sequence then repeats with 
the next phase encoding gradient, Gy,2, until the end of the phase encoding steps. 
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1.3.5.2. Gradient Echo Sequence 
The gradient echo sequence is similar to the spin echo sequence in terms 
of gradient application and signal acquisition (discussed in Section 1.3.5.1). The 
main difference is that only a single RF pulse is used with gradient echo. The RF 
pulse used in a gradient echo sequence is typically less than 90° (Fig. 1.14). A 
single RF pulse flips the magnetization onto the transverse plane and over time, 
T2
*
 relaxation occurs. There is no 180° RF pulse to correct for the dephasing of 
the nuclei. As a result the image formed by this technique will be T2
*
-weighted. 
Only the rephasing gradients are present for phase-shift correction due to the 
application of the gradients. The low flip angle RF pulses allows for considerable 
shortening of the TR time since spins experiencing smaller flip angles will return 
to the equilibrium state at a quicker rate. Also, the absence of a 180° RF pulse 
allows the gradient echo sequence to achieve very short TE times. The 
disadvantage of this technique is acquiring images at a lower signal-to-noise 
compared to the spin echo technique. 
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Figure 1.14 – A complete gradient echo pulse sequence diagram showing two different 
gradient values of Gy, Gy,1 and Gy,2. The repetition time (TR) is the duration between the 
applications of two RF pulses at angle θ. The echo time (TE) is the time between the 
center of the RF pulse and center of the generated spin echo. The RF pulse is applied at 
a slice-selective gradient. The phase encoding gradient, Gy,1, is then applied 
immediately. During the signal acquisition time the readout gradient is turned on for 
frequency encoding. The grey lobes represent rephasing gradients that apply a phase-
shift correction. The sequence then repeats with the next phase encoding gradient, Gy,2, 
until the end of the phase encoding steps. 
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2.1. Statistics 
Stroke is caused by a disturbance of cerebral blood flow that leads to 
reduction of oxygen and nutrient supply to cerebral tissue resulting in loss of 
normal physiological cell function and eventually cell death. Stroke is the third 
largest cause of death, ranking behind heart disease and cancer, and a leading 
cause of long-term disability in the United States. According to the National 
Institute of Neurological Disorders and Stroke (NINDS), about 795,000 people 
suffer a new or recurrent stroke each year. In 2006, stroke claimed the lives of 
137,119 people according to the figures from the American Heart Association 
(AHA). The AHA also estimates there are about 6.4 million stroke survivors today 
in the United States which is almost twice the number recorded in 1998. The 
increase in survival is owed to the methods of treatment and drugs that have 
been available during the past decade. Aspirin and tissue plasminogen activator 
(tPA) are drugs commonly used that attempt to restore blood flow to the brain by 
their anti-coagulant effect and clot-dissolving ability, respectively. Depending on 
the severity of the cerebral blood flow blockage, surgical treatments such as 
mechanical removal of clots, carotid endarterectomy, angioplasty, and stent 
placement can aid to not only restore cerebral blood flow, but prevent the 
occurrence of another stroke in that location. In the more severe hemorrhagic 
stroke cases, surgery can be used to repair blood vessel abnormalities using 
procedures like aneurysm clipping. In any case, a reliable method of identifying 
the severity of stroke within its onset could allow appropriate specific therapy to 
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be instituted as early as possible to the patient to further increase the chances of 
survival. 
 
2.2. Cerebral Physiology 
The function of cells under normal and pathological conditions will be 
discussed in this section. 
 
2.2.1. Normal Cell Function 
Cerebral tissue maintains normal cell function by receiving oxygen and 
nutrients from the cerebral blood circulation. The main fuel for cells in the 
cerebral tissue is glucose. Since glucose storage in the brain is negligible, the 
cells depend on the cerebral circulation for a constant supply of glucose. Thus, 
maintenance of perfusion is crucial to ensure normal cell function. In normal 
cells, mitochondria use oxygen to produce adenosine triphosphate (ATP) via 
aerobic respiration. The energy generated from ATP metabolization supports all 
cell functions including maintenance of the sodium-potassium pump (Na+-K+-
ATPase). This pump, amongst its other functions, maintains the normal ionic 
gradient (resting potential) across the cell membrane and stabilizes the cell 
volume by maintaining osmotic balance (2). Under resting conditions, the 
intracellular (IC) level of K+ far exceeds the extracellular (EC) concentration while 
Na+, chloride (Cl-), and calcium (Ca2+) dominate in the EC space. 
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2.2.2. Pathophysiology of Ischemic Stroke 
 Stroke is a cerebrovascular disease that occurs in two categories: 
ischemic and hemorrhagic. Ischemic strokes are caused by disruption in normal 
cerebral blood flow due to occlusion of a blood vessel, while hemorrhagic strokes 
result from the rupture of a blood vessel. In either case, the disruption of cerebral 
blood flow initiates a chain of biochemical events that disrupts normal cell 
function. The reduction in blood flow leads to limited supply of oxygen in the cell 
for aerobic respiration to produce ATP. To compensate for the loss in oxygen 
supply, the cells begin anaerobic respiration from glucose metabolism to 
maintain an adequate level of ATP. Once the limited reserve of glucose is 
depleted in the brain, anaerobic metabolism results in an accumulation of lactic 
acid which disrupts the normal acid-base balance in the brain. Lack of ATP 
prevents the cells from maintaining the sodium-potassium pump, thus 
compromising the resting potential of the cell. Failure of ion homeostasis leads to 
anoxic depolarization of the cell membrane, in which K+ leaves the cell and Na+, 
Ca2+, and Cl- move into the cell. This movement of ions disrupts the osmotic 
balance causing an influx of water from the EC space to the IC space which 
leads to cell swelling (cytotoxic edema) (Fig. 2.1). Elevated Ca2+ levels in the 
cells trigger the release of excitatory amino acid neurotransmitters such as 
glutamate, which further activates other receptors resulting in excessive 
accumulation of Ca2+ in the cell. Excess Ca2+ activates enzyme systems such as 
proteases, lipases, and endonucleases which break down the cellular structure. 
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Free radicals, reactive oxygen species, and other harmful chemicals are released 
as metabolic products of enzyme activity. These agents further increase the rate 
of cellular breakdown. Once the mitochondria breaks down, apoptotic factors are 
released in the cell which initiates the caspase-dependent apoptosis cascade 
that leads to cell death. Cell death can also occur by necrosis, which is a sudden 
and uncontrolled cell death unlike apoptosis, which is classified by a complex set 
of events in response to ischemic injury.  
 
 
 
 
 
 
 
 
Figure 2.1 – Cartoon illustrating ionic movement in normal and ischemic cells. Left: In 
normal cells, the sodium-potassium pump (Na+-K+-ATPase) maintains a high level of K+ 
in the ICS and a high level of Na+, Ca2+, and Cl- in the ECS. Right: In ischemic cells, lack 
of Na+-K+-ATPase function leads to movement of K+ from the ICS to ECS and 
movement of Na+, Ca2+, and Cl- from the ECS to the ICS, which results in a net 
movement of water molecules from the ECS to the ICS. This water movement results in 
intracellular swelling (cytotoxic edema). ECS = Extracellular space, ICS = Intracellular 
space, K+ = potassium ions, Na+ = sodium ions, Ca2+ = calcium ions, Cl- = chloride ions. 
Ion concentrations shown were obtained from Alberts et al. (1). 
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2.3. Apparent Diffusion Coefficient 
The apparent diffusion coefficient (ADC), measured using diffusion-
weighted MRI, is a diffusion parameter that can measure the magnitude of water 
molecule movement in cerebral tissue. In normal tissue, the ADC of water in the 
EC space is presumed to be greater than that of the IC space because the cell 
membrane and IC organelles can restrict water diffusion, thereby reducing the 
ADC of IC water. Wesbey et al. and Le Bihan et al. first demonstrated the 
application of diffusion-weighted NMR techniques to in vivo systems (3,4). Due to 
the sensitivity of ADC to changes in tissue water diffusion properties that occur 
during cerebral ischemia, ADC measurement has been established as an 
effective technique which has been extensively used to study acute stroke. 
Moseley et al. demonstrated in a cat stroke model that during cerebral ischemia, 
there is a reduction in the ADC value of cerebral tissue water (5). In addition to 
cerebral ischemia, decline in ADC of cerebral water has been observed in other 
neurological disorders such as cortical spreading depression, low-grade 
astrocytoma (4), status epilepticus (6) and hypoglycemia. Even though the cell 
volume changes in all these pathophysiological states follow a similar pattern, the 
reason for ADC decline is not very well understood. 
 
2.4. ADC Decline Hypotheses 
Several hypotheses have been suggested in the last two decades to 
explain the decrease in overall ADC in response to cerebral injury (Fig. 2.2): 
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1. During ischemia, movement of water occurs from the EC space to the 
IC space resulting in cytotoxic edema. This results in a net loss of fast 
diffusing water molecules (high ADC) in the EC space and a net 
increase of slow diffusing water molecules (low ADC) in the IC space. 
Thus, in the final state there is a larger population of water molecules 
with lower ADC values (in the IC space) which is responsible for the 
overall ADC decline (5-9). 
2. Due to energy depletion on the onset of ischemic injury, there is a loss 
of intracytoplasmic motion and/or an increase in the viscosity of IC 
milieu. This leads to further retardation of water molecule motion 
resulting in a lowering of IC water ADC. This lowering of IC water ADC 
is responsible for the overall ADC decline (6,10-14). 
3. Ischemia causes a net movement of water from the EC space to the IC 
space causing cytotoxic edema. This causes an increase in the IC 
volume fraction and a decrease in the EC volume fraction. As a result, 
due to loss of EC volume, EC water diffuses with more restrictions and 
increased tortuosity. That causes the EC water ADC to decrease. This 
decrease in EC water ADC is responsible for the overall ADC decline 
(10,15-17). 
4. Reduction in movement of water molecules across the cell membrane 
due to membrane permeability changes is responsible for the overall 
ADC decline (18). 
P a g e  | 48 
 
Even though one mechanism may dominate the reduction of overall water ADC 
decline, the more likely scenario is that the change in overall water ADC is a 
result from a combination of all these mechanisms due to the complex nature of 
water diffusion (19). 
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2.5. Exogenous and Metabolite Surrogates 
Since conventional NMR data contains combined signals from the IC and 
EC water, it is difficult to determine which compartment is responsible for the 
Figure 2.2 – Cartoon illustrating Hypotheses #1–#4 of overall water ADC decline in 
ischemic cells. The blue circles and red circles represent ICS and ECS water molecules, 
respectively. The number of circles corresponds to water volume and the size of the 
circles corresponds to water ADC magnitude in the respective compartments.  Thus, in 
normal cells, the ICS water volume is approximately four times larger than the ECS 
water volume (IC/EC fraction ≈ 80/20). The size of the water molecules in the ICS is 
smaller than that of the ECS indicating a lower ADC value of ICS water compared to 
ECS water in normal cells. A – Hypothesis #1: Following ischemic injury, ECS water 
moves into the ICS resulting in a loss of high ADC water from the ECS and an increase 
of low ADC water in the ICS. In the final state, a larger population of water is comprised 
of low ADC values (water molecules shaded in yellow), which causes an overall water 
ADC decline. B – Hypothesis #2: Following ischemic injury, energy depletion in normal 
cells results in a loss of intracytoplasmic motion and/or an increase in the viscosity of 
ICS milieu. This leads to further retardation of ICS water resulting in lowering of ICS 
water ADC. This lowering of ICS water ADC is responsible for the overall ADC decline 
(water molecules shaded in yellow). C – Hypothesis #3: Following ischemic injury, ECS 
water moves into the ICS space causing an increase in the ICS volume and a decrease 
in the ECS volume. Loss of ECS volume causes the ECS water to diffuse with more 
restrictions and increased tortuosity resulting in a decrease in the ECS water ADC. This 
decrease in ECS water ADC is responsible for the overall ADC decline (water molecules 
shaded in yellow). D – Hypothesis #4: Following ischemic injury, there is a reduction in 
movement of water molecules across the cell membrane due to membrane permeability 
changes (represented by thick dark line). This causes an overall ADC water decline.  
ADC = Apparent diffusion coefficient; ECS = Extracellular space; ICS = Intracellular 
space.  
 
P a g e  | 51 
 
overall change in water ADC during cerebral ischemia. To isolate the diffusion 
properties of IC and EC water, many studies have employed the use of 
exogenous and metabolite surrogates as an indirect method of gaining insight 
about compartmental water diffusion (10-14). Neil et al. studied the in vivo 
diffusion properties of cesium-133 (133Cs), an IC marker and K+ analog, and 
found that the changes in the 133Cs ADC correlated with the reduction of water 
ADC within the same order of magnitude following cerebral ischemia (12). Duong 
et al. investigated the use of 2-[19F]luoro-2-deoxyglucose-6-phosphatase (2FDG-
6P) as a compartment-specific marker that could be selectively isolated either to 
the IC space or EC space depending on the method on 2FDG-6P infusion (13). 
This study concluded that the change in 2FDG-6P ADC in the IC and EC spaces 
matched the water ADC decline during global ischemia in a rat model. Another 
study by Duong et al. measured the ADC of extracellular markers – mannitol, 
phenylphosphonate, and polyethylene glycol – to infer the ADC of EC water (14). 
Other spectroscopic studies of cerebral metabolites suggest that changes in IC 
water dominate the overall ADC change during ischemia based on reduction in 
the ADCs of metabolites such as N-acetyl-aspartate, creatine, and choline during 
focal ischemia in rat brain (10,11). In all these studies, changes in water ADC are 
being inferred from the behavior of exogenous molecular tracers and/or 
metabolites, which may have different molecular sizes, binding properties, 
diffusion coefficient temperature dependence, and exchange properties in normal 
and ischemic tissue compared to water. 
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2.6. Diffusigraphy 
Diffusigraphy is another technique that has been used to isolate IC and 
EC diffusion water properties (20). This method involves acquiring a series of 
diffusion-weighted NMR data while systematically changing the diffusion-
weighting parameter (b values) over a large range, and then fitting the diffusion 
signal attenuation curves to a sum of two decaying exponentials (biexponential 
model). As per the conventional hypothesis, the fast ADC value should correlate 
with the EC volume fraction while the slow ADC value should correlate with the 
IC volume fraction. Results from studies in the rat and human brain showed that 
the ADC values did not agree with the known fractions of IC and EC volume (21-
23). This discrepancy could be attributed to T2 relaxation time differences 
between the IC and EC water and diffusion anisotropy (24). Moreover, Mulkern et 
al. admit that even though the biexponential model of the diffusion attenuation 
curves allowed extraction of two ADC values, there was not enough experimental 
evidence to conclude that the two exponential decay terms arise from two 
independently diffusing compartments, i.e. the IC and EC compartments (23). A 
study by Helmer et al. showed that due to restriction effects, a single 
compartment can exhibit biexponential decay of a diffusion signal (25). Thus, a 
biexponential model of diffusion signal attenuation does not necessarily imply the 
signal must arise from two compartments. Biexponential signal decay could 
occur due to restrictions, water exchange, relaxation time effects, compartmental 
ADC differences or a combination of these effects in a single or multiple-
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compartment system. Thus, application of diffusigraphy alone is not enough to 
for accurate compartmental water ADC measurements. 
 
2.7. Relaxo-diffusigraphy 
Silva et al. demonstrated a unique technique where they combined 
relaxography with diffusion encoding to measure compartment-specific ADC 
values using diffusion-weighted inversion-recovery spin-echo spectroscopy (DW-
IRSE) and diffusion-weighted echo-planar imaging (DW-EPI) (26,27). 
Relaxography is a technique that uses a contrast reagent (CR) to distinguish 
between IC and EC water signal based on differences in their respective T1 
relaxation times (28). Silva et al. used gadopentate dimeglumine (Gd-DTPA) as 
the CR which is selective to the EC compartment (27). As a result, the CR 
enhanced the relaxation of EC water by decreasing the T1 relaxation time in the 
EC space, thereby separating the signal contributions of IC and EC water signal. 
Diffusion experiments were then performed which enabled direct measurement 
of apparent T1, T2, ADC, and volume fraction of the IC space. The apparent T1, 
T2, ADC, and volume fraction of the EC space was calculated indirectly from the 
IC data. The volume fraction for the IC space calculated using this method 
matches the physiologically known values for IC fraction (~80%) which was not 
obtained when using diffusigraphy alone. Thus, this method of combined 
diffusigraphy and relaxography allows compartment-specific measurement of 
ADC. 
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Silva et al. concluded from their study that the ADC value measured in 
normal brain (comprised of IC and EC water) were statistically similar to the ADC 
value of the CR-infused brain (comprised only of IC water) suggesting that the 
major determinant of overall ADC value in the rat cerebral tissue is the water 
ADC of the IC space (26). In cerebral ischemic rats, the reduction of ADC 
measured in the CR-free brain was statistically similar to the ADC value 
measured in the CR-infused brain. From these results, Silva et al. conclude that 
the diffusion-weighted contrast during cerebral ischemia is primarily a result of 
the ADC reduction in the IC compartment. This finding is in agreement with 
Hypothesis #2 and with results obtained using ADC of exogenous and metabolite 
surrogates to infer the ADC of water (10-14). Nonetheless, in spite of these 
promising findings, the other hypotheses cannot be completely ruled out.  
 
2.8. Manganese-Enhanced MRI 
Divalent manganese ion (Mn2+) is a widely used T1 CR in manganese-
enhanced MRI (MEMRI) studies for animal neuroimaging. Mn2+ acts as Ca2+ 
analog and enters the neuronal IC space via voltage-gated calcium channels (29) 
following neuronal activation (30-33) which results in accumulation of IC Mn2+. 
T1-weighted MRI can then readily detect a reduction of regional water proton T1 
due to the paramagnetic Mn2+. This approach is different from the previous case 
that used Gd-DTPA since Gd-DTPA only resides in the EC space, while Mn2+ 
ends up in both the EC and IC space mainly populating the IC space. Using Mn2+ 
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as an IC CR could provide interesting insight in relation to IC and EC ADC 
measurements compared to the use of an EC-CR. Residence of Mn2+ in the 
larger water volume fraction affects the relaxation time of the majority of water in 
the cell, whereas the EC-CR only affects a small water volume fraction in the EC 
space. Application of relaxo-diffusigraphy using Mn2+ will be interesting to see if 
this method yields similar or different results compared to EC-CR. This 
information could provide further insight into the role of ADC decline during 
cerebral ischemia. 
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3.1. Preface 
 This study was done to determine if manganese (Mn2+) can be used to 
separate the intracellular and extracellular water components in the rat brain. I 
completed all aspects of this study by performing animal injections, collecting 
NMR data, reconstructing images, MATLAB programming for image analysis, 
and principal authorship in the writing of the manuscript. The manuscript work is 
in progress to be submitted for publication. 
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3.2. Abstract 
Diffusion-weighted NMR techniques have established that the apparent 
diffusion coefficient (ADC) of cerebral tissue water decreases during ischemia. 
However, it is unclear whether the ADC change occurs due to changes in the 
intracellular (IC) space, extracellular (EC) space, or both. To better understand 
the mechanism of water ADC changes in response to ischemic injury, making IC 
and EC compartment specific measurements of water diffusion is essential. Past 
studies have measured compartment-specific diffusion coefficients using 
gadolinium (Gd-DTPA) as the MR contrast agent in yeast cells to distinguish 
between the IC and EC water proton signals based on differences in their 
respective longitudinal (T1) relaxation times. Gd-DTPA was employed as an EC 
contrast agent, thereby reducing the T1 value of the EC space. In this study we 
apply an alternate approach by using manganese (Mn2+) as the IC contrast 
agent. Mn2+ uptake by cells causes shortening of the T1 relaxation time of IC 
water. The relative difference in T1 relaxation times between the IC and EC 
compartments can be used to discriminate between the MR signals arising from 
water in the respective compartments.  
 
P a g e  | 63 
 
3.3. Introduction 
Water is an essential fluid necessary to sustain life. All cells of the body 
live in a highly regulated fluid environment. The fluid within the cells occupies 
what is known as the intracellular (IC) compartment whereas the fluid outside the 
cells occupies the extracellular (EC) compartment. The cell membrane is a 
barrier that separates these two compartments and plays a crucial role in 
maintaining the volume and composition of the two compartments by regulating 
transport across the membrane. Movement of water between the two 
compartments and also within the cells is of particular interest since 
abnormalities in water movement and changes in compartmental volume 
fractions can lead to pathophysiological states such as acute ischemic stroke.  
Over three decades ago, Andrasko (2) observed that the NMR signal 
measured from human erythrocytes could be emanating from a mixture of water 
molecule signals exchanging from both IC and EC compartments. Thus, the 
measured NMR signal may contain information that is a composite of NMR 
parameters (e.g., longitudinal and transverse relaxation times) and physical 
parameters (e.g., diffusion coefficients and membrane permeability) of the two 
compartments. Since these parameters can change values in response to 
pathology, it is essential to distinguish between the signals arising from the IC 
and EC compartments separately so that we can determine if one or both 
compartments are responsible for the change in overall NMR signal. 
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The apparent diffusion coefficient (ADC), measured using diffusion-
weighted MRI (DW-MRI), is a diffusion parameter that can measure the 
magnitude of water molecule diffusion in cerebral tissue. DW-MRI techniques 
have established that the ADC of cerebral tissue water decreases during 
ischemia (3-5). Several hypotheses have been proposed assigning the ischemic 
ADC decrease to changes in the IC space, EC space, or both (5-18). However, 
the exact mechanism responsible for the ADC change remains a subject of 
debate due to the complex nature of water diffusion process in cells.  
To better understand the mechanism of water ADC changes in response 
to ischemic injury, making IC and EC compartment specific measurements of 
water diffusion would be useful. Silva et al. (19) measured compartment-specific 
diffusion coefficients using gadolinium (Gd-DTPA) as the MR contrast reagent 
(CR) in yeast cells to distinguish between the IC and EC water proton signals 
based on differences in their respective longitudinal T1 relaxation times. Gd-
DTPA was employed as an EC CR, thereby reducing the T1 value of the EC 
space. Silva et al. (18) extended the study to animals and measured 
compartment-specific diffusion coefficients in the brain in normal and ischemic 
rats using an EC CR. 
In this study, we applied an alternate approach by using manganese 
(Mn2+), which is a widely used T1 CR in manganese-enhanced MRI (MEMRI) 
studies for animal neuroimaging. Mn2+ acts as Ca2+ analog and enters the 
neuronal intracellular space via voltage-gated calcium channels (20) following 
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neuronal activation (21-24). This results in accumulation of intracellular Mn2+. T1-
weighted MRI can then readily detect a reduction of regional water proton T1 due 
to the paramagnetic Mn2+. The relative difference in T1 relaxation times between 
the IC and EC compartments can be used to discriminate between the MR 
signals arising from water in the respective compartments.  
The goal of this project was to separate the IC compartment from the EC 
compartment based on their respective longitudinal T1 relaxation times and water 
content in rat brains using MEMRI. 
 
3.4. Theory 
Signal intensity data obtained from inversion recovery MRI can be fit using 
non-linear least squares fitting to inversion recovery models derived from the 
Bloch equations to extract T1 relaxation times. A one-compartment model is 
illustrated by the following equation: 
    )1(),,;( 1010
T
TI
z ebMTbMTIM

      [3.1] 
where Mz is the signal intensity, TI is the inversion time, b is the efficiency of 
inversion, M0 corresponds to the overall compartmental signal, and T1 is the 
longitudinal relaxation time.  
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For a two-compartment system, Eq. [3.1] can be modified to include the 
signals arising from each compartment: 
)1()1(),,,,;( 11 001100
ba T
TI
b
T
TI
ababaz ebMebMTTbMMTIM


              [3.2] 
 
where M0a and M0b correspond to the signals emanating from compartments a 
and b, and T1a and T1b are the longitudinal relaxation times for the respective 
compartments. 
With slight modification to Eq. [3.2], the two-compartment exchange 
equation has been analytically solved (25) where the normalized signal intensity 
is given by the following equation: 
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              [3.3] 
where 
       ba MM 00 '1'         [3.4] 
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where T’1a and M’0a correspond to the fast recovering components of the 
signal, and T’1b and M’0b correspond to the slow recovering components of the 
signal; T1a, T1b, M0a, and M0b correspond to the actual compartmental 
longitudinal relaxation times and volume fractions; τa and τb are the mean 
lifetimes (residence times) of the spins in their respective compartments. 
 We can notice from the equations that when the system is in slow 
exchange (i.e., the spins in the respective compartments reside therein for a long 
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period of time causing τa → ∞ and τb → ∞), the fast and slow recovering 
components of relaxation approach the actual fast and slow relaxation times of 
the respective compartments (i.e., T’1a → T1a and T’1b → T1b), thus causing a 
biexponential recovery of the signal. On the contrary, when the system exhibits 
fast exchange (i.e., τa → 0 and τb → 0), the exchange rate constants, 
a
1
 and 
b
1
, dominate the effect causing a monoexponential signal recovery. 
 In the absence of any CR, a two-compartment system displaying a 
monoexponential signal recovery indicates that the system is in fast exchange 
and the signal distribution represents a weighted average of water signal 
emanating from both the compartments (IC and EC). When sufficient amounts of 
Mn2+ (an IC CR) is added to the system, relaxation times of the water in the IC 
space will decrease, and the IC T1 will dominate the fast recovering terms in Eqs. 
[3.6] and [3.7] causing the system to shift from a fast-exchange (τa and τb 
dominated) to a slow-exchange (T1a and T1b dominant) regime. Thus, a 
biexponential recovery will be exhibited by the inversion signal containing an 
effective fast relaxation component (T’1a) with an effective compartmental 
volume fraction (M’0a), and an effective slow relaxation component (T’1b) with an 
effective compartmental volume fraction (M’0b). 
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3.5. Materials and Methods 
3.5.1. Animal Preparation 
All procedures were performed as approved by the Institute Animal Care 
and Use Committee (IACUC) of the University of Massachusetts Medical School 
(Worcester, MA, USA).  Adult male Sprague-Dawley rats (weighing from 200-450 
g) were anesthetized using 5% isoflurane. MnCl2 (Sigma-Aldrich, St. Louis, MO, 
USA) was administered via subcutaneous (SC) injection at three different doses: 
75 mg/kg using 25 mM MnCl2 (N=3), 150 mg/kg using 50 mM MnCl2 (N=3), and 
300 mg/kg using 100 mM MnCl2 (N=6). Different concentrations of Mn
2+ were 
used for the three administered doses to ensure an approximately equal volume 
of MnCl2 solution injection. The SC injections were administered on the dorsal 
region, bilaterally, slightly posterior to the midline. Following the injection, rats 
were returned to their cages and allowed normal access to food and water.  
During the imaging sessions, animals were anesthetized with 3% 
isoflurane. After anesthesia was induced, the anesthetic level was reduced to 
2%. The head of the anesthetized animal was positioned in a birdcage RF coil 
with a nose cone providing a continuous supply of the anesthetic. The animals 
were placed prone into the magnet bore. A respiratory sensor was placed on the 
chest area to monitor the respiration rate throughout the imaging session. 
MEMRI was performed in each animal before SC injection of Mn2+, and then at 6, 
12, 24, 72, and 168 h after Mn2+ injection. 
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3.5.2. MR Measurements 
All MR imaging was performed on a Bruker BioSpin 2.0-T/45-cm 
horizontal bore system (Bruker BioSpin, Billerica, MA, USA) equipped with 200 
mT/m gradients and an in-house-built, 45-mm-diameter, birdcage RF coil that 
was 30 mm long for RF transmit and receive. Three 2-mm-thick axial MRI slices 
were acquired anterior to the pituitary gland with the imaging plane referenced to 
the tip of the pituitary in the sagittal plane. T1-weighted imaging was performed 
using the following acquisition parameters: TR/TE = 700/15 ms; FOV = 38.4 mm 
× 38.4 mm; data acquisition matrix = 256 × 128 (zero-filled to 256 × 256); and 
number of averages (NEX) = 2. The T1 relaxation times were measured using a 
spin-echo inversion recovery sequence. A sech pulse was used for adiabatic 
spin-inversion and 16 inversion time values were logarithmically spaced from 15–
3300 ms. Other imaging parameters were: TR = 10 s, TE = 4.8 ms, FOV = 38.4 
mm × 38.4 mm; data acquisition matrix = 128 × 64 (zero-filled to 128 × 128); and 
NEX = 1. T2 relaxation times were measured using a Carr-Purcell-Meiboom-Gill 
(CPMG) spin-echo sequence (TR = 2 s, TE = 5 ms, echoes = 16).  
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Figure 3.1 – ROI definitions for different brain regions. Three 2-mm-thick axial MRI 
slices (slice gap of 0.2 mm) were selected anterior to the pituitary gland with the imaging 
plane referenced to the tip of the pituitary in the sagittal plane. Representative axial 
slices from T1-weighted image of a rat after 300 mg/kg injection of MnCl2 at the 24 h 
time point are shown (right) correlated with corresponding schematic brain slices from 
the rat brain atlas (1). The schematic brain slices correspond to the initial part of the 2-
mm-thick MR image slices. The ROI along the perimeter of the brain corresponds to the 
right and left cortex ROIs in all the three slices. These ROIs were averaged together to 
obtain an averaged cortex ROI. The left and right ROIs at the center of the brain in Slice 
1 and Slice 2 were averaged together to obtain an averaged sub-cortical ROI. The left 
and right ROIs in Slice 3 were averaged together to obtain an averaged caudate nucleus 
ROI.  
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3.5.3. Data Analysis 
Using the ImageJ software package (26), three different regions of interest 
(ROI) were selected: cortex, sub-cortical region, and caudate nucleus, from the 
collected slices as shown in Fig. 3.1. They were correlated with the 
corresponding schematic slices from the rat brain atlas (1). The mean signal 
intensity values within each of the ROIs were calculated using ImageJ and non-
linear least squares fitting calculations were performed using MATLAB (The 
Mathworks Inc., Natick, MA). For each animal, the signal intensity data obtained 
from inversion recovery MRI was fit using Eqn. [3.1]. Mean T1 relaxation time 
values were obtained for each ROI. Student‟s paired t test was performed to 
check for any significant changes in T1 relaxation time between different doses 
on Mn2+ administered. Note that ANOVA measurements on monoexponential T1 
measurements were performed and are reported in a separate study in Chapter 
5 of this dissertation. 
The signal intensity data was also fit using variants of Eqn. [3.3] and semi-
log plots (procedures explained in the Simulation Study Section) to extrapolate 
the short and long effective T1 relaxation times (T’1a and T’1b) and the 
corresponding effective volume fractions (M’0a and M’0b). Mean values of T’1b 
and M’0b (from semi-log plots) were obtained for each ROI of each animal. 
Analysis of variance (ANOVA) for mixed models was used to determine if there 
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was a significant change in T’1b and M’0b values: 1) after the administration of 
Mn2+, 2) at the different doses of Mn2+ administered via the SC route, and 3) due 
to interaction between the time after Mn2+ injection and the Mn2+ dose 
administered. In the presence of significant effects (main or interaction), the 
Tukey-Kramer HSD multiple comparisons procedure was used to compare the 
mean T1 times of the same anatomical region between different time points and 
to determine if any difference existed among various Mn2+ doses administered. 
Statistical analyses were carried out using the SAS statistical software package. 
 To determine which model (monoexponential or biexponential) better 
represented the normalized data, the 2 statistics for the monoexponential 
(2monoexp) and biexponential (
2
biexp) models were compared using an F test 
based on a variant of the reduced 2-squares ratio: 
  
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2
expbi
expbiexpmono
2
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2
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),( expbiexpbiexpmono
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               [3.8] 
where υmonoexp and υbiexp are the number of degrees of freedom corresponding to 
2monoexp and 
2
biexp for the monoexponential and biexponential model, 
respectively (27). For this study, the F statistic ratio simplifies to: 
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where N is the number of data points. This ratio measures how much the 
additional exponential term in the biexponential model improves the reduced 2 
by taking into account the number of parameters in the fitting equation (28). This 
calculated F statistic was compared to tabulated values of the F statistic with 1 
and N – 4 degrees of freedom. If the F statistic was greater than the tabulated F 
value for the desired statistical confidence, then the biexponential model was 
accepted as the better fitting model for the data. If the F statistic was less than 
the tabulated F value, then the monoexponential model was chosen for fitting the 
data. 
 
3.6. Results 
3.6.1. Dose Dependence and Time Course of Manganese Distribution 
 Fig. 3.2 shows a series of T1-WT MEMRI data sets of Slice 3 (defined in 
Fig. 3.1) in the rat brain both as a function of varying doses of Mn2+ and as a 
function of time after SC administration of Mn2+. At 6 h following Mn2+ injection, 
T1-WT signal enhancement was apparent around the ventricle regions (which 
contain the CSF) at all doses. With time, the T1-WT signal enhancement 
uniformly expanded to the cortical and sub-cortical regions. Uniform 
enhancement was achieved throughout the brain by the 72 h time point at all 
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administered Mn2+ doses. The T1-WT signal enhancement persisted in all the 
images up to the 168 h time point for all Mn2+ doses. The T1-WT signal 
enhancement was proportional to the dose of Mn2+ administered: image slices at 
300 mg/kg showed the most T1-WT signal enhancement while the image slices at 
75 mg/kg showed the least T1-WT signal enhancement at all time points 
observed (data not shown). 
 
3.6.2. Time Course and Dose Dependence of Monoexponential T1 Values 
 The temporal evolution of monoexponential T1 relaxation times at three 
different doses of Mn2+ in the cortex region of the rat brain is shown in Fig. 3.3A. 
The T1 relaxation times reduced steadily from 1156 ± 79 ms and leveled off near 
the 72 h time point. The largest reduction in the T1 relaxation time (~407 ms) was 
observed at the highest Mn2+ dose administered (300 mg/kg) and the smallest 
reduction in the T1 relaxation time (~258 ms) was observed at the lowest Mn
2+ 
dose administered (75 mg/kg). Student‟s paired t test showed a significant 
differences in monoexponential T1 relaxation times between different doses of 
Mn2+ administered as indicated in Fig. 3.3A. 
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Figure 3.2 – Dose dependence and time-course of MEMRI contrast. T1-weighted (T1-
WT) axial MR image sets (TR/TE = 700/15 ms) of Slice #3 from Fig. 3.1 are shown as a 
function of varying doses of MnCl2 and as a function of time after subcutaneous injection 
of MnCl2. T1-WT signal enhancement was apparent in all the 2-mm-thick slices around 
the ventricle regions which contain the cerebrospinal fluid. Over time, the region of T1-
WT signal enhancement expanded to the cortical and sub-cortical regions. The images 
at 75 mg/kg and 150 mg/kg achieved uniform enhancement throughout the brain by the 
24 h time point, whereas the image at 300 mg/kg achieved uniform enhancement by the 
72 h time point (see Fig. 3.1). The T1-WT signal enhancement was proportional to the 
dose of MnCl2 administered: image slices at 300 mg/kg showed the most T1-WT signal 
enhancement while the image slices at 75 mg/kg showed the least T1-WT signal 
enhancement at all time points observed (data not shown). All images have the same 
relative intensity scaling; therefore, changes in T1-WT signal contrast are directly 
proportional to changes in tissue Mn2+ concentration over time. These images were 
filtered to remove high-intensity pixel artifacts caused by motion. 
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 Fig. 3.3B shows the temporal evolution of monoexponential T1 relaxation 
times at three different doses of Mn2+ in the sub-cortical region of the rat brain. 
The T1 relaxation times reduced steadily from 959 ± 74 ms and leveled off near 
the 72 h time point similar to the cortex region in Fig. 3.3A. However, the 
reduction in T1 relaxation times was greater in the sub-cortical region than that 
observed in the cortex region at the same administered dose. The largest 
reduction in the T1 relaxation time (~448 ms) was observed at the highest Mn
2+ 
dose administered (300 mg/kg) and the smallest reduction in the T1 relaxation 
time (~320 ms) was observed at the lowest Mn2+ dose administered (75 mg/kg). 
Student‟s paired t test showed significant differences in monoexponential T1 
relaxation times between different doses of Mn2+ administered as indicated in 
Fig. 3.3B. These differences were more significant than that observed in the 
cortex region. 
 The temporal evolution of monoexponential T1 relaxation times at three 
different doses of Mn2+ in the caudate nucleus region of the rat brain is shown in 
Fig. 3.3C. The T1 relaxation times reduced steadily from 1033 ± 84 ms and 
leveled off near the 72 h time point similar to the cortex and sub-cortical regions; 
however, the reduction in T1 relaxation times was greater in the caudate nucleus 
region than that observed in the cortex region and similar to that observed in the 
sub-cortical region at the same administered dose. The largest reduction in the 
T1 relaxation time (~515 ms) was observed at the highest Mn
2+ dose 
administered (300 mg/kg) and the smallest reduction in the T1 relaxation time 
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(~343 ms) was observed at the lowest Mn2+ dose administered (75 mg/kg). 
Student‟s paired t test showed significant differences in monoexponential T1 
relaxation times between different doses of Mn2+ administered as indicated in 
Fig. 3.3C. These differences were more significant than that observed in the 
cortex region. 
 
 
 
P a g e  | 79 
 
 
 
 
 
 
 
 
 
3.6.3. Time Course & Dose Dependence of the Effective Long T1 
Relaxation Time (T’1b) 
 The temporal evolution of the effective long T1 relaxation time (T’1b) at 
three different doses of Mn2+ in the cortex region of the rat brain is shown in Fig. 
Figure 3.3 – Bar-plots of in vivo monoexponential T1 relaxation times as a function of 
time after subcutaneous injection of MnCl2 at three different doses in A) cortex ROI, B) 
sub-cortical region ROI, and C) caudate nucleus ROI. A total of 13 animals were used in 
this study with the following Mn2+ doses: 75 mg/kg (N=3), 150 mg/kg (N=3), and 300 
mg/kg (N=7). Three of the thirteen animals were imaged before administration of MnCl2. 
All the animals were imaged at the following time points after MnCl2 injection: 6, 24, 72, 
and 168 h. Some animals were also imaged at 12 h and 48 h. For each ROI, the mean 
(+1 SD) ROI monoexponential T1 relaxation times were plotted against the time point 
after Mn2+ injection for all animals at the same administered dose. Statistical 
comparisons between the different time points at each ROI were performed using 
Student‟s paired t test. *0.01 < P < 0.05 (Student‟s t test using multiple comparisons), 
**0.001 < P < 0.01, and ***P < 0.001. 
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3.4A. The T1 relaxation times reduced steadily from 1160 ± 88 ms and leveled off 
near the 72 h time point. The largest reduction in the T1 relaxation time (~415 
ms) was observed at the highest Mn2+ dose administered (300 mg/kg) and the 
smallest reduction in the T1 relaxation time (~275 ms) was observed at the lowest 
Mn2+ dose administered (75 mg/kg). Fig. 3.5A shows the same information as 
Fig. 3.4A with the effective long T1 relaxation times plotted as a function of Mn
2+ 
dose at different time points after Mn2+ injection. In Fig. 3.5A, the effective long T1 
relaxation times reduced with increasing Mn2+ dose. The largest reduction in the 
T1 relaxation times occurred at the 72 h and 168 h time points. ANOVA test for 
mixed models showed a significant effect of Mn2+ dose (P < 0.01) and time point 
after Mn2+ injection (P < 0.0001) on the reduction of the effective long T1 
relaxation times. There was no significant effect of the interaction between the 
Mn2+ dose and time after Mn2+ injection. Table 3.1 and Table 3.2 show the 
statistical significance of differences of least square means of the effective long 
T1 relaxation times between the different time points after Mn
2+ injection and 
between the different Mn2+ doses administered, respectively, in the cortex region. 
 Fig. 3.4B shows the temporal evolution of the effective long T1 relaxation 
times at three different doses of Mn2+ in the sub-cortical region of the rat brain. 
The effective long T1 relaxation times reduced steadily from 950 ± 108 ms and 
leveled off near the 72 h time point similar to the cortex region in Fig. 3.4A; 
however, the reduction in effective long T1 relaxation times was greater in the 
sub-cortical region than that observed in the cortex region at the same 
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administered dose. The largest reduction in the effective long T1 relaxation time 
(~420 ms) was observed at the highest Mn2+ dose administered (300 mg/kg) and 
the smallest reduction in the effective long T1 relaxation time (~340 ms) was 
observed at the lowest Mn2+ dose administered (75 mg/kg). Fig. 3.5B shows the 
same information as Fig. 3.4B with the effective long T1 relaxation times plotted 
as a function of Mn2+ dose at different time points after Mn2+ injection. In Fig. 
3.5B, the effective long T1 relaxation times reduced with increasing Mn
2+ dose 
similar to the cortex region in Fig. 3.5A; however, the reduction in effective long 
T1 relaxation times of the sub-cortical region was greater than that of the cortex 
region. The largest reduction in the effective long T1 relaxation times occurred at 
the 72 h and 168 h time points. ANOVA test for mixed models showed a 
significant effect of Mn2+ dose (P < 0.01) and time point after Mn2+ injection (P < 
0.0001) on the reduction of the effective long T1 relaxation times. The interaction 
between the Mn2+ dose and time after Mn2+ injection was not significant. Table 
3.1 and Table 3.2 show the statistical significance of differences of least square 
means of effective long T1 relaxation times between the different time points after 
Mn2+ injection and between the different Mn2+ doses administered, respectively, 
in the sub-cortical region. 
 The temporal evolution of the effective long T1 relaxation times at three 
different doses of Mn2+ in the caudate nucleus region of the rat brain is shown in 
Fig. 3.4C. The effective long T1 relaxation times reduced steadily from 1083 ± 
144 ms and leveled off near the 72 h time point similar to the cortex and sub-
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cortical regions; however, the reduction in effective long T1 relaxation times was 
greater in the caudate nucleus region than that observed in the cortex region and 
similar to that observed in the sub-cortical region at the same administered dose. 
The largest reduction in the effective long T1 relaxation time (~580 ms) was 
observed at the highest Mn2+ dose administered (300 mg/kg) and the smallest 
reduction in the effective long T1 relaxation time (~415 ms) was observed at the 
lowest Mn2+ dose administered (75 mg/kg). Fig. 3.5C shows the same 
information as Fig. 3.4C with the effective long T1 relaxation times plotted as a 
function of Mn2+ dose at different time points after Mn2+ injection. In Fig. 3.5C, the 
effective long T1 relaxation times reduced with increasing Mn
2+ dose similar to 
the cortex and sub-cortical regions; however, the reduction in effective long T1 
relaxation times of the caudate nucleus region was greater than that of the cortex 
region and similar to that of the sub-cortical region. The largest reduction in the 
effective long T1 relaxation times occurred at the 72 h and 168 h time points. 
ANOVA test for mixed models showed a significant effect of Mn2+ dose (P < 
0.001) and time point after Mn2+ injection (P < 0.0001) on the reduction of 
effective long T1 relaxation times. There was no significant effect of the 
interaction between the Mn2+ dose and time point after Mn2+ injection. Table 3.1 
and Table 3.2 show the statistical significance of differences of least square 
means of effective long T1 relaxation times between the different time points after 
Mn2+ injection and between the different Mn2+ doses administered, respectively, 
in the caudate nucleus region. 
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Figure 3.4 – Plots of in vivo effective long T1 relaxation times (T’1b) as a function of time 
after subcutaneous injection of MnCl2 at three different doses (75 mg/kg, 150 mg/kg, and 
300 mg/kg) in A) cortex ROI, B) sub-cortical region ROI, and C) caudate nucleus ROI. 
All the animals were imaged at the following time points after MnCl2 injection: 6, 24, 72, 
and 168 h. For each ROI, the mean (–1 SD) ROI effective long T1 relaxation times were 
plotted against the time point after Mn2+ injection for all animals at the same 
administered dose. Statistical comparisons between the different time points at each 
ROI were performed using analysis of variance (ANOVA) shown in Table 3.1. 
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Table 3.1 
Statistical Significance of Differences of Least Squares Means of Effective Long 
T1 Relaxation Times in the Rat Brain Between the Different Mn
2+ Doses 
Administered. NS = not significant (P > 0.05), *0.01 < P < 0.05 (ANOVA with 
Tukey-Kramer HSD multiple comparisons procedure), **0.001 < P < 0.01, and 
***P < 0.001. 
 
 Mn2+ dose (mg/kg) 
Cortex 
 150 300 
75 NS ** 
150 - * 
Sub-cortical Region 
 150 300 
75 NS * 
150 - * 
Caudate Nucleus 
 150 300 
75 NS *** 
150 - ** 
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Figure 3.5 – Plots of the in vivo effective long T1 relaxation times as a function of Mn
2+ 
dose administered at four different time points in A) cortex ROI, B) sub-cortical ROI, 
and C) caudate nucleus ROI. These plots contain the same information as the 
respective plots in Fig. 3.4 representing the data as a function of dose instead of time. 
For each ROI, the mean (–1 SD) ROI effective long T1 relaxation times were plotted 
against Mn2+ dose for all animals at the same time point after Mn2+ injection. Statistical 
comparisons between the different Mn2+ doses at each ROI were performed using 
analysis of variance (ANOVA) shown in Table 3.2. 
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Table 3.2 
Statistical Significance of Differences of Least Squares Means of Effective Long 
T1 Relaxation Times in the Rat Brain Between the Different Time Points after 
Mn2+ Administration. NS = not significant (P > 0.05), *0.01 < P < 0.05 (ANOVA 
with Tukey-Kramer HSD multiple comparisons procedure), **0.001 < P < 0.01, 
and ***P < 0.001. 
 
 Time after Mn2+ injection (hrs) 
Cortex 
 24 72 168 
6 *** *** *** 
24 - ** * 
72 - - NS 
Sub-cortical Region 
 24 72 168 
6 *** *** *** 
24 - * ** 
72 - - NS 
Caudate Nucleus 
 24 72 168 
6 *** *** *** 
24 - * ** 
72 - - NS 
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3.6.4. Time Course of the Effective Volume Fraction of the Long T1 
Component (M’0b) 
 The temporal evolution of the effective volume fraction of the long T1 
component (M’0b) at three different doses of Mn
2+ in the cortex, sub-cortical, and 
caudate nucleus regions of the rat brain are shown in Figs. 3.6A, 3.6B, and 3.6C, 
respectively. The effective volume fraction values varied between approximately 
0.9 and 1 for all Mn2+ doses administered at all the time points. Thus, the 
effective long T1 component was associated with the effective large volume 
fraction. There were no significant effects of Mn2+ dose and time point after Mn2+ 
injection on the effective volume fraction of the long T1 component in all three 
ROIs.  
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Figure 3.6 – Plots of in vivo effective volume fraction of long T1 component as a 
function of time after subcutaneous injection of MnCl2 at three different doses in A) 
cortex ROI, B) sub-cortical region ROI, and C) caudate nucleus ROI. For each ROI, the 
mean (–1 SD) ROI effective volume fraction of long T1 component were plotted against 
the time point after Mn2+ injection for all animals at the same administered dose. There 
were no statistically significant differences between either different time points or 
different Mn2+ doses at each ROI using analysis of variance (ANOVA). 
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3.6.5. The Effective Short T1 Relaxation Time (T’1a) 
Table 3.3 lists the effective short T1 relaxation times (T’1a) in the cortex, 
sub-cortical, and caudate nucleus regions of the rat brain at the respective Mn2+ 
dose and time after Mn2+ injection. Values are displayed only for the MRI data 
that showed a better fit for the biexponential model [Eq. 3.2] than the 
monoexponential model [Eq. 3.1] using an F test on 2 statistics. The empty cells 
in the table showed a better fit with the monoexponential model. We can notice 
from the displayed data that the overwhelming biexponential behavior was 
observed at the highest Mn2+ dose administered (300 mg/kg). Due to the sparse 
number of animals displaying biexponential behavior, no statistical conclusions 
could be made in regards to the dependence of time after Mn2+ injection on the 
effective short T1 relaxation times. 
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Table 3.3 
Effective Short T1 Relaxation Times in the Rat Brain at Different Mn
2+ Doses and 
Time After Mn2+ Injection. The Mean Effective Short T1 Relaxation Times are 
shown in milliseconds (± 1 SD) and the number in parentheses indicates number 
of animals. The values displayed in the table were obtained from animals that 
showed statistical significance of biexponential over monoexponential model of 
inversion MRI data using F-statistics. The monoexponential model was a better 
model for the animals in the empty cell groups. 
 
 
 
Time after Mn
2+
 injection (hrs) 
6 12 24 72 168 
Cortex 
M
n
2
+
 d
o
s
e
 
(m
g
/k
g
) 75 - - - - - 
150 - - - - - 
300 27±0.1 (2) 28±19 (2) 33±11 (3) 35±5 (2) 33±18 (2) 
 
Sub-cortical 
Region 
M
n
2
+
 d
o
s
e
 
(m
g
/k
g
) 75 - - - - - 
150 - - - 45 (1) - 
300 21 (1) 31 (1) 29±20 (4) 47±25 (2) 37±18 (2) 
 
Caudate 
Nucleus 
M
n
2
+
 d
o
s
e
 
(m
g
/k
g
) 75 - - - - - 
150 - - - - - 
300 24 (1) - 41±16 (3) - 23 (1) 
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3.7. Discussion 
 In order to shift the water exchange system from a fast exchange regime (
ab 
11
 >>
ab TT 11
11
 ) to a slow exchange regime (
ab 
11
 <<
ab TT 11
11
 ), a high dose 
of Mn2+ is required to affect the relaxation time of the IC compartment. We chose 
the SC route to administer Mn2+ based on a study which concluded that SC 
injection of Mn2+ affects T1 relaxation time the most compared to administration 
of Mn2+ via intravenous or intraperitoneal injection (29). We used three different 
doses on SC Mn2+ injection in an attempt to identify the dose at which the slow 
exchange regime of water becomes apparent, thereby allowing distinct 
measurements of compartmental T1 relaxation times and volume fractions. An 
attempt was made to resolve a longitudinal relaxogram for Mn2+, similar to the 
one established with EC GdDTPA2- for yeast cell suspensions by Labadie et al. 
(30). 
With a SC injection, Mn2+ primarily enters the cerebrospinal fluid via the 
choroid plexus and diffuses in the proximity of the ventricles into the sub-cortical 
region (sub-cortical region and caudate nucleus ROIs). With time, Mn2+ diffuses 
throughout the brain and eventually reaches the cortex. This is clearly evident in 
the enhanced regions (bright areas) across the brain slices in Fig. 3.2. A dose-
dependent behavior was also observed in MEMRI contrast (Fig. 3.2) which 
correlated with the monoexponential T1 relaxation times (Fig. 3.3). The general 
trend from the bar plots indicates that the monoexponential T1 relaxation time 
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significantly decreased when a higher dose of Mn2+ was administered. An 
extended dose study was done as described in Chapter 5 of this dissertation. 
Separation of IC and EC T1 relaxation times was observed only in a limited 
number of ROIs at a SC Mn2+ dose of 300 mg/kg (Table 3.3). The majority of ROI 
slices in this study depicted a monoexponential recovery of IR data. The dose-
dependent reduction of effective long T1 relaxation times in all ROIs (Fig. 3.5) 
was very similar to that of monoexponential T1 relaxation times (compare Figs. 
3.3 and 3.4) suggesting that the second T1 relaxation component is either too 
small to be detected or is completely absent. This might occur due to a decrease 
in the IC T2 value because of the presence of Mn
2+. Lowering the echo time in 
data acquisition could perhaps resolve this issue; however, we used the lowest 
possible echo time in all our experiments and thus were bound by hardware 
limits. In spite of this, several ROI slices showed a significant presence of an 
effective short T1 relaxation time (Table 3.3) with values in the range of ~30-40 
ms. From our simulation study we know that this value is approximately a 30% 
underestimate of the actual parameter. Thus, the actual effective short T1 
relaxation time falls in the range of ~43-57ms. 
The ROI slices that showed biexponential T1 relaxation times had the 
effective long T1 relaxation times (~700 ms) associated with the effective large 
volume fractions (~0.95) (Fig. 3.6) and the effective short T1 relaxation times (~50 
ms) associated with the effective small volume fractions (~0.05). These 
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associations are contrary to the hypothesis that Mn2+ enters the IC compartment. 
There are several reasons why this reverse association might occur:  
1.)  Mn2+ could be getting sequestered in the IC organelles, thereby not 
affecting the IC water T1 relaxation times significantly. The Mn
2+ that 
remains in the EC space affects the T1 relaxation time of the EC water 
since there is no Mn2+ sequestration in the EC compartment. This 
could explain the association of the long T1 relaxation time with the 
large volume fraction and the short T1 relaxation time with the small 
volume fraction. 
2.) Attenuation of the IC T2 signal from Mn
2+ entry could be killing off the 
NMR signal making it difficult to decipher the short T1 relaxation time. 
As a result, the effective long T1 relaxation time is essentially 
portraying the EC compartment T1 relaxation time. 
3.) The concentration of Mn2+ used was not enough to shift the water 
exchange system from the fast exchange regime to the slow exchange 
regime. Since most of the ROI data exhibited the monoexponential 
model as a better fit than the biexponential model, the water exchange 
system might still be in the fast exchange regime where the water 
residence times (τa and τb) dominate the effective T1 relaxation times 
instead of the compartmental T1 relaxation times. 
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3.8. Conclusion 
 Mn2+, when injected at a high dose using the SC route, appears to give a 
local concentration of Mn2+ in the brain that might be sufficient to achieve the 
slow exchange regime for water exchange in the rat brain. Biexponential T1 
behavior was observed in some ROIs only at the highest dose of Mn2+ (300 
mg/kg) administered possibly indicating a distinction between the IC and EC 
spaces; however, the corresponding signal fractions did not agree with the 
known water volume fractions of cerebral tissue. In spite of that, this approach, 
when combined with diffusion measurements, might allow separate 
measurements of the corresponding component ADCs under both normal and 
pathological conditions. 
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CHAPTER IV 
 
SIMULATION STUDY 
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4.1. Simulation Study 
A simulation study was conducted on simulated inversion recovery (IR) 
data sets in MATLAB to assess the robustness of the biexponential fitting model 
and accuracy of the fit parameters. IR data sets were generated with two 
exponential signal recovery components, each having a known T1 value and a 
known volume fraction. These data sets were mathematically generated and 
summed together to form a biexponential IR data set. The resulting data set was 
then subjected to decomposition by adding noise to it.  Simulated IR data were 
generated and processed as illustrated in the flowchart in Fig. 4.1. Simulated IR 
data sets were generated at different signal-to-noise ratios (SNRs) for different 
combinations of the fitting parameters in Eq. [3.2]: M0a, M0b, T1a, T1b, and b. Fig. 
4.2 shows an example of simulated IR data with an SNR of ~25 (approximate 
SNR of the slice ROI data in our animal experiments). Each spectral window 
(Fig. 4.2, Top) corresponds to a single point in the inversion recovery curve (Fig. 
4.2, Bottom). The IR curve was generated with the following parameters which 
we would expect to see if Mn2+ is isolated in the IC compartment: M0a = 0.8, M0a 
= 0.2, T1a = 75 ms, T1b = 750 ms, and b = 2; i.e., Mn
2+ will reduce the IC water 
(80% water fraction) T1 relaxation time. 
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Figure 4.1 – Flowchart showing the generation of noisy inversion recovery (IR) data 
using free induction decay (FID) curves to perform simulated biexponential fitting 
analysis. 
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Figure 4.2 – Top: Sequence of spectra for noisy inversion recovery data generated at 
SNR~25 using the following parameters: M0a = 0.8, M0a = 0.2, T1a = 75 ms, T1b = 750 ms, and 
b = 2. Bottom: Simulated inversion recovery data generated from the spectra shown on 
top. Each spectral window peak is represented by a single time point in the inversion 
recovery curve. 
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Five-parameter biexponential fitting (Eq. [3.2]) showed a large degree of 
error on the fit parameters compared to the actual T1 relaxation times and their 
compartmental volume fractions. So, to increase the robustness of biexponential 
non-linear least squares fitting, the inversion recovery data were normalized and 
Eq. [3.2] was modified to Eq. [3.2a] reducing a 5-parameter fit to a 4-parameter fit 
model: 
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 [3.2a] 
where M0a is replaced by (1 – M0b).  
A 3-parameter fit model was derived from Eq. [3.2] as follows: 
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            [3.2b] 
where T1b and M0b are constants (derived from semi-log plots), and T1a and M0a 
are the short T1 relaxation time and the corresponding compartmental volume 
fraction. T1b and M0b are the long T1 relaxation time and the corresponding 
compartmental volume fraction which can be derived from semi-log plots as 
shown in Fig. 4.3. 
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Figure 4.3 – Top: Simulated biexponential inversion recovery data set from Fig. 4.2 at 
SNR~25 with the following parameters: M0a = 0.8, M0a = 0.2, T1a = 75 ms, T1b = 750 ms, and b = 
2. Bottom: Semi-log plot corresponding to the data points in the encircled region on the 
top graph. The semi-log plot can clearly distinguish between the two different slopes 
(dotted lines) which correspond to the two different T1 relaxation times. 
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 In the ROI IR data sets obtained from our animal experiments, the long T1 
relaxation time from biexponential IR did not necessarily correspond to the 
smaller volume fraction. To validate errors in fits due to mixed volume fractions, 
we ran several simulation scenarios with the 3- and 4-parameter fit models 
assigning the long T1 relaxation time to the large volume fraction and the short T1 
relaxation time to the small volume fraction and vice versa. As seen in Figs. 4.4 
and 4.5, simulations were run with different ratios of the T1 relaxation times and 
the volume fractions. Our experimental data happened to fall in the category of 
the circled graph shown in Figs. 4.4 and 4.5: the ratio of the short to long T1 
relaxation times was ~1:10 and the ratio of the small to large volume fractions 
was also ~1:10.  
However, contrary to our hypothesis that the long T1 relaxation time will be 
associated with the small volume fraction, we found in all our animal experiments 
that the long T1 relaxation time was always associated with the larger volume 
fraction. This would increase the error in the fitting for the smaller T1 relaxation 
time using the 3-parameter fit (Eq. [3.2b]) as illustrated in the circled graph in Fig. 
4.4: after 100 fits, the error in the short T1 relaxation time was ~130% (a specified 
value of 75 ms returned a fit value of 172±73 ms in 100 runs). On the contrary, 
when the long T1 relaxation time is associated with the smaller volume fraction 
(data not shown), the error associated with short T1 relaxation time was only ~5% 
(a specified value of 75 ms returned a fit value of 71±2 ms in 100 runs). 
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Thus, for all our experimental data, we used the semi-log plots to calculate 
the long T1 relaxation time and the large volume fraction. This inherently provided 
us with the small volume fraction since we fit normalized data. The short T1 
relaxation time was difficult to decipher in the semi-log plots due to the 
association of the small volume fraction with the short T1 relaxation time; thus, we 
used the 4-parameter fit model (Eq. [3.2a]) to calculate the short T1 relaxation 
time even though the fit values underestimated the actual short T1 relaxation time 
as shown in Fig. 4.5 (error with the 4-parameter fit was ~30% compared to 
~130% for the 3-parameter fit). The error associated with fitting the short T1 
relaxation time using the 4-parameter model may still cause a misrepresentation 
of the actual short T1 relaxation time. From 100 fits of simulated IR data, a 
specified value of 75 ms returned a fit value of 53±79 ms (Fig. 4.5). Even though 
the error is ~30%, the standard deviation associated with the fit is quite large. 
This might further introduce errors in the calculated value of the short T1 
relaxation times in our experimental data. 
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Figure 4.4 – Biexponential fitting of simulated inversion recovery data with the 3-
parameter model (Eq. [3.2a]) at SNR~25 with different ratios of the T1 relaxation times 
and the volume fractions. The long T1 relaxation times are associated with the large 
volume fractions and the short T1 relaxation times are associated with the small volume 
fractions.  In each graph, the first, second, third, and fourth columns show the parameter 
labels, the specified input parameters, the fit parameter average of 100 fits, and the 
standard deviation of the fit parameter in 100 runs, respectively. The encircled graph 
shows the ratios of T1 relaxation times and volume fractions that we observed in our 
animal experiments. Notice, the error in the short T1 relaxation time was ~130% (a 
specified value of 75 ms returned a fit value of 172±73 ms). 
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Figure 4.5 – Biexponential fitting of simulated inversion recovery data with the 4-
parameter model (Eq. [3.2b]) at SNR~25 with different ratios of the T1 relaxation times 
and the volume fractions. The long T1 relaxation times are associated with the large 
volume fractions and the short T1 relaxation times are associated with the small volume 
fractions.  In each graph, the first, second, third, and fourth columns show the parameter 
labels, the specified input parameters, the fit parameter average of 100 fits, and the 
standard deviation of the fit parameter in 100 runs, respectively. The encircled graph 
shows the ratios of T1 relaxation times and volume fractions that we observed in our 
animal experiments. Notice, the error in the short T1 relaxation time was ~30% (a 
specified value of 75 ms returned a fit value of 53±79 ms). 
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5.1. Preface 
 This study was done to investigate the MRI dose response of manganese 
(Mn2+) in the rat brain following subcutaneous administration of MnCl2. I 
completed all aspects of this study by performing animal injections, collecting 
NMR data, reconstructing images, MATLAB programming for image analysis, 
and principal authorship in the writing of the manuscript. The manuscript work is 
in progress to be submitted for publication. 
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5.2. Abstract 
Divalent manganese ion (Mn2+) is a widely used T1 contrast agent in 
manganese-enhanced MRI (MEMRI) studies to visualize functional neural tracts 
and anatomy in the brain in vivo. In animal studies, the goal is to use a dose of 
Mn2+ that will maximize the contrast while minimizing its toxic effects. In rodents, 
systemic administration of Mn2+ via intravenous (IV) injection creates a unique 
MRI contrast in the brain at a maximum dose of 175 mg/kg. The subcutaneous 
(SC) route can deliver Mn2+ at a maximum dose of 320 mg/kg (LD50 value). 
However, IV administration of Mn2+ results in faster bioelimination of excess Mn2+ 
from the plasma due to a steep concentration gradient between plasma and bile. 
By contrast, following SC injection, Mn2+ is released more slowly into the 
bloodstream, thus avoiding immediate hepatic elimination. Therefore, SC 
administration of Mn2+ will result in prolonged accumulation of Mn2+ in the brain 
via the choroid plexus than that obtained via IV administration of Mn2+. The goal 
of this study was to investigate the MRI dose response of Mn2+ in rat brain 
following SC administration of Mn2+. The dose dependence and temporal 
dynamics of Mn2+ after SC injection can prove useful for longitudinal in vivo 
studies that require brain enhancement to persist for a long period of time to 
visualize neuroarchitecture like in neurodegenerative disease studies. 
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5.3. Introduction 
 Divalent manganese ion (Mn2+) is a widely used T1 contrast agent in 
manganese-enhanced MRI (MEMRI) studies for animal neuroimaging. Mn2+ is 
highly paramagnetic making it an excellent contrast agent for visualizing brain 
neuroarchitecture. Applications of MEMRI have been described in three main 
areas as outlined by Silva et al. (1): neuronal tract tracing, activation-induced 
MEMRI (AIM-MEMRI), and whole-brain contrast enhancement. In neuronal tract 
tracing, Mn2+ is directly injected into a specific brain region; for the other two 
MEMRI applications, Mn2+ is administered either systemically into the 
bloodstream via intraperitoneal (IP) (2-4), intravenous (IV) (2,5,6) or 
subcutaneous (SC) (2,7-9) injections, or directly into the cerebrospinal fluid 
(CSF) via intrathecal (10) or intracerebroventricular injection (8,11).  
Under normal conditions, Mn2+ in the bloodstream gains entry into the 
brain through facilitated transport in the capillary endothelial cells of the blood-
brain barrier, and by filtration through the choroid plexus of the blood-CSF barrier 
which delivers Mn2+ directly into the ventricles (12). However, at high systemic 
doses, transport across the blood-brain barrier is saturated; so, Mn2+ primarily 
enters the CSF via the choroid plexus (13,14). Mn2+ acts as calcium ion (Ca2+) 
analog and enters the neuronal intracellular space via voltage-gated calcium 
channels (15) following neuronal activation (16-19) and accumulates in the 
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intracellular compartment. T1-weighted (T1-WT) MRI can then readily detect a 
reduction of regional water proton T1 due to the paramagnetic Mn
2+. 
In MEMRI applications involving systemic administration of Mn2+, the 
concentration of Mn2+ needs to be sufficiently high in order to attain better MR 
contrast and signal-to-noise ratio. However, Mn2+ is toxic at high concentrations 
producing both systemic and neurological effects (20,21). When administered in 
low doses, only a small fraction of Mn2+ reaches the brain. Disruption of the 
blood-brain barrier is an option where even at a low dose Mn2+ can gain access 
to the brain achieving efficient detection by MRI (1,22). Since the concentration 
of Mn2+ accumulation in the brain is proportional to the Mn2+ dose administered 
systemically, the easiest alternative without compromising the blood-brain barrier 
is to deliver a relatively high dose of Mn2+ while staying within the limits of toxic 
effects. 
The maximum dose of Mn2+ administered in MEMRI studies in rodent 
brains vary depending upon the route of administration taken. The maximum 
nontoxic dose of Mn2+ administered via IV injection ranges between 175–180 
mg/kg (1,23). The maximum nontoxic Mn2+ dose administered via the IP route in 
previous MEMRI studies has been 100 mg/kg (2,24). Via the SC route, we found 
a maximum nontoxic dose of 200 mg/kg (2) administered. In comparison to IV 
and IP injections, SC injection leads to a slower release of Mn2+ into the 
bloodstream, thus avoiding the „first wave‟ hepatic loss (25). Therefore, a much 
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larger dose of Mn2+ can be injected via the SC route while minimizing any acute 
effects on the cardiovascular system; any higher dose of Mn2+ via IV or IP route 
will exceed the LD50 values, thereby increasing the likelihood of mortality due to 
toxic effects of Mn2+. 
In this study, dose dependence and temporal evolution of T1 relaxation 
time was investigated in the rat brain using SC injection of Mn2+ at doses up to 
300 mg/kg, which is slightly less than the LD50 value of 320 mg/kg (Source: 
Material Safety Data Sheet for MnCl2; product number M3634, Sigma-Aldrich, 
Castle Hill, Australia). Most MEMRI studies report the time course of contrast 
enhancement in different regions of the brain at a single dose of MnCl2.  Fewer 
studies have quantified the T1 values of different brain regions at their respective 
administered dose (2,5,6,9,10,23,26). Only a single study to date has 
investigated dose dependence and temporal evolution with calculated T1 values 
using IV injection of Mn2+ in the mouse brain (5). In this study, we looked at dose 
effects from 6–168 hrs and at doses up to 300 mg/kg in the rat brain. Dose 
effects were quantified by calculating T1 values of different brain regions.  
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5.4. Materials and Methods 
5.4.1. Animal preparation 
All procedures were performed as approved by the Institute Animal Care 
and Use Committee (IACUC) of the University of Massachusetts Medical School 
(Worcester, MA, USA).  Adult male Sprague-Dawley rats (weighing from 200-450 
g) were anesthetized using 5% isoflurane. MnCl2 (Sigma-Aldrich, St. Louis, MO, 
USA) was administered via SC injection at three different doses: 75 mg/kg using 
25 mM MnCl2 (N=3), 150 mg/kg using 50 mM MnCl2 (N=3), and 300 mg/kg using 
100 mM MnCl2 (N=6). Different concentrations of Mn
2+ were used for the three 
administered doses to ensure an approximately equal volume of MnCl2 solution 
injection. The SC injections were administered on the dorsal region, bilaterally, 
slightly posterior to the midline. Following the injection, rats were returned to their 
cages and allowed normal access to food and water.  
During the imaging sessions, animals were anesthetized with 3% 
isoflurane. After anesthesia was induced, the anesthetic level was reduced to 
2%. The head of the anesthetized animal was positioned in a birdcage RF coil 
with a nose cone providing a continuous supply of the anesthetic. The animals 
were placed prone into the magnet bore. A respiratory sensor was placed on the 
chest area to monitor the respiration rate throughout the imaging session. 
MEMRI was performed on each animal before SC injection of Mn2+, and then at 
6, 12, 24, 72, and 168 h after Mn2+ injection. 
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5.4.2. MR Measurements 
5.4.2.1. MnCl2 Phantom Experiments 
Nine 1-cm spherical phantoms containing MnCl2 standards (25, 50, 100, 
250, 500, 1000, 2000, 3000, and 5000 µM) were prepared in PBS. T1 relaxation 
time measurements were performed using inversion recovery spectroscopy with 
20 inversion time values logarithmically spaced from 15–4400 ms. Other 
parameters were: TR = 10 s, TE = 7.4 ms, field-of-view (FOV) = 103.4 mm × 
103.4 mm; data acquisition matrix = 128 × 128. With the same dimensions, T2 
relaxation time measurements were performed using a Carr-Purcell-Meiboom-
Gill (CPMG) sequence. At least sixteen echoes were acquired with intervening 
TE values of 7 ms and TR = 2 s. 
 
5.4.2.2. MEMRI Experiments 
All MR imaging was performed on a Bruker BioSpin 2.0-T/45-cm 
horizontal bore system (Bruker BioSpin, Billerica, MA, USA) equipped with 200 
mT/m gradients and an in-house-built, 45-mm-diameter, birdcage RF coil that 
was 30 mm long for RF transmit and receive. Three 2-mm-thick axial MRI slices 
(slice gap of 0.2 mm) were acquired anterior to the pituitary gland with the 
imaging plane referenced to the tip of the pituitary in the sagittal plane. T1-
weighted imaging was performed using the following acquisition parameters: 
P a g e  | 121 
 
TR/TE = 700/15 ms; FOV = 38.4 mm × 38.4 mm; data acquisition matrix = 256 × 
128 (zero-filled to 256 × 256); and number of averages (NEX) = 2. The T1 
relaxation times were measured using a spin-echo inversion recovery sequence. 
A sech pulse was used for adiabatic spin-inversion and 16 inversion time values 
were logarithmically spaced from 15–3300 ms. Other imaging parameters were: 
TR = 10 s, TE = 4.8 ms, FOV = 38.4 mm × 38.4 mm; data acquisition matrix = 
128 × 64 (zero-filled to 128 × 128); and NEX = 1. T2 relaxation times were 
measured using a Carr-Purcell-Meiboom-Gill (CPMG) spin-echo sequence (TR = 
2 s, TE = 5 ms, echoes = 16).  
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Figure 5.1 – ROI definitions for different brain regions. Three 2-mm-thick axial MRI 
slices (slice gap of 0.2 mm) were selected anterior to the pituitary gland with the imaging 
plane referenced to the tip of the pituitary in the sagittal plane. Representative axial 
slices from T1-weighted image of a rat after 300 mg/kg injection of MnCl2 at the 24 h time 
point are shown (right) correlated with corresponding schematic brain slices from the rat 
brain atlas (27). The schematic brain slices correspond to the initial part of the 2-mm-
thick MR image slices. The ROI along the perimeter of the brain corresponds to the right 
and left cortex ROIs in all the three slices. These ROIs were averaged together to obtain 
an averaged cortex ROI. The left and right ROIs at the center of the brain in Slice 1 and 
Slice 2 were averaged together to obtain an averaged sub-cortical ROI. The left and 
right ROIs in Slice 3 were averaged together to obtain an averaged caudate nucleus 
ROI. This figure is identical to Fig. 3.1. 
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5.4.3 Data Analysis 
Using the ImageJ software package (28), three different regions of interest 
(ROI) were selected (cortex, sub-cortical region, and caudate nucleus) from the 
collected slices as shown in Fig. 5.1 and correlated with the corresponding 
schematic slices from the rat brain atlas (27). Due to the position of the brain 
slices and relatively low resolution to capture detailed neuroarchitecture, the 
ROIs were selected accordingly where all relaxation time measurements from 
these regions represent an average over the heterogeneity within the tissues in 
the ROIs. The mean signal intensity values within each of the ROIs were 
calculated using ImageJ and non-linear least squares fitting calculations were 
performed using MATLAB (The Mathworks Inc., Natick, MA) to calculate the 
relaxation times. Analysis of variance (ANOVA) for mixed models was used to 
determine if there was a significant change in T1 relaxation times: 1) after the 
administration of Mn2+, 2) at the different doses of Mn2+ administered via the SC 
route, and 3) due to interaction between the time after Mn2+ injection and the 
Mn2+ dose administered. In the presence of significant effects (main or 
interaction), the Tukey-Kramer HSD multiple comparisons procedure was used to 
compare the mean T1 times of the same anatomical region among different time 
points and to determine if any difference existed between the different Mn2+ 
doses administered. Statistical analyses were carried out using the SAS 
statistical software package. 
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5.5 Results 
5.5.1. MnCl2 Phantoms 
 Fig. 5.2A shows a plot of R1 (1/T1) relaxation rate (s
-1) as a function of 
Mn2+ concentration (mM).  The best-fit straight line through all of the data gives: 
R1 = 7.19 ± 0.16∙[Mn
2+] (mM) + 0.15 ± 0.34 (r2 = 0.9993).The errors on the least-
square fitting parameters are ±1 SE. From the slope of the line, the r1 relaxivity of 
Mn2+ is equal to 7.19 ± 0.16 s-1mM-1. Fig. 5.2B shows a plot of R2 (1/T2) 
relaxation rate (s-1) as a function of Mn2+ concentration (mM). The best-fit straight 
line through all of the data gives: R2 = 97.4 ± 7.78∙[Mn
2+] (mM) + 4.58 ± 16.27 (r2 
= 0.9909). The errors on the least-square fitting parameters are ±1 SE. The r2 
relaxivity of Mn2+ is equal to 97.4 ± 7.78 s-1mM-1. 
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Figure 5.2 – A) Plot of R1 (1/T1) relaxation rate (s
-1) as a function of MnCl2 concentration 
(mM) at 2 Tesla. The best-fit straight line through all of the data gives: R1 = 7.19∙[MnCl2] 
(mM) + 0.15. The r1 relaxivity given by the slope of the line was equal to 7.19 s
-1mM-1. B) 
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Plot of R2 (1/T2) relaxation rate (s
-1) as a function of MnCl2 concentration (mM). The best-
fit straight line through all of the data gives: R2 = 97.4∙[MnCl2] (mM) + 4.58. The r2 
relaxivity given by the slope of the line was equal to 97.4 s-1mM-1. 
 
5.5.2. Time Course of Manganese Distribution 
 Fig. 5.3 shows a series of T1-weighted (T1-WT) MEMRI data sets as a 
function of time after SC administration of 300 mg/kg Mn2+ in the rat brain. At 6 h 
following Mn2+ injection, T1-WT signal enhancement was apparent in all three 
slices around the ventricle regions which contain the CSF. With time, the T1-WT 
signal enhancement uniformly expanded to the cortical and sub-cortical regions. 
By the 72 h time point there was a uniform enhancement throughout the brain 
which persisted up to the 168 h time point. 
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Figure 5.3 – Time-course of Mn2+ distribution in rat brain. Three-slice T1-weighted (T1-
WT) axial MR image sets (TR/TE = 700/15 ms) are shown as a function of time after 
subcutaneous injection of MnCl2 (100 mM, dose = 300 mg/kg). At 6 h following MnCl2 
injection, T1-WT signal enhancement was apparent in the three 2-mm-thick slices around 
the ventricle regions which contain the cerebrospinal fluid. Over time, the region of T1-
WT signal enhancement expanded to the cortical and sub-cortical regions. By the 72 h 
time point there was uniform T1-WT signal enhancement throughout the brain which is 
apparent even at the 168 h time point. All images have the same relative intensity 
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scaling; therefore, changes in T1-WT signal contrast are directly proportional to changes 
in tissue Mn2+ concentration over time. These images were filtered to remove high-
intensity pixel artifacts caused by motion. 
 
5.5.3. Dose Dependence and Time Course of Manganese Distribution 
 Fig. 5.4 shows a series of T1-WT MEMRI data sets of Slice 3 in the rat 
brain (defined in Fig. 5.1) both as a function of varying doses of Mn2+ and as a 
function of time after SC administration of Mn2+. At 6 h following Mn2+ injection, 
T1-WT signal enhancement was apparent in the slices at all doses around the 
ventricle regions which contain the CSF. With time, the T1-WT signal 
enhancement uniformly expanded to the cortical and sub-cortical regions. 
Uniform enhancement was achieved throughout the brain by the 72 h time point 
at all administered Mn2+ doses. The T1-WT signal enhancement persisted in all 
the images up to the 168 h time point for all Mn2+ doses. The T1-WT signal 
enhancement was proportional to the dose of Mn2+ administered: image slices at 
300 mg/kg showed the most T1-WT signal enhancement while the image slices at 
75 mg/kg showed the least T1-WT signal enhancement at all time points 
observed (data not shown). 
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Figure 5.4 – Dose dependence and time-course of MEMRI contrast. T1-weighted (T1-
WT) axial MR image sets (TR/TE = 700/15 ms) of Slice #3 from Fig. 5.1 are shown as a 
function of varying doses of MnCl2 and as a function of time after subcutaneous injection 
of MnCl2. T1-WT signal enhancement was apparent in all the 2-mm-thick slices around 
the ventricle regions which contain the cerebrospinal fluid. Over time, the region of T1-
WT signal enhancement expanded to the cortical and sub-cortical regions. The images 
at 75 mg/kg and 150 mg/kg achieved uniform enhancement throughout the brain by the 
24 h time point, whereas the image at 300 mg/kg achieved uniform enhancement by the 
72 h time point (see Fig. 5.1). The T1-WT signal enhancement was proportional to the 
dose of MnCl2 administered: image slices at 300 mg/kg showed the most T1-WT signal 
enhancement while the image slices at 75 mg/kg showed the least T1-WT signal 
enhancement at all time points observed (data not shown). All images have the same 
relative intensity scaling; therefore, changes in T1-WT signal contrast are directly 
proportional to changes in tissue Mn2+ concentration over time. These images were 
filtered to remove high-intensity pixel artifacts caused by motion. This figure is identical 
to Fig. 3.2. 
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5.5.4. Time Course and Dose Dependence of Regional T1 Values 
 The temporal evolution of T1 relaxation times at three different doses of 
Mn2+ in the cortex region of the rat brain is shown in Fig. 5.5A. The T1 relaxation 
times reduced steadily from 1156 ± 79 ms and leveled off near the 72 h time 
point. The largest reduction in the T1 relaxation time (~407 ms) was observed at 
the highest Mn2+ dose administered (300 mg/kg) and the smallest reduction in 
the T1 relaxation time (~258 ms) was observed at the lowest Mn
2+ dose 
administered (75 mg/kg). Fig. 5.6A shows the same information as Fig. 5.5A with 
the T1 relaxation times plotted as a function of Mn
2+ dose at different time points 
after Mn2+ injection. In Fig. 5.6A, the T1 relaxation times reduced with increasing 
Mn2+ dose. The largest reduction in the T1 relaxation times occurred at the 72 h 
and 168 h time points. ANOVA test for mixed models showed a significant effect 
of Mn2+ dose (P < 0.01) and time point after Mn2+ injection (P < 0.0001) on the 
reduction of T1 relaxation times. There was no significant effect of the interaction 
between the Mn2+ dose and time point after Mn2+ injection. Table 1 and Table 2 
show the statistical significance of differences of least square means of T1 
relaxation times between the different time points after Mn2+ injection and 
between the different Mn2+ doses administered, respectively, in the cortex region 
of the rat brain. 
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Figure 5.5 – Plots of in vivo T1 relaxation times as a function of time after subcutaneous 
injection of MnCl2 at three different doses in A) cortex ROI, B) sub-cortical region ROI, 
and C) caudate nucleus ROI. A total of 13 animals were used in this study with the 
following Mn2+ doses: 75 mg/kg (N=3), 150 mg/kg (N=3), and 300 mg/kg (N=7). Three of 
the thirteen animals were imaged before administration of MnCl2. All the animals were 
imaged at the following time points after MnCl2 injection: 6, 24, 72, and 168 h. For each 
ROI, the mean (–1 SD) ROI T1 relaxation times were plotted against the time point after 
Mn2+ injection for all animals at the same administered dose. Statistical comparisons 
between the different time points at each ROI were performed using analysis of variance 
(ANOVA) shown in Table 5.1. 
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Table 5.1 
Statistical Significance of Differences of Least Squares Means of T1 Relaxation 
Times Between the Different Time Points in Three Different Regions of the Rat 
Brain After SC Administration of Mn2+. NS = not significant (P > 0.05), *0.01 < P < 
0.05 (ANOVA with Tukey-Kramer HSD multiple comparisons procedure), **0.001 
< P < 0.01, and ***P < 0.001. 
 
 Time after Mn2+ injection (hrs) 
Cortex 
 24 72 168 
6 * *** *** 
24 - *** *** 
72 - - NS 
Sub-cortical Region 
 24 72 168 
6 *** *** *** 
24 - *** ** 
72 - - NS 
Caudate Nucleus 
 24 72 168 
6 *** *** *** 
24 - *** *** 
72 - - NS 
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 Fig. 5.5B shows the temporal evolution of the T1 relaxation times at three 
different doses of Mn2+ in the sub-cortical region of the rat brain. The T1 
relaxation times reduced steadily from 959 ± 74 ms and leveled off near the 72 h 
time point similar to the cortex region in Fig. 5.5A; however, the reduction in T1 
relaxation times was greater in the sub-cortical region than that observed in the 
cortex region at the same administered dose. The largest reduction in the T1 
relaxation time (~448 ms) was observed at the highest Mn2+ dose administered 
(300 mg/kg) and the smallest reduction in the T1 relaxation time (~320 ms) was 
observed at the lowest Mn2+ dose administered (75 mg/kg). Fig. 5.6B shows the 
same information as Fig. 5.5B with the T1 relaxation times plotted as a function of 
Mn2+ dose at different time points after Mn2+ injection. In Fig. 5.6B, the T1 
relaxation times reduced with increasing Mn2+ dose similar to the cortex region in 
Fig. 5.6A; however, the reduction in T1 relaxation times of the sub-cortical region 
was greater than that of the cortex region. The largest reduction in the T1 
relaxation times occurred at the 72 h and 168 h time points. ANOVA test for 
mixed models showed a significant effect of Mn2+ dose (P < 0.001) and time point 
after Mn2+ injection (P < 0.0001) on the reduction of T1 relaxation times. There 
was no significant effect of the interaction between the Mn2+ dose and time point 
after Mn2+ injection. Table 1 and Table 2 show the statistical significance of 
differences of least square means of T1 relaxation times between the different 
time points after Mn2+ injection and between the different Mn2+ doses 
administered, respectively, in the sub-cortical region of the rat brain. 
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Figure 5.6 – Plots of the in vivo T1 relaxation times as a function of Mn
2+ dose 
administered at four different time points in A) cortex ROI, B) sub-cortical ROI, and C) 
caudate nucleus ROI. These plots contain the same information as the respective plots 
in Fig. 5.5 representing the data as a function of dose instead of time. For each ROI, the 
mean (–1 SD) ROI T1 relaxation times were plotted against Mn
2+ dose for all animals at 
the same time point after Mn2+ injection. Statistical comparisons between the different 
Mn2+ doses at each ROI were performed using analysis of variance (ANOVA) shown in 
Table 5.2. 
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Table 5.2 
Statistical Significance of Differences of Least Squares Means of T1 Relaxation 
Times Between the Different Mn2+ Doses in Three Different Regions of the Rat 
Brain After SC Administration of Mn2+ Administered in the Rat Brain. NS = not 
significant (P > 0.05), *0.01 < P < 0.05 (ANOVA with Tukey-Kramer HSD multiple 
comparisons procedure), **0.001 < P < 0.01, and ***P < 0.001. 
 
 
 Mn2+ dose (mg/kg) 
Cortex 
 150 300 
75 NS ** 
150 - NS 
Sub-cortical Region 
 150 300 
75 NS *** 
150 - ** 
Caudate Nucleus 
 150 300 
75 NS *** 
150 - *** 
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 The temporal evolution of the T1 relaxation times at three different doses 
of Mn2+ in the caudate nucleus region of the rat brain is shown in Fig. 5.5C. The 
T1 relaxation times reduced steadily from 1033 ± 84 ms and leveled off near the 
72 h time point similar to the cortex and sub-cortical regions; however, the 
reduction in T1 relaxation times was greater in the caudate nucleus region than 
that observed in the cortex region and similar to that observed in the sub-cortical 
region at the same administered dose. The largest reduction in the T1 relaxation 
time (~515 ms) was observed at the highest Mn2+ dose administered (300 mg/kg) 
and the smallest reduction in the T1 relaxation time (~343 ms) was observed at 
the lowest Mn2+ dose administered (75 mg/kg). Fig. 5.6C shows the same 
information as Fig. 5.5C with the T1 relaxation times plotted as a function of Mn
2+ 
dose at different time points after Mn2+ injection. In Fig. 5.6C, the T1 relaxation 
times reduced with increasing Mn2+ dose similar to the cortex and sub-cortical 
regions; however, the reduction in T1 relaxation times of the caudate nucleus 
region was greater than that of the cortex region and similar to that of the sub-
cortical region. The largest reduction in the T1 relaxation times occurred at the 72 
h and 168 h time points. ANOVA test for mixed models showed a significant 
effect of Mn2+ dose (P < 0.0001) and time point after Mn2+ injection (P < 0.0001) 
on the reduction of T1 relaxation times. There was no significant effect of the 
interaction between the Mn2+ dose and time point after Mn2+ injection. Table 1 
and Table 2 show the statistical significance of differences of least square means 
of T1 relaxation times between the different time points after Mn
2+ injection and 
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between the different Mn2+ doses administered, respectively, in the caudate 
nucleus region of the rat brain. 
 
5.5.5. Temporal Evolution of Change in Manganese Relaxivity 
 Figs. 5.7A, 5.7B, and 5.7C show the time course of change in relaxivity 
(ΔR1) after SC injection of Mn
2+ at three different doses in the cortex region, sub-
cortical region, and caudate nucleus region of the rat brain, respectively. The 
graphs in Fig. 5.7 essentially contain the same information as Fig. 5.5. ΔR1 was 
calculated as ΔR1 = R1 – R0, where R1 is the inverse of T1 relaxation time (1/T1) 
at a given Mn2+ concentration and R0 is the inverse of T1 relaxation time without 
any injected manganese. ΔR1 corresponds to the uptake of Mn
2+ in the rat brain. 
The largest change in ΔR1 was observed at the highest Mn
2+ dose administered 
(300 mg/kg) and the smallest change in ΔR1 was observed at the lowest Mn
2+ 
dose (75 mg/kg). The maximum ΔR1 value measured in the cortex ROI was 
smaller than that in the sub-cortical region and caudate nucleus ROI for all doses 
administered. The maximum ΔR1 was observed using 300 mg/kg Mn
2+ dose at 
the 168 h time point for each ROI region: 0.47 ± 0.09 s-1 in the cortex ROI, 0.91 ± 
0.12 s-1 in the sub-cortical region ROI, and 0.96 ± 0.17 s-1 in the caudate nucleus 
ROI. 
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Figure 5.7 – Plots of change in relaxivity ΔR1 as a function of time after subcutaneous 
injection of MnCl2 at three different doses in A) cortex ROI, B) sub-cortical region ROI, 
and C) caudate nucleus ROI. These plots contain the same information as the 
respective plots in Fig. 5.5 representing the change in relaxivity as a function of time for 
quantitative comparison with other studies. For each ROI, the mean (–1 SD) ROI ΔR1 
values were plotted against the time point after Mn2+ injection for all animals at the same 
administered dose. Statistical comparisons between the different time points at each 
ROI were identical to Fig. 5.5. 
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5.6. Discussion 
This study investigated the dose dependence of Mn2+ on the T1 relaxation 
time in the rat brain following SC administration of Mn2+. The uptake of Mn2+ into 
the cells was evaluated by monitoring the temporal evolution of: 1.) MEMRI 
signal enhancement, 2.) T1 relaxation times, and 3.) change in ΔR1 in three 
different regions of the rat brain: cortex, sub-cortical region, and the caudate 
nucleus (Fig. 5.1). In this study, the r1 and r2 relaxivities of MnCl2 were measured 
(Fig. 5.2). To our knowledge, these values have not been reported at 2 T. The 
values are consistent with the extrapolated values mentioned in previous studies 
(1,29).  
Due to the high doses of Mn2+ administered in this study, there is limited 
transport of Mn2+ across the BBB; thus, Mn2+ primarily enters the CSF via the 
choroid plexus and diffuses in the proximity of the ventricles into the sub-cortical 
region (sub-cortical region and caudate nucleus ROIs). With time, Mn2+ diffuses 
throughout the brain and eventually reaches the cortex. This is clearly evident in 
the enhanced regions across the three brain slices in Fig. 5.3. However, the 
amount of Mn2+ that reaches the cortex is less compared to the amount of Mn2+ 
that is available near the sub-cortical region. Thus, greater Mn2+ uptake occurs in 
the sub-cortical region than the cortex for all the SC Mn2+ doses administered 
causing greater shortening of the T1 relaxation time in the sub-cortical region and 
caudate nucleus ROIs than the cortex ROI (Fig. 5.5). The enhancement 
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observed with a very high SC dose of Mn2+ (300 mg/kg) at the 6 h time point in 
Fig. 5.3 is in agreement with previous studies that administered Mn2+ using SC 
injection at much lower doses (7,8,30). 
SC injection of Mn2+ resulted in a dose-dependent behavior of MEMRI 
contrast (Fig. 5.4) and T1 relaxation time (Fig. 5.6) in the rat brain. Due to a 
greater presence of Mn2+ near the sub-cortical region than the cortex, the sub-
cortical region and caudate nucleus ROIs showed greater significant differences 
in T1 relaxation times between the Mn
2+ doses than the cortex ROI (Table 2). 
Proximity of the sub-cortical region and caudate nucleus ROIs to the ventricles 
exposed them to the bulk of Mn2+ that diffused from the choroid plexus into the 
CSF in the ventricles resulting in a significant dose effect.  
The dose dependent behavior of MEMRI contrast in this study is 
consistent with results from other studies. A study in the mouse brain at 11.7 T 
observed a similar dose-dependent behavior of T1 relaxation times in different 
brain regions after IV injection of Mn2+ (5). Both studies showed significant 
decreases in T 1 relaxation times with increasing Mn
2+ dose indicating a route-
independent dependence of Mn2+ dose on T 1 relaxation times (Table 2 and Fig. 
5.2b in (5)). Another study in the mouse brain at 9.4 T reported a 25% decrease 
in T 1 relaxation times in the cortex region by the 72 h time point using SC 
injection of 200 mg/kg of Mn2+ (2), while we observed a 30% decrease in the 
cortex ROI with SC injection of 300 mg/kg of Mn2+ at the same time point. Our 
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findings are consistent with the fact that a larger dose of Mn2+ causes a greater 
decrease in T 1 relaxation time.  
At 2 T, a study was done in the rat brain which reported T1 relaxation 
times during postnatal development; at 24 h post-IV Mn2+ injection of 175 mg/kg, 
they reported T1 relaxation time of 860 ± 40 ms in the cortex of 31-day old rats 
(6). Our study recorded T1 relaxation times of 895 ± 28 ms at 24 h post-SC Mn
2+ 
injection of 150mg/kg and 828 ± 69 ms at 24 h post-SC Mn2+ injection of 300 
mg/kg. Even though the route of administration and the age of rats were different 
in our study, the T1 relaxation time at 175 mg/kg of IV-Mn
2+ injection falls within 
the boundary of the T1 relaxation times at 150 mg/kg and 300 mg/kg of SC- Mn
2+ 
injection, conforming to consistent dose-dependent behavior. This comparison 
attests to the validity of our relaxation times, not just in terms of percent change 
but the actual value of the T1 relaxation times as well, since this study and our 
study were both done at 2 T. 
Following SC injection, Mn2+ gets released into the systemic circulation at 
a slow rate of absorption thus avoiding the „first wave„ of elimination via the 
hepatic system (25). Thus, uptake of Mn2+ by cells also occurs at a slow rate. 
This is demonstrated in Fig. 5.3 where enhancement of the brain slices continues 
to increase until the 72 h time point, which is consistent with the reduction in T1 
relaxation times in Fig. 5.5 at the same time point. SC delivery of Mn2+ also 
causes the Mn2+ to remain within the cells for a longer period of time before 
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being eliminated. After reaching a maximum level of enhancement in the brain 
slices by the 72 h time point (Fig. 5.3), the enhancement persisted up to the 168 
h time point. This is also supported by the statistical insignificance between the 
T1 relaxation times at the 72 h and the 168 h time point (Table 1). This 
observation is consistent with a toxicology study which reported maximum Mn2+ 
concentration levels in the rodent brain even at the 168 h time point following SC 
injection of MnCl2 (31). 
The results of prolonged enhancement obtained with SC injection of Mn2+ 
are contrary to the results of Aoki et al. (32) who injected Mn2+ via the IV route. 
When Mn2+ was administered IV at the highest non-toxic IV dose of 175 mg/kg, 
maximum enhancement was observed at the 24 h time point after which there 
was a decrease in enhancement by the 96 h time point (32). A high-dose Mn2+ 
injection directly into the plasma creates a steep concentration gradient between 
plasma and bile resulting in an immediate elimination of Mn2+ in the bile. As a 
result, lower amounts of Mn2+ reach the brain and thereby reside there for a 
shorter period of time before being eliminated by the cells. A similar result was 
observed when 50µL of 25 mM MnCl2 was administered via intrathecal injection 
in the mouse brain (10). Maximum enhancement occurred at the 48 h time point, 
and by the 96 h time point a decline in enhancement was observed. SC 
administration of Mn2+, on the other hand, results in maximum enhancement that 
persists up to at least 168 h after Mn2+ injection. 
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To compare uptake of Mn2+ across studies at different magnet strengths 
and with different administered doses of Mn2+, ΔR1 graphs can be used for 
quantitative comparison (Fig. 5.7). An MEMRI study showed that a greater 
enhancement in the brain could be achieved using the intrathecal injection as 
opposed to the IV or IP injection route with an intact BBB (10). They reported 
maximum ΔR1 values of 0.29 ± 0.13 s
-1 and 0.49 ± 0.30 s-1 in the frontal cortex 
and basal ganglia, respectively, which were achieved 3-4 days after intrathecal 
injection of 50µL of 25 mM MnCl2 and declined gradually thereafter. The volume 
and concentration combination of the injection used was optimum to avoid animal 
mortality. With the SC injection of Mn2+ at a dose of 300 mg/kg, our calculated 
ΔR1 values were approximately 1.5 times greater in the cortex ROI (compared to 
the frontal cortex) and approximately two times greater in the sub-cortical region 
ROI (compared to basal ganglia). Moreover, even after 7 days, there was no 
indication of a decline in the ΔR1 values across all ROIs using SC injection. Thus, 
a high dose SC injection of Mn2+ can achieve greater enhancement in the brain 
for a longer duration of time than that obtained with intrathecal injection. 
 
5.7. Conclusion 
This study showed a dose-dependent response of Mn2+ on T1 relaxation 
times in the cortex, sub-cortical region, and caudate nucleus ROIs in the rat brain 
following SC injection of Mn2+ which was comparable to a previous dose 
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response study using IV injection of Mn2+. This study also suggests that SC 
administration of Mn2+ at a high dose (near LD50 value) can deliver a greater 
amount of Mn2+ than the highest non-toxic dose possible with intrathecal injection 
in the rodent brain. SC administration of Mn2+ can also lead to prolonged 
enhancement in the brain than IV administration since SC route avoids the 
immediate elimination of Mn2+ from plasma via bile upon injection which occurs 
during IV injection. A high dose SC Mn2+ injection releases Mn2+ in the plasma at 
a slow rate, thus avoiding systemic toxic effects; the same high dose Mn2+ 
injection via IV route releases the entire dose directly into the plasma which can 
lead to cardiac dysfunction. The dose dependence and temporal dynamics of 
Mn2+ after SC injection can prove useful for longitudinal in vivo studies that 
require brain enhancement to persist for a long period of time to visualize 
neuroarchitecture like in Alzheimer‟s disease, Parkinson‟s disease, amyotrophic 
lateral sclerosis, and other neurodegenerative diseases. 
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6.1. Preface 
 This study was done to target EGF receptors in human glioma model 
using MR signal-amplifying enzymes. My contributions to this work were 
collection of the NMR data, reconstructing images, MATLAB programming for 
image analysis, development of mathematical models and statistical analysis of 
contrast washout kinetics, and principal authorship in the writing of the 
manuscript. This work has been submitted to Cancer Research (2010, in review). 
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6.2. Abstract 
The imaging of EGF receptors in brain tumors is essential for visualizing 
overexpression of EGFRvIII variant as a signature of highly aggressive gliomas 
and for identifying patients that would benefit from anti-EGFR therapy. We tested 
a novel pretargeting imaging approach that includes the administration of 
humanized monoclonal antibody (anti-EGFR mAb, EMD72000) linked to 
enzymes with complementing activities that use a low-molecular weight 
paramagnetic molecule (diTyr-GdDTPA) as a reducing substrate administered 
following the mAb conjugates. The conjugates reacted with both membrane-
isolated wild-type EGFR and EGFRvIII.  However, the conjugates bound 
primarily to EGFRvIII-expressing cells (Gli36EGFR) and not to EGFRwt-
expressing Gli36 cells. We analyzed the differential magnetic resonance (MR) 
tumor signal decay in vivo using orthotopic models of human glioma. We 
hypothesized that diTyr-GdDTPA becomes enzyme-activated and retained due 
to the binding to tissue proteins. The patterns of MR signal change following 
substrate administration revealed differences in elimination patterns that allowed 
distinguishing between non-specific and specific modes of MR signal decay. We 
observed biexponential signal decay in tumors only if Gli36EGFR tumor-bearing 
animals were preinjected with EGFR-targeted mAb conjugates. The endpoint MR 
in vivo imaging after preinjection of conjugates showed detailed images of 
tumors, which correlated with immunohistochemical detection of EGFR 
expression. 
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6.3. Introduction 
 Epidermal growth factor receptor (EGFR) is a member of ErbB receptor 
kinase family, which is overexpressed predominantly in non-small cell lung 
cancer, colorectal and squamous carcinomas as well as in glioma cells (1-3).  
EGFR plays an important role in cancer pathogenesis by readily undergoing 
ligand-dependent dimerization followed by autophosphorylation of the EGFR 
dimer resulting in downstream proliferative and anti-apoptotic signaling in cancer 
cells (4). Wild-type EGFRwt overexpression closely correlates with receptor gene 
amplification and has been previously established as a significant and 
independent unfavorable predictor of overall survival of glioblastoma patients (5). 
The truncated EGFRvIII variant of the receptor is constitutively activated and is a 
hallmark of aggressive gliomas (6,7). Since EGFR level is low or even 
undetectable in normal brain cells, this receptor is an appealing molecular target 
not only for molecular therapies but also as a potential marker molecule for 
visualization and characterization of gliomas during their response to therapy. 
Several recombinant monoclonal antibodies (mAbs) have been developed during 
the past decade for achieving specific targeting of the N-terminal extracellular 
domain III of EGFR with the resultant inhibition of EGF binding and/or receptor 
dimerization (8-10). Anti-EGFR monoclonal antibodies (11,12) and EGF ligand 
(13,14) have recently been suggested for imaging of EGFR expression using 
near-infrared fluorescence.  Unlike in vivo imaging of fluorescence, MRI does not 
suffer from the drawback of limited depth penetration and scattering of light.  
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However, the sensitivity of MRI to the local molar concentration of contrast agent 
(CA) is orders of magnitude lower than fluorescence or radionuclide imaging, 
which limits applicability of MRI for receptor imaging (15-17). Proton MR receptor 
imaging relies on the ability of CAs associated with the receptor site to shorten 
relaxation times of nearby water molecules. The number of CA molecules, e.g. 
chelated paramagnetic cations that can be used for direct labeling of mAbs – 
while maintaining the appropriate binding affinity of mAbs to the target site – is 
usually not sufficient for generating adequate MR contrast. Other studies 
circumvented the problem of insufficient sensitivity by coating iron oxides with 
mAbs (18-22), or by using gadolinium (Gd)-based targeted micelles (23) and 
dendrimers (24). MRI sensitivity is thus increased due to either clustering of 
many Gd cations or, alternatively, due to high superparamagnetism of iron oxide. 
However, linking of nano-sized CAs to antibodies can result in a decrease in 
tissue penetration after extravasation in tumors and in an increase of non-specific 
MR signal (25,26).  
Several studies have looked into alternate use of mAbs for imaging tumor-
associated receptors using contrast-enhanced MRI (27-29). For example, a pre-
targeting technique has been suggested for enhancing mammary 
adenocarcinomas by injecting Gd-labeled avidin (25) or dendrimers (29) for 
achieving specific association with HER-2/neu-bound biotinylated mAb 
(trastuzumab) (28). We have previously developed a novel pre-targeting 
approach based on an enzyme-mediated amplification of MR signal as a result of 
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accumulation of small molecular weight, Gd-labeled substrates at the target site 
(30). The advantage of this imaging strategy is that small CA molecules 
accumulate in brain tumors at a faster rate and with lesser heterogeneity than 
macromolecular agents (26). The resultant target-to-background contrast ratio 
can potentially be achieved earlier than in the case of nanoparticle or dendrimer 
pretargeting due to much faster elimination of the non-reacted CA substrate from 
the circulation as compared to non-bound Gd-labeled macromolecules or 
nanoparticles. The other potential advantage is in achieving higher MR signal 
due to the Gd relaxivity increase that results from the enzyme-activated substrate 
binding to proteins (31,32). The increase in relaxivity depends on magnetic field 
strength and is strongly contributing to MR signal increase at 1.0-2.0 Tesla.   
The main goals of the current work were to: 1) test in vitro and in vivo 
tumor-pretargeted enzyme-mediated amplification system using cells expressing 
either EGFRwt, or both EGFRwt and EGFRvIII; 2) to compare in vivo kinetics of 
MR signal decay after the administration of Gd-labeled peroxidase substrate 
(diTyr-GdDTPA) with or without pre-targeting of the EGF receptor with mAb 
conjugated to a signal-amplification pair of enzymes.  
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6.4. Materials and Methods 
6.4.1 Syntheses of Reagents and Cell Culture Experiments 
6.4.1.1. Synthesis of DTPA Bis-tyramide  
One mmol DTPA-bis (anhydride) was reacted with 2.2 mmol tyramine in 
the presence of triethylamine in dry dimethylformamide for 48h at room 
temperature followed by purification by repeated acetone precipitation from 50% 
methanol. The resultant compound was analyzed using 1H NMR and mass-
spectrometry (FAB-MS: found: 632 [M+H]+, theoretical m/e, 631.29).  The 
gadolinium salt of DTPA bis-tyramide (diTyr-DTPA(Gd) was prepared (Fig. 6.1) 
by dissolving 0.1 mmol of DTPA bis-tyramide in 0.5M trimethylammonium citrate 
(pH 6) and adding 1.05 eq. GdCl3 hexahydrate under argon in the dark for 72 h at 
room temperature. The solution was dried in vacuum, solubilized in water, and 
purified using reversed-phase HPLC. 
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Figure 6.1 – A) Synthesis of peroxidase-reducing paramagnetic substrate di(tyramido)-
DTPA(Gd); B) Reaction of diTyr-GdDTPA with the peroxidase/glucose oxidase enzyme 
pair conjugated to anti-EGFR mAb. 
 
6.4.1.2. Synthesis of Monoclonal Antibody Conjugates  
Conjugates were synthesized and purified as described in (30). 
Humanized anti-EGFR EMD72000 (humanized mAb 425 (33)) and anti-EpCAM  
were from Merck KGaA, Darmstadt, Germany. Antibodies were dialyzed against 
10 mM PBS, pH 7.5 before use. EMD72000 (60 µM in 0.1M sodium bicarbonate 
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pH 8) was covalently modified using SANH (Thermo-Fisher Corp.) in DMF (final 
concentration - 300µM) for 30 min at room temperature. The modified antibody 
was purified on Sephadex G25m spin-columns (PD10, GE Healthcare 
BioSciences Corp., Piscataway NJ) equilibrated with 0.1 M sodium acetate, pH 
4.9.  Recombinant glucose oxidase (GOX) from Aspergillus niger (EMD Merck-
Calbiochem), 120 µM in 0.1 M sodium bicarbonate pH 8, (25 nmol), was modified 
by adding 100 nmol C6-SFB (Thermo-Fisher Corp.). After 30 min incubation, 
GOX-formyl benzoate was purified as described above.  Horseradish peroxidase 
(100 nmol, Type IX, Sigma) in 0.25 ml of 0.1 M sodium acetate, pH 5 was 
oxidized using 10-molar excess of sodium periodate for 30 min.  The reaction 
was stopped by adding 0.1 M glycerol (final concentration) followed by 
purification in Sephadex G25m spin-columns. The oxidized peroxidase was 
incubated in the presence of 0.1 M hydroxylamine for 3 h and purified using 
Sephadex G25m chromatography. Conjugation of formylbenzoyl groups to 
peroxidase was performed by using a 10-fold molar excess of C6-SFB. The 
number of covalently conjugated 4-formylbenzoyl groups was determined by 
spectrophotometry at 350 nm (=18000 M-1 cm). Conjugated 4-
hydraziniumnicotinate was determined by using 4-nitrobenzaldehyde and 
measuring absorbance at 380 nm ( =22000 M-1cm-1). Protein concentrations 
were determined by using Micro BCA assay (Pierce). 4-hydraziniumnicotinate-
modified antibody (final concentration – 2 mg/ml) were combined with the 
modified enzymes at molar ratios of 1:2 (antibody: enzyme) in 0.1 M sodium 
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acetate, 0.1% Tween-20, pH 4.9. The incubation was completed in 4 h. To block 
the remaining aldehyde groups, 2-hydrazinopyridine was added at a final 
concentration of 0.1 mM. The reaction mixture was separated using Superdex 
200 columns (GE-Healthcare) in 0.1 M ammonium acetate, pH 7.0. The peaks 
that eluted before 200 kD protein and contained peroxidase or glucose oxidase 
activity were pooled separately, concentrated and washed with PBS using 
Ultracel-50 membrane concentrators (Millipore, Billerica MA). Concentrated 
conjugates were analyzed using 4-15% gradient SDS-PAGE.  
 
6.4.2. In Vitro Cell Culture Experiments  
Gli36EGFR (34) and wild-type Gli36wt cells (35) were propagated on 
10%FCS 90% RPMI1640 in the presence of penicillin/streptomycin and 0.5 µg/ml 
puromycin (Gli36EGFR). Both cell lines were binding chimeric anti-EGFR 
antibody (cetuximab, C225) and EMD72000 (Fig. 6.2 A,B).  For cross-titration 
experiments cells were plated in 96 wells and used when confluent. Conjugates 
were cross-tittered using sequential 2x dilutions (8x8 wells) in 2% FCS in DPBS, 
pH 7.4 and used in the range of 7.5 – 1000 ng total conjugate (i.e., a mixture of 
mAb-HRP and mAb-GOX) per well. Cells were incubated with conjugates for 30 
min, washed and peroxidase activity associated with the cells was determined at 
405 nm using 2 mM ABTS in 5 mM glucose in 50 mM sodium citrate-phosphate 
buffer, pH 5.7. In some experiments, 2 µg of free EMD72000 per well was used 
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as a competitive inhibitor. Titration of conjugate mixtures in Gli36EGFR culture 
was performed by using dilutions of mAb-HRP/mAb-GOX mixture at 2:1 (w/w 
ratio).  Measurements of longitudinal relaxation time (T1) changes were 
performed on Bruker Minispec mq20 by using reaction mixtures containing 0.05-
0.75 mM diTyr-GdDTPA, 5mM glucose, PBS, pH 7.4 in the presence or in the 
absence of 1 µg conjugate mixture.  Cell viability was determined using the XTT 
technique. Titration data fitting and analysis were performed using GraphPad‟s 
Prism4 software (La Jolla, CA). 
 
6.4.2.1. Flow Cytometry and Fluorescence Microscopy  
Flow cytometry and fluorescence of Gli36EGFR and Gli36wt cells were 
performed using 1 µg/ml AlexaFluor488-labeled EMD72000 or cetuximab 
(humanized mAb C225 (36)). 
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Figure 6.2 – A, B – flow cytometry of Gli36EGFR and Gli36wt cells incubated 
with cetuximab (C225 antibody, A) and EMD72000 (B). C, D – Cross-titration of 
two mAb EMD72000 conjugates: mAb-HRP and mAb-GOX in live Gli36EGFR 
(C) and Gli36wt (D) cell cultures using ABTS/glucose for visualization of HRP 
activity.  
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6.4.2.2. Internalization Experiments  
Internalization experiments were performed by using mAb-HRP/mAb-GOX 
conjugate mixture at 2:1 (w/w ratio). Adherent cells in 6-well plates (4 million 
cells/well) were incubated with conjugate mixtures either at 40C or at 370C.  The 
surface bound conjugates were eluted with 0.5 ml cold glycine solution pH 2.5 for 
15 min. The eluate was immediately neutralized with 1M Tris pH 8.0. To extract 
internalized conjugates 0.5 ml of 1.0% Igepal CA-630 in the presence of protease 
inhibitors was added to each well and plates were incubated for 15 min. The 
amount of bound and internalized conjugates were determined by measuring the 
initial rates of HRP/GOX-coupled ABTS oxidation by adding 5 mM ABTS and 
5mM glucose (final concentrations) in sodium citrate, pH 5.5, to the sample 
aliquots and measuring absorbance at 405 nm over time. The serially diluted 
conjugate mixture at a constant mAb-HRP:mAb-GOX ratio and known 
concentrations was used for calibration.  
 
6.4.2.3. Membrane Proteins Extraction From the Cells 
Membrane proteins from Gli36EGFR and Gli36WT cells were extracted 
using CNM compartmental protein extraction kit (BioChain Institute Inc., 
Hayward, CA) following manufacturer‟s recommendations. Cells were harvested 
using TrypLE Express cell detachment solution (Invitrogen Corp. Carlsbad, CA) 
and washed with PBS buffer. The cells were counted, centrifuged at 1000 RPM 
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for 5 min and supernatant was removed. A cocktail of protease inhibitors was 
added to extraction buffers at the recommended concentration before protein 
extraction. All extraction steps were performed at 4°C. 
To the cell pellet ice cold buffer C (2 ml/ 2. 107 cells) was added. The cells 
were suspended and rotated using Labquake rotating Micro-Tube mixer for 20 
min. Cell mixture was passed ~75 times through a 3 ml syringe fitted with a 28 
gauge needle base after removing the needle tip to disrupt the cells. The cell 
suspension was centrifuged at 15,000 g for 20 min. 
The supernatant containing cytoplasmic proteins was transferred to a new 
tube and saved. The remaining pellet was washed by suspending it in ice cold 
buffer W (4.0 ml per 20 million cells), rotated for 5 min and centrifuged at 15,000 
g for 20 min. The supernatant was discarded and the cell pellet was resuspended 
in ice cold buffer N at 1.0 ml per 20 million cells and rotated for 20 minutes. 
Nuclear proteins were recovered by centrifugation at 15,000 g for 20 min. To the 
remaining pellet, ice cold buffer M at 1.0 ml per 20 million cells was added and 
tube rotated for 20 min. Cells were spun at 15,000 g for 20 min to recover the 
membrane proteins in the supernatant.  The protein concentration was measured 
in all the fractions by Micro BCA Protein Assay kit (Thermo Scientific). Fractions 
were aliquoted and stored at –70°C. 
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6.4.3. Histology  
Following the MRI studies, animals were euthanized and their brains were 
removed. Under a dissecting microscope, histological slices were obtained ±2 
mm anterior/posterior of the needle track and then embedded in O.C.T. medium. 
Frozen sections (6 µm) were treated with acetone: ethanol (1:1, –20oC), treated 
in TBS/EDTA, pH 8 at 65°C for blocking endogenous phosphatase activity and 
blocked using 2% serum. The sections were incubated with anti-EGFR mouse 
mAb (Abcam), or anti-HRP mAb (Abcam) followed by anti-mouse alkaline-
phosphatase linked antibodies and BCIP/NBT (Roche). Staining for residual 
peroxidase activity was achieved by using a DAB kit (Vector Labs).  
Immunofluorescent staining was performed on frozen sections blocked with 2% 
serum, 0.05% Tween-20, PBS, pH 7.4. AlexaFluor488-labeled EMD72000, Cy3-
labeled mouse anti-rat CD31 mAb (clone TLD-3A12, Abcam, Cambridge MA) 
were used for visualizing EGFR and endothelial CD31 expression, respectively. 
For detecting HRP in the tissue sections, digoxigenin-labeled mouse anti-HRP 
mAb (clone 2H11, Abcam, Cambridge MA) was used. Digoxigenin-labeled 
antibody binding was visualized using custom Cy5.5-labeled anti-digoxigenin 
F(ab‟)2 (Roche, Indianapolis IN). 
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6.4.4. Animal Model and Imaging  
All procedures were performed as approved by the Institute Animal Care 
and Use Committee (IACUC) of the University of Massachusetts Medical School 
(Worcester, MA).   
An orthotopic human glioma xenograft model was obtained by 
stereotaxically implanting 1.105 Gli36EGFR or Gli36WT cells suspended in 3 µl 
of 10% MatrigelTM in serum-free RPMI under aseptic conditions at 37°C (2.5 mm 
posterior to bregma, 2 mm lateral to midline, and depth of 3.5 mm) in the brain of 
athymic rats (Harlan, 150-200g, n=16) 14 d prior to first imaging session. 
Throughout imaging the animals were maintained at 37°C and anesthetized 
using 1.5% isofluorane in a 30% oxygen/70% nitrogen mixture.  A 45-mm-
diameter, 30-mm-long birdcage RF coil was used. A 26-gauge catheter capped 
with a needle port was placed in the tail vein for CA administration.   
 
6.4.4.1. MRI Protocol, Pulse Sequences, and Measurements 
MRI measurements were performed using Philips Achieva 3.0T/60 cm 
bore equipped with 80mT/m actively shielded gradients. To monitor temporal 
evolution of signal enhancement following CA delivery, multi-slice, T1-WT MR 
images (TR/TE=700/8.2 ms) were acquired at various time points following CA 
infusion. Other imaging parameters were: slice thickness = 1.5 mm; slice 
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separation = 0.15 mm; field-of-view = 25.6 mm x 25.6 mm; data acquisition 
matrix = 256x128, 4 NEX. Two weeks after tumor cell implantation, each animal 
was imaged on two occasions: on Day 1 (two weeks after tumor cell 
implantation), a pre-contrast image was acquired followed by IV injection of 0.1 
mmol/kg diTyr-GdDTPA. Twenty T1-WT images were then acquired continuously 
over a 2-h period. On Day 2 (the day after Day 1), the animals were first pre-
injected with 150 µg of mAb-HRP/mAb-GOX mixture at 2:1 (w/w ratio, 0.3 ml) in 
the tail vein. In a separate group of Gli36EGFR tumor animals were preinjected 
with non-specific antibody conjugates. Five hours later, a pre-contrast image was 
acquired followed by IV injection of 0.1 mmol/kg diTyr-GdDTPA. Thirty T1-WT 
images were then acquired continuously over a 3-h period. Pre-contrast T2-WT 
images were acquired on both Day 1 and Day 2 to corroborate the presence of 
tumor observed in the T1-WT slices. 
 
6.4.5. Image Analysis 
The temporal evolution of the signal decay in the tumor following infusion 
of diTyr-GdDTPA was evaluated separately for each of the two groups (Day 1 
and Day 2). Depending on the size of the tumor, one to four slices were selected 
covering the central core region of the tumor at each time point. Using the 
ImageJ software package (37), a region-of-interest (ROI) was carefully drawn to 
delineate the boundary of the contrast-enhanced region for each slice. ROIs 
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were also drawn to distinguish the tumor interface and tumor core regions (Fig. 
6.3). The whole ROI was drawn to circumscribe the entire contrast-enhanced 
region of the tumor visible at the first time point collected after the contrast 
injection. The core ROI was drawn using a later time point that better depicted 
the outline of the core region due to the faster signal decay in the core as 
compared to the interface. The interface ROI was drawn by tracing over the 
region defined by the difference between the whole ROI and the core ROI. The 
mean signal intensity values within each of the ROIs were then calculated using 
ImageJ. 
For each animal, the signal intensity data for the core and interface ROIs 
from each relevant tumor slice was plotted to generate a separate time-series 
plot for Day 1 (no conjugates) and Day 2 (with conjugates). Due to the 
heterogeneity of tumor growth and variability in the exact dose of contrast 
delivered from one animal to another, each signal-intensity time point was 
normalized relative to the pre-contrast time point for each slice: 
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where SN(t) is the normalized signal intensity at time t, Spost(t) is the signal 
intensity at time t, and Spre(0) is the signal intensity in the pre-contrast slice. 
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For each animal, the normalized signal-decay plots for each brain slice 
from Day 1 and Day 2 were used to calculate signal-decay time constants using 
a monoexponential and a biexponential model: 
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where ymonoexp(t) and ybiexp(t) are the signal intensities at time t, A0, A1, and A2 
are the amplitudes of each signal-decay component; 0, 1, and 2 are the signal-
decay time constants for the respective models. 
 For each animal, the normalized signal-decay plots of the core and 
interface ROIs for each brain slice from Day 1 and Day 2 were fitted with both 
models. Mean values for 0, 1, and 2 were obtained for the core ROI and the 
interface ROI for each animal by averaging the respective signal-decay time 
constants of each ROI from all relevant tumor slices of the same animal. The 
mean values for 0, 1, and 2 were calculated for each animal on Day 1 and on 
Day 2. Student‟s paired t test was performed on the overall average of the signal-
decay time constants from all the animals to check for any significant differences 
either between the ROIs or between Day 1 and Day 2. 
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To determine which model (monoexponential or biexponential) better 
represented the normalized signal-decay data, the 2 statistics for the 
monoexponential (2monoexp) and biexponential (
2
biexp) models were compared 
using an F test based on a variant of the reduced 2-squares ratio: 
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where υmonoexp and υbiexp are the number of degrees of freedom corresponding to 
2monoexp and 
2
biexp for the monoexponential and biexponential model, 
respectively (38). For this study, the F statistic ratio simplifies to: 
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where N is the number of data points. This ratio measures how much the 
additional exponential term in the biexponential model improves the reduced 2 
by taking into account the number of parameters in the fitting equation (39). This 
calculated F statistic was compared to tabulated values of the F statistic with 1 
and N – 4 degrees of freedom. If the F statistic was greater than the tabulated F 
value for the desired statistical confidence, then the biexponential model was 
accepted as the better fitting model for the data. If the F statistic was less than 
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the tabulated F value, then the monoexponential model was chosen for fitting the 
data. P values less than 0.05 were considered statistically significant. 
 
 
 
Fig. 6.3 – Placement of ROI for image analysis. A single tumor slice showing three 
different ROIs (whole, core, and interface) at 7 min and 31 min post contrast injection 
drawn using ImageJ is shown as an example. A – The whole ROI was drawn around the 
outline of the enhanced tumor at the first time point collected after the contrast injection; 
B – The core ROI was drawn using a later time point that better depicted the outline of 
the core due to the faster signal decay in the core as compared to the interface; C – The 
interface ROI was drawn by tracing over the region defined by the difference between 
the whole ROI and the core ROI. 
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6.5. Results 
6.5.1. Synthesis and Testing of Targeted MR Signal Amplification 
System In Vitro 
The synthesis of peroxidase (HRP) and glucose oxidase (GOX) 
conjugates of humanized chimeric antibody (EMD72000, Merck) that catalyze 
oligomerization of substrate di(tyramido)-DTPA(Gd) (Fig. 6.1) was performed 
using conditions optimized to facilitate enzyme conjugation via the formation of 
bisaromatic hydrazones with minimal antibody binding affinity loss (30).  Gel 
electrophoresis of purified conjugates showed the formation of mAb-GOX  (290 
and 460 kD bands) and mAb-HRP (220 and 400 kD bands) Fig. 6.4A. Since 
GOX is a two-subunit enzyme, the band corresponding to the 69 kD 
deglycosylated GOX subunit was present in the SDS-treated mAb-GOX 
conjugates (Fig. 6.4A, lane 4). The conjugation reaction conditions prevented the 
formation of cross-linked products that showed no binding specificity to EGFR-
positive cells. Immunoblotting experiments showed that optimized conjugates 
reacted with the same set of receptor variants (i.e. EGFRwt in Gli36wt and 
EGFRwt/EGFRvIII in Gli36EGFR cell lysates) as did the control anti-EGFR 
antibody (Fig. 6.4B, a2). Overall, Gli36EGFR cells contained 2.8-times more 
mAb-reactive EGF receptors than Gl36wt cells and this result correlated with the 
results of flow cytometry performed using fluorescent-labeled cetuximab (Fig. 
6.2A). However, EMD72000 showed stronger preference for Gli36EGFR cells, 
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i.e. 7.2-times higher binding levels than Gli36wt cells (Fig. 6.2B). Using 
111InDTPA-labeled EMD72000 mAb we determined that Gli36EGFR had 
4.6±0.3.105 binding sites/cell as opposed to a control non-binding anti-EpCAM 
antibody, which showed no detectable binding to the surface of Gli36EGFR 
cells. Optimization of the mAb-HRP:mAb-GOX conjugate ratios was performed to 
determine the conditions that provide sustainable release of hydrogen peroxide 
as a result of D-glucose oxidation, without inhibiting the binding of mAb-HRP to 
cells (Fig. 6.2 B,C). These experiments showed no detectable loss of cell viability 
observed below 0.25 µg mAb-GOX/well. Cross-titration demonstrated that the 
highest HRP activity was detectable at the weight ratios of mAb-HRP:mAb-GOX 
of 1:2 in the range of 0.03(0.06) µg - 0.25(0.5) µg of mAb-GOX (mAb-HRP) 
conjugate/well. In contrast to Gli36EGFR, the same dilutions of conjugates 
added to Gli36wt cells resulted in lower levels of cell-associated enzymatic 
activity. The titration of mAb-HRP:mAb-GOX conjugate mixture (1:2 w/w) allowed 
us to determine the effective EC50 = 0.21 µg (Fig. 6.4C). Finally we studied 
binding and internalization of optimized conjugate mixtures (Fig. 6.4D) in both 
cell lines by measuring the complementing enzymatic activities which are 
essential for MR signal amplification. The differences observed during flow 
cytometry were further confirmed in these experiments showing that 
Gli36EGFR cells bound 10-times more of mAb conjugate-mediated enzymatic 
activity than Gli36wt, of which about 25% remained externalized on the surface 
of the cells.  
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Figure 6.4 – A) SDS-PAGE (4-15% gradient) of anti-EGFR mAb (EMD72000) 
conjugation products or with deglycosylated enzymes:  HRP (37 kD,  lanes 1 and 2) and 
with GOX (69 kD subunit,  lanes 3, 4) Lanes 1 and 3- before and 2,4- after the 
purification of conjugates;  B) immunoblotting of membrane protein fraction isolated from 
Gli36EGFR () and Gli36wt (WT) cells using mouse monoclonal anti-EGFR antibody 
C225 or by using HRP-EMD72000 conjugate. EGFR variants are identified on the right; 
C) titration of the mixture of anti-EGFR mAb-HRP and mAb-GOX on Gli36EGFR cells 
at the optimized complementing ratio (1:2, w/w); D) binding and internalization of 
conjugate mixture at the optimized ratio (1:2, w/w) in Gli36EGFR () and Gli36wt (WT) 
cells 1,3, 5,7 – cell-surface bound fraction of conjugates; 2,4,6,8  – internalized fraction 
of conjugates. 
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The HRP/GOX mediated increase of relaxivity in the reaction mixture 
containing the paramagnetic substrate diTyr-GdDTPA was compared between 
low external magnetic field and the field of the MR imaging unit that was used for 
animal experiments.  Mixture of conjugates and paramagnetic substrate diTyr-
GdDTPA in the presence of D-glucose always resulted in shorter T1 relaxation 
times (i.e. higher average longitudinal relaxivity r1, Table 6.1). The measured 
difference in molar relaxivity between the substrate alone and reaction mixtures 
containing HRP and GOX conjugates was clearly greater at lower magnetic field 
(0.47T vs. 3T). The reaction resulted in 2.7 times higher r1 if measured at 0.47T 
as opposed to 5% increase of r1 at 3T. The simple addition of proteins in the 
solution did not result in large relaxivity increases. However, in the presence of 
both plasma proteins and mAb conjugates, the relaxivity increase was 
measurable and higher at 3T and showed a 20% r1 increase. 
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Table 6.1  
Changes of longitudinal relaxivity of Gd as a result of conjugate catalytic activity.  
Sample components r1 (average 
longitudinal 
relaxivity at 
0.47T), 400C 
[mM-1·s-1] 
Relaxivity 
increase at 
0.47T 
relative to 
substrate, 
%  
r1 (average 
longitudinal 
relaxivity at 
3T), 200C [mM-
1·s-1] 
Relaxivity 
increase at 
3T  relative to 
substrate, % 
diTyr-GdDTPA a) 
 
4.3 
 
- 3.6 - 
diTyr-GdDTPA 
+ plasma b) 
5.0 20 4.0 10 
diTyr-GdDTPA 
+ mAb conjugates c) 
11.8 270 3.8 5 
diTyr-GdDTPA 
+ mAb 
conjugates+plasma c) 
12.5 290 4.4 20 
 
a) Concentrations used for relaxivity measurements were in the range of 40-250 
µM; Goodness of r1 fits – R2>0.99. Reaction time – 40 min at 370C.  
b) 50% human or rat plasma solution in heparinized saline was used.  
c) 2U/ml HRP and 0.7 U/ml GOX in 5 mM glucose-containing DPBS were used.   
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6.5.2. In Vivo Imaging Experiments and Corroboration 
The paramagnetic-substrate-mediated enhancement of human glioma 
xenografts (Gli36EGFR and Gli36wt) was studied using MRI in vivo. To account 
for tumor heterogeneity, the experiments were performed on consecutive days in 
each animal.  On the first day, only the CA substrate was administered (Day 1).  
On the next day – after CA had been completely eliminated– a second 
experiment was conducted with pre-injection of mAb conjugates 5 h before 
injecting the CA (Day 2). Fig. 6.5A shows sequential T1-WT rat brain MR images 
depicting Gli36EGFR xenograft enhancement as a function of time post-IV 
injection of diTyr-GdDTPA. The top row of images shows the temporal washout 
of diTyr-GdDTPA with no anti-EGFR mAb conjugate pre-treatment (Day 1). The 
bottom row of images shows the temporal washout of diTyr-GdDTPA at 5 h 
following pre-treatment with anti-EGFR mAb conjugates (Day 2) in the same slice 
for the same animal. For both days, the T1-WT images showed strong initial 
enhancement of the tumor within minutes after IV diTyr-GdDTPA injection. 
However, the initial enhancement, following IV injection of diTyr-GdDTPA, with 
EGFR-targeted conjugate pre-treatment (Fig. 6.5A: Day 2 – 8 min) was 
significantly higher than without EGFR-targeted conjugate pre-treatment (Fig. 
6.5A: Day 1 – 9 min), especially in the tumor interface region. Moreover, images 
obtained after the EGFR-targeted conjugate pre-injection (Fig. 6.5A: bottom row ) 
showed more detailed tumor structure with areas of focal enhancement in both 
the tumor/normal brain interface and core at all time points post-injection of the 
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paramagnetic MR CA. With or without conjugate pre-treatment, the tumor 
interface consistently showed higher T1-WT signal enhancement compared to 
the core. 
Animals pre-injected with anti-EGFR mAb conjugates displayed a delayed 
retention of MR CA compared to animals not receiving EGFR-targeted conjugate 
pre-treatment. Without a pre-injection of anti-EGFR conjugates (Day 1), most of 
the diTyr-GdDTPA had washed out of both the tumor/normal brain interface and 
core regions by 117 minutes after IV injection (Fig. 6.5A: top row). However, after 
allowing the EGFR-targeted conjugates to accumulate in the tumors (Day 2), 
significant T1-WT hyperintensity persisted in the tumor interface at approximately 
the same time point (Fig. 6.5A: Day 2 – 116 min) post-diTyr-GdDTPA-injection. 
Furthermore, T1-WT enhancement in the tumor interface remained visible for 170 
min after CA administration (Fig. 6.5A: Day 2 – 170 min). In contrast to EGFR-
targeted conjugates pre-injection, no retention of MR signal was observed when 
Gli36EGFR-bearing animals were pre-injected with anti-EpCAM targeted 
conjugates which do not bind to Gli36 cells (Fig. 6.5B: compare top and bottom 
rows). 
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Figure 6.5 – A) 3T MR imaging of Gli36EGFR human glioma xenografts without and 
with pre-injection of targeted conjugates. T1-WT sequential rat brain images depicting 
enhancement as a function of time post injection of diTyr-GdDTPA.  The top row - 
temporal washout of diTyr-GdDTPA with no conjugate pre-injection (Day 1).  The bottom 
row - washout of diTyr-GdDTPA following pre-treatment with anti-EGFR conjugates (Day 
2) in the same slice for the same animal. Time intervals (in minutes) after the injection of 
diTyr-GdDTPA are shown below; B) MRI and comparative histology. Note distal 
expansion of the tumor along the ventricle. The images were obtained pre-, immediately 
post- and 1 h post-CA administration; C) Detection of EGFR overexpression using anti-
EGFR antibody-digoxigenin/anti-digoxigenin-AP system in the tumor shown in Fig. 6.5B; 
D) Detection of EGFR expression (anti-EGFR-DIG/anti-DIG-AP staining, left; and HRP 
activity (right) in the same tumor on the parallel sections. HRP activity was detected by 
using diaminobenzidine staining. Arrowheads point to tumor location; arrows show 
presence of tumor expansion as microdeposits in normal brain tissue stained for EGFR 
expression. Bars in B, C = 1 mm. 
 
 
The corroborative histology performed after the final MRI session showed 
areas of EGFR-positive staining and revealed two tumor masses (2.7-3 mm in 
diameter) with multiple microdeposits around the tumor/normal brain interface 
(arrows, Fig. 6.5D). These same features were also easily identifiable on MR 
images after the injection of anti-EGFR conjugate followed by the CA (Fig. 6.5C). 
These areas of tumor/brain were also positively stained for HRP activity using 
diaminobenzidine (Fig. 6.5D). By performing immunofluorescent visualization of 
EGFR and CD31 expression, we observed the presence of multiple blood 
vessels feeding the expanding tumor (Fig. 6.6A). Visualization of HRP 
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accumulation by using anti-HRP antibodies (Fig. 6.6B) verified the results 
obtained using peroxidase enzymatic activity detection in brain sections (Fig. 
6.5D).  
Detailed kinetic analysis of in vivo MR signal enhancement as a function 
of time was performed to assess the efficacy of EGFR targeted imaging. Fig. 6.7 
shows the normalized T1-WT signal intensities in the Gli36EGFR tumor 
interface and core regions as a function of time post-CA injection. Fig. 6.7A 
shows diTyr-GdDTPA signal-intensity-decay curves before conjugate injection 
(Day 1) for tumor interface and core regions. Fig. 6.7B shows CA signal-intensity-
decay curves after EGFR-targeted and EpCAM-targeted conjugate injection (Day 
2) for tumor interface and core regions. These plots were derived from the tumor 
images of the same representative animals shown in Figs. 6.5A and 6.5B. The 
relative percent change in T1-WT signal intensity of the interface and core 
regions was significantly higher with EGFR-targeted conjugate administration 
(Day 2) – as compared to without pre-treatment (Day 1) – at the initial time 
points. With EpCAM-targeted conjugate administration (Day 2), there was no 
significant change in initial T1-WT signal intensities of the interface and core 
regions between Day 1 and Day 2; both days showed similar washout behavior 
of the interface and core signal-intensity-decay curves (Fig. 6.7).  
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Figure 6.6 – Immunofluorescent detection of EGF receptor, endothelial cells and mAb 
conjugate delivery in Gli36EGFR tumors. A) Detection of EGFR  expression (green) 
and blood vessels (anti-CD31, red). The inset shows area of vascularized tumor/brain 
interface at higher magnification; B) Binding of anti-EGFR-HRP conjugate to cells in the 
tumor interface after injection of conjugate IV. Binding of digoxigenin-labeled anti-HRP 
antibody (detected by using anti-digoxigenin F(ab‟)2-Cy5.5 conjugate) is shown in red. 
Nuclei are stained with DAPI. Bar – 50 µm. t- tumor, nb- normal brain. 
 
 Interestingly, the signal-intensity-decay curves for tumor interface and 
core regions in animals pre-treated with EGFR-targeted conjugates (Day 2; Fig. 
6.7B) depict two separate decay components (long 1 and short 2) whereas the 
washout curves for the corresponding regions without EGFR-targeted conjugate 
injection  (Day 1; Fig. 6.7A) show only a single decay component (0).  Based on 
the 2 analysis using an F test discussed earlier, a biexponential function was 
found to best model the signal-intensity-decay curves for the tumor interface and 
core regions after injection of EGFR-targeted conjugates (Day 2). Without EGFR-
targeted conjugate preinjection (Day 1), a monoexponential function was 
appropriate fitting model for both the regions. For treatment with and without 
EpCAM-targeted conjugates, and Gli36EGFR tumors (treated with and without 
EGFR-targeted conjugates), a monoexponential elimination function was the best 
model for all signal-intensity-decay curves (see Table 6.2 for all decay time 
constant (DTC) values).  
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Figure 6.7 – Normalized T1-WT signal intensities measured in the interface or core regions of the 
representative Gli36EGFR tumors prior to injection of conjugates (A), or after the pre-injection of 
either specific anti-EGFR (“EGFR”) or non-specific EpCAM (“EpCAM”) conjugates (B) as a 
function of time post-diTyr-GdDTPA injection. These plots were derived from the same 
representative tumors shown in Fig. 6.5A and B.  The signal intensities are normalized as percent 
change relative to pre-contrast image.  Tumor core and interface regions of animals pre-injected 
with anti-EGFR conjugates (B, curves 1,2) exhibited biexponential signal decay whereas the MR 
signal decay curves with no conjugate pre-injection or after the pre-injection of non-specific 
conjugate (A, curves 1-4, B curves 3,4) showed a single (monoexponential) decay component. 
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Table 6.2 – Decay time constants (DTC) for diTyr-GdDTPA or its products in the tumor 
interface and core regions with (Day 2) and without conjugate pre-treatment (Day 1).         
 
a) Region of interest placement is explained in Fig. 6.3; 
b) For tumor core and interface regions without 
conjugates injection (Day 1), a monoexponential function 
was the most appropriate fitting model; 
Based on 
2 analysis using an F test (Eq. [6.5]): c) values 
in shaded area – a biexponential function was found to 
best model the signal-intensity-decay (SID) curves for the 
tumor regions in animals with Gli36ΔEGFR tumors pre-
injected with anti-EGFR (EMD72000) conjugates (Day 2); 
a monoexponential function best modeled the SID curves 
for the tumor regions in animals with: d) Gli36ΔEGFR 
tumors pre-injected with EpCAM conjugates (Day 2); e) 
Gli36-WT tumors pre-injected with anti-EGFR 
(EMD72000) conjugates (Day 2). 
P values correspond to comparisons in animals with 
Gli36ΔEGFR tumors (preinjected with EMD72000 
conjugates) between: f) 0 and 1 in the tumor core region; 
g) 0 and 2 in the tumor core region; h) 0 and 1 in the 
tumor interface region; i) 0 and 2 in the tumor interface 
region; j) P < 0.01 for 0 values in the tumor core and 
interface regions; k) P < 0.03 for 2 values in the tumor 
core and interface regions. 
l) P value corresponds to comparisons between0 values 
in the tumor core region of animals with Gli36-WT tumors 
(preinjected with EMD72000 conjugates); 
m) No significant differences in DTCs were observed in 
the tumor regions between Day 1 and Day 2 in animals 
with Gli36ΔEGFR tumors preinjected with EpCAM 
conjugates. 
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6.6. Discussion 
Imaging of receptor expression in cancer with high spatial resolution 
usually requires MR imaging assisted with imaging probes (40,41). Due to the 
inherent non-specific uptake of nano-sized probes in non-target cells and slow 
elimination of non-bound CA from blood the specific imaging signal is frequently 
obscured. With a goal of imaging EGF receptor expression in gliomas we 
investigated a novel strategy based on specific local retention of paramagnetic 
products of di(tyramido)-DTPA(Gd) (diTyr-GdDTPA, Fig. 6.1), i.e. a substrate of 
peroxidase (30,42). We applied the strategy in models of orthotopic human 
gliomas that either expressed the wild-type EGFR or both the wild type receptor 
and EGFRvIII (43). The anti-EGFR mAb (EMD72000) was covalently linked with 
HRP and GOX, i.e. to the enzymes that function as a self-complementing 
enzymatic signal amplification system (30). In cell culture experiments these 
conjugates showed a remarkable preference for truncated EGFRvIII mutant form, 
which may be explained by the sterical constraints in accessibility of mAb epitope 
(Ser460-Gly461) on EGFR domain III (44). We anticipated that our strategy 
allows reliable MR imaging of EGFRvIII, a marker of aggressive gliomas with 
high specificity due to the retention of CA at the sites of mAb conjugates binding 
to the tumor cells.  
To test this assumption, we designed experiments that directly compared 
in vivo elimination kinetics of diTyr-GdDTPA in the same tumor-bearing animals. 
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These experiments were performed initially in the absence of mAb conjugates 
and then after the pre-injection of a mixture of conjugates at the optimized 
HRP:GOX ratio. As a result, we were able to compare kinetics of the measured 
MR signal decrease due to the washout of diTyr-GdDTPA and its reactive 
products from the total tumor volume, as well as from volumes corresponding to 
highly vascularized tumor “interface” (Figs. 6.6 and 6.3) and the remaining “core” 
volumes.  From the quantitative kinetic analysis of the MR signal intensities, we 
concluded that the initial MR signal intensity enhancement for both interface and 
core regions was significantly higher for Gli36ΔEGFR tumors that were pre-
treated with EGFR-targeted mAb conjugates (Day 2) as compared to the same 
tumors before the injection of conjugates (Day 1), or Gli36wt tumors. When non-
targeted mAb conjugates (control) were preinjected into Gli36ΔEGFR tumors, no 
significant signal change was observed compared to Day 1. Binding of 
paramagnetic products of enzymatic reaction to the EGFRvIII-positive cells 
results in a long-term retention/enhancement (Fig. 6.5A), while oligomerization or 
binding to proteins in the extracellular compartment result in more short-term 
tumor enhancement. The effects caused by paramagnetic products binding was 
previously observed and characterized in several similar enzyme-mediated 
reactions (32,45).  
The long-term enhancement was more pronounced since the products of 
enzymatic reaction are more efficient MR contrast agents. The increase of r1 that 
reflects the efficiency was sufficient to cause the initial transient MR signal 
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enhancement observed after anti-EGFR mAb conjugate pre-injection in the 
presence of the same concentration of CA – relative to that observed without 
conjugate injection. 
The retention of T1-weighted MR signal enhancement in tumors that were 
pre-treated with specific targeted conjugates relative to those that were not, 
resulted in an increase of DTC ()  (i.e. in a slower CA elimination) consistent 
with the binding of the CA to the target cells in the presence of targeted enzyme 
amplification pair. The signal enhancement of  the tumor interface was 
consistently higher than that of the rest of the tumor volume (“core”), independent 
of whether the animals were preinjected with conjugates or not. This was caused 
by high vascular density of the tumor interface (Fig. 6.5), which corresponds to 
an area of enhanced transvascular permeability. This higher local permeability 
translates into higher concentrations of targeted conjugates as well as the 
substrate compared to less vascularized core.  The results of direct staining for 
HRP activity or detection of HRP in tumors by using immunofluorescence 
suggest this difference (Figs. 6.5 and 6.6). The early phase of strong 
enhancement in tumors that were pre-treated with EGFR-targeted conjugates 
(Day 2) can be explained by rapid binding of the activated substrate to 
macromolecules in tumor extravascular space and tumor cells since highly 
vascularized tumor-brain interface regions should display higher retention of 
contrast relative to poorly vascularized regions due to the higher functional blood 
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volume (46). This hypothesis is supported by the tumor interface showing a 
significantly higher MR signal DTC than that of the core (Table 6.2). 
The inevitable variations in tumor size and tumor heterogeneity dictated 
the need in a parameter that would allow comparing MR imaging results obtained 
in different animals and tumors. We determined that kinetic analysis of temporal 
decay of the normalized MR signal intensities can be used for this purpose 
(Table 6.2). The calculated DTC values can be correlated to tumor perfusion, 
vascular permeability, and the volume of the extravascular extracellular space 
(EES). 
The DTCs of diTyr-GdDTPA derived from the temporal decay of the 
normalized signal intensities were used as the basis for comparing the CA 
kinetics between individual animals. This approach is analogous to that 
employed in dynamic contrast-enhanced MRI (DCE-MRI) (47) except that only 
the washout portion of the kinetic curve was measured in our study.  Although 
the kinetic parameters calculated in this study differ from those used in the model 
of Tofts and Kermode (47), the parameters still relate to tumor perfusion, 
vascular permeability, and the volume of the EES. 
By performing signal intensity decay analysis we found that in the absence 
of conjugate preinjection, the washout of diTyr-GdDTPA was monoexponential 
throughout the tumor volume generating a single DTC (0) in both tumor models 
(Fig. 6.7A; Table 6.2). In each case 0 was attributed to the washout of the free 
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CA since the substrate does not bind to plasma proteins. This assignment is 
justified because diTyr-GdDTPA is not expected to have any affinity for tumor 
cells in the absence of receptor-targeted conjugates. The control EpCAM-
targeted conjugate in Gli36ΔEGFR tumors (Day 2) as well as EGFR-targeted 
conjugate in Gli36wt cells (Day 2) similarly resulted in monoexponential decay 
(Table 6.2) since control anti-EpCAM conjugates did not bind to glioma cells of 
our study and Gli36wt cells were binding very low amounts of EMD72000 
conjugates. 
Following the pre-injection of Gli36ΔEGFR -bearing animals with EGFR-
targeted conjugates on Day 2, the diTyr-GdDTPA elimination changed from 
monoexponential to biexponential for both the tumor interface and core regions 
(Fig. 6.7; Table 6.2). The elimination of free (and/or oligomerized) substrate was 
responsible for short DTC (2) while the long DTC (1) component was attributed 
to paramagnetic reaction products retained by tumor cells. Importantly, the 
comparison of both 1 and 2 DTC values suggest that delayed MR imaging in 
addition to dynamic imaging can also be potentially useful in imaging receptors: 
the retention of tumor bound paramagnetic product of specific enzymatic reaction 
can be detectable at in the tumor interface for several hours post administration 
of the substrate while the free substrate is eliminated within an hour.  
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6.6.1. Derivation of Relationship Between Decay Time Constant and 
EES Volume Using the Tofts and Kermode Model  
The short DTCs (2) for free diTyr-GdDTPA following conjugate pre-
treatment (Day 2) was significantly shorter than the corresponding diTyr-
GdDTPA DTCs (0) without conjugate pre-treatment (Day 1). The reduced DTCs 
for free diTyr-GdDTPA following conjugate pre-treatment may arise from a 
decrease in vascular permeability which could occur due to a reduction in the 
volume of the EES (derivation shown below). This reduction in volume might 
arise due to a “binding site barrier” effect (48), which would imply that successful 
binding of the anti-EGFR conjugates impedes the penetration of unbound 
conjugates, thus leaving less EES volume available for the CA to permeate into 
from the blood plasma (48,49). Using the Tofts and Kermode model, we 
established that a reduction in the DTC is proportional to a reduction in the EES 
volume fraction. 
The Tofts and Kermode model derives the lesion curve C1(t) by solving a 
first-order linear differential equation (Eq. A9 in (47)), which has the following 
solution (Eq. A10 in (47)):  
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where a1, a2, m1, and m2 are parameters that are calculated from the plasma 
curve Cp(t) (Eq. 1 in (47)), D is the contrast dose administered, c is a constant 
that is calculated from the initial condition C1(0+)=0, and m3 is the variable that 
is calculated from applying this model to a lesion curve data set with wash-in and 
wash-out phases. The parameter m3 is defined as the exchange rate constant 
between EES and blood plasma (kep) as defined by Tofts et. al. (50): 
    ce
trans
ep Kk  1           [6.7] 
where K
trans
 is the volume transfer constant between blood plasma and the EES, 
e is the volume fraction of the EES, and c is the DTC. In our study we 
calculated the DTC, which is inversely proportional to kep. We can establish from 
this relationship that c is directly proportional to e. Thus, a decrease of the DTC 
would suggest that there is a decrease of EES volume fraction. K
trans
 can also be 
reduced (due to a decrease in transendothelial permeability in the presence of 
conjugates) since it is equal to the permeability surface area product between 
blood plasma and the EES per unit volume of tissue (50). However, the decrease 
in e is greater than the decrease of K
trans
, which is supported by the fact that we 
observed a decrease of diTyr-GdDTPA DTCs on Day 2, i.e. after the pre-injection 
of conjugates. 
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6.7. Conclusion 
We performed quantitative analysis of MR dynamic signal enhancement in 
human glioma xenografted animals that were: 1) imaged first by using “non-
specific” paramagnetic CA; 2) imaged with the same CA after preinjecting of anti-
EGFR antibody conjugates. The enzyme linked to EGFR-targeted antibodies 
converted the CA into reactive products thereby profoundly changing the tissue 
elimination kinetics. Therefore, in addition to imaging of the MR signal 
enhancement associated with tumor tissues in vivo the amplification strategy 
results in a kinetic signature. The analysis of images acquired dynamically or by 
using end point imaging can establish the presence of cell surface marker and 
quickly delineate the areas where this marker molecule can be targeted for 
therapeutic purposes.  
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7.1. Concluding Remarks 
In this dissertation use of contrast agents (CAs) was explored in MRI 
studies to differentiate between compartments, to study dose dependence of 
relaxation times, and to characterize tumors using signal amplifying enzymes in 
the brain. 
 
7.1.1 Compartmental Differentiation 
In the compartment differentiation study, the goal was to differentiate 
between the water signal emanating from the intracellular (IC) and extracellular 
(EC) space. This information would be useful in measuring the compartmental 
apparent diffusion coefficient (ADC) values during diffusion-weighted NMR 
experiments. Such measurements could eventually lead to an early diagnosis of 
stroke since abnormalities in ADC measurements indicate the early onset of 
stroke. This is an important goal because proper therapeutic intervention during 
the early stage of stroke can prevent the progression of ischemic injury.  
Past studies have measured compartment-specific diffusion coefficients 
using gadolinium (Gd-DTPA) as the MR contrast agent in yeast cells to 
distinguish between the IC and EC water proton signals based on differences in 
their respective longitudinal (T1) relaxation times (1). Gd-DTPA was employed as 
an EC contrast agent, thereby reducing the T1 value of the EC space. In our 
study we applied an alternate approach by using manganese (Mn2+) as an IC 
contrast agent. It was hypothesized that Mn2+ uptake by cells would cause 
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shortening of the T1 relaxation time of the IC water. The relative difference in T1 
relaxation times between the IC and EC compartments could then be used to 
discriminate between the MR signals arising from water in the respective 
compartments. 
From our experiments we were unable to conclude with certainty whether 
Mn2+ can differentiate between the IC and EC compartments. When Mn2+ is 
administered in the animals, Mn2+ resides first in the EC compartment and then in 
the IC compartment. At some point in time, Mn2+ occupies both compartments as 
Mn2+ is taken up by the cells. Also, once in the IC compartment, Mn2+ can be 
sequestered within organelles. Thus, it is unclear which water population the 
Mn2+ affects. 
To test the hypothesis of using Mn2+ to differentiate between the IC and 
EC compartments, perhaps a simpler biological model than the brain should be 
investigated. For example, some sort of cell suspension studies could be done 
where Mn2+ is isolated to the IC compartment (with a larger water volume 
fraction) and any Mn2+ in the EC compartment (lower volume fraction) is 
excluded from the system. That way an accurate assessment can be made 
whether Mn2+ can differentiate between the IC and EC compartments. 
 
7.1.2 Dose Response 
In the dose response study, the goal was to investigate the MRI dose 
response of Mn2+ in rat brain following SC administration of Mn2+. From our 
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experiments, we showed a dose-dependent response of Mn2+ on T1 relaxation 
times in different regions of the rat brain following SC injection of Mn2+ which was 
comparable to a previous dose response study using IV injection of Mn2+ (2). 
This study also suggests that SC administration of Mn2+ at a high dose (near 
LD50 value) can deliver a greater amount of Mn
2+ than the highest non-toxic dose 
possible with intrathecal injection in the rodent brain.  
SC administration of Mn2+ also led to prolonged enhancement in the brain 
than IV administration since SC route avoids the immediate elimination of Mn2+ 
from plasma via bile (3) upon injection which occurs during IV injection. A high 
dose SC Mn2+ injection releases Mn2+ in the plasma at a slow rate, thus avoiding 
systemic toxic effects; the same high dose Mn2+ injection via IV route releases 
the entire dose directly into the plasma which can lead to cardiac dysfunction.  
The dose dependence and temporal dynamics of Mn2+ after SC injection 
can prove useful for longitudinal in vivo studies that require brain enhancement to 
persist for a long period of time to visualize neuroarchitecture like in Alzheimer‟s 
disease, Parkinson‟s disease, amyotrophic lateral sclerosis, and other 
neurodegenerative diseases. 
7.1.3 Tumor Characterization 
The imaging of EGF receptors in brain tumors is essential for visualizing 
overexpression of EGFR as a signature of highly aggressive gliomas and for 
identifying patients that would benefit from anti-EGFR therapy.  
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Several methods have been utilized in the last three decades to visualize 
gliomas in the brain using MRI. The simplest of all is a straightforward 
administration of paramagnetic CAs such as Gd-DTPA in the vasculature (4-8). 
This method makes the glioma readily detectable due to the leakiness of the 
blood vessels in the glioma. The small molecular weight of Gd-DTPA (<1kD) 
causes rapid extravasation from the vascular space into the interstitial space. 
Sometimes, the CAs are bound to macromolecular proteins to keep the CAs 
circulating within the vascular space (9, 10). This is desirable since an 
intravascular CA can detect alterations in tumor vasculature that cannot be 
revealed by extravascular CA which leak out of the vascular space (11, 12). In 
either case, the CA only provides non-specific enhancement. Since gliomas tend 
to have a heterogeneous morphology, regions of the glioma that are poorly 
vascularized will show inadequate enhancement. 
Utilizing monoclonal antibodies is an approach that specifically targets the 
extracellular domain of EGFR. Several investigators have used CAs conjugated 
with monoclonal antibodies to detect different types of tumors (13-15). Anti-
EGFR monoclonal antibodies have a high affinity for binding to the receptor. 
Once the antibody is bound to other molecules, its binding affinity gets 
compromised. The CA concentration achieved by directly labeling monoclonal 
antibodies while maintaining appropriate binding affinity of mAb is not sufficient to 
generate adequate MR contrast. Other studies attempted to go around this 
problem by coating magnetic particles with mAb not having to chemically alter 
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the mAb (16-18). However, the resolution obtained using this method is not 
suitable to properly characterize tumors. A few studies have looked into alternate 
use of mAb in enhancing tumors (19, 20). Artemov et al. developed an indirect 
way of enhancing breast carcinomas by injecting CAs that bind to receptor bound 
mAbs (19). They prelabeled the extracellular domain of HER-2/neu receptor with 
biotinylated mAb and injected Gd-labeled avidin after clearance of unbound mAb. 
The Gd-labeled avidin bound to the biotinylated mAb with high affinity and 
produced high T1 contrast. They were able to target and image the receptors 
specifically. 
In the tumor characterization study, we investigated a novel pretargeting 
imaging approach using humanized monoclonal antibody (anti-EGFR mAb, 
EMD72000) linked to enzymes with complementing activities that use a low-
molecular weight paramagnetic molecule (diTyr-GdDTPA) as a reducing 
substrate administered following the mAb conjugates. We performed quantitative 
analysis of MR dynamic signal enhancement in human glioma xenografted 
animals that were: 1) imaged first by using “non-specific” paramagnetic CA; 2) 
imaged with the same CA after preinjecting of anti-EGFR antibody conjugates.  
The enzyme linked to EGFR-targeted antibodies converted the CA into 
reactive products thereby profoundly changing the tissue elimination kinetics. 
Therefore, in addition to imaging of the MR signal enhancement associated with 
tumor tissues in vivo the amplification strategy results in a kinetic signature 
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(biexponential contrast decay). The analysis of images acquired dynamically or 
by using end point imaging can establish the presence of cell surface marker and 
quickly delineate the areas where this marker molecule can be targeted for 
therapeutic purposes. For future studies, it will be interesting to see if other types 
of tumors display the same type of contrast washout kinetics with our novel 
pretargeting imaging approach.  
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infrared cameras during supine medical imaging 
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ABSTRACT 
 
    Patient motion during SPECT acquisition causes inconsistent projection data and reconstruction artifacts which can 
significantly affect the diagnostic accuracy of SPECT. The tracking of motion by infrared monitoring spherical 
reflectors (markers) on the patient’s surface can provide 6-Degrees-of-Freedom (6-DOF) motion information capable of 
providing clinically robust correction. Object rigid-body motion can be described by 3 translational DOF and 3 
rotational DOF. Polaris marker position information obtained by stereo infrared cameras requires algorithmic 
processing to correctly record the tracked markers, and to calibrate and map Polaris co-ordinate data into the SPECT co-
ordinate system. Marker data then requires processing to determine the rotational and translational 6-DOF motion to 
ultimately be used for SPECT image corrections. This processing utilizes an algorithm involving least-squares fitting, to 
each other, of two 3-D point sets using singular value decomposition (SVD) resulting in the rotation matrix and 
translation of the rigid body centroid. We have demonstrated the ability to monitor 12 clinical patients as well as 7 
markers on 2 elastic belts worn by a volunteer while intentionally moving, and determined the 3 axis Euclidian rotation 
angles and centroid translations. An anthropomorphic phantom with Tc-99m added to the heart, liver, and body was 
simultaneously SPECT imaged and motion tracked using 4 rigidly mounted markers. The determined rotation matrix 
and translation information was used to correct the image resulting in virtually identical “no motion” and “corrected” 
images. We plan to initiate routine 6-DOF tracking of patient motion during SPECT imaging in the future. 
 
Keywords: Motion, monitoring, correction, infrared, cameras 
 
1. INTRODUCTION 
 
    Patient motion during SPECT acquisition causes inconsistent projection data and reconstruction artifacts which can 
significantly affect the diagnostic accuracy of SPECT if not corrected [1-4]. There has been a significant amount of 
research on motion detection and correction in recent years. Optical and infrared cameras have been utilized to track 
patient motion [5-8]. Our current hypothesis is that the detection of patient motion by optical or infrared monitoring of 
the motion of spherical reflectors on the patient’s surface can provide 6-Degree-of-Freedom (6-DOF) motion 
information which can be used for clinically robust correction of patient motion [9, 10]. 
 
2. METHODS 
 
    Rigid-body motion of an object can be described by 3 translational degrees-of-freedom and 3 rotational degrees-of-
freedom (i.e., 6-DOF). We have previously demonstrated the feasibility of monitoring reflective spheres on elastic belts 
placed on the upper chest and lower abdomen of supine patients [8].   
 
2.1 Setup for patient motion tracking 
Fig.1 shows the setup used for tracking patient motion. A volunteer is shown on the imaging table of  the SPECT 
system employed positioned similar to that employed with patients. The upper and lower belts containing 4 retro-
reflective markers each, are both in the imaging volume. The Polaris system can be seen mounted on the wall to the 
right.  
 
2.2 Analysis methods  
Marker position information obtained by Polaris stereo-infrared cameras requires algorithmic processing to remove 
false marker indications, and then to calibrate and map the Polaris data into the SPECT co-ordinate system [8, 11]. A 
Neural Network algorithm [11] then decomposes marker data into periodic respiratory and non-periodic (assumed rigid-
body) motion. 
This assumed rigid-body motion marker data is then processed to determine patient 6-DOF motion. The x, y, and z 
motion data from the markers on the two belts is then input into an algorithm which involves the least-squares fitting of 
two 3-D point sets. One set is the initial marker positions and the second set the positions after a time period. The 
algorithm uses singular value decomposition (SVD) and results in the rotation matrix and translation of the rigid body 
centroid [12] from the initial to the time period position. Simulations of known rotations and translations have been 
successfully used to verify algorithm operation. 
Ultimately the 6-DOF data will be used for SPECT image corrections as previously demonstrated [10]. The image 
correction method works as the interpolation step during projection and backprojection. It moves the current emission 
voxel estimates and attenuation maps to the new location when calculating the projection, and moves back the 
contribution to the voxel estimates to the original location after performing backprojection. 
 
2.3 Volunteer feasibility study 
     A total of 14 volunteers were monitored by Polaris while positioned for SPECT imaging, but without SPECT image 
acquisition. The 5 males and 9 females were successfully tracked by the Polaris system. This served as an initial test as 
to the feasibility of monitoring to acquire the necessary marker position data to compute the 6-DOF motion information 
necessary for image motion correction.  
    One male volunteer was asked to move during this testing phase in order to validate the 6-DOF rotation and 
translation computation based on the rigid-body motion component obtained by our Neural Network algorithm 
decomposition [11].  
   The remaining 4 males and 9 females were asked to remain motionless, thus the respiratory motion was the primary 
component. Detailed results of the respiratory amplitudes observed for a medially located sphere on the upper and lower 
belts for the lateral X axis, vertical Y axis and axial Z axis have been reported previously for these volunteers [13]. 
 
2.4 Clinical patient acquisitions 
    A total of 12 clinical patients (4 females, 8 males) were monitored by Polaris while wearing the upper chest and 
lower abdomen 4 marker belts and undergoing clinical SPECT imaging. A total of at least 3 markers from the two belts, 
with at least 2 from either belt, are necessary to compute 6-DOF information when the body is assumed to be moving as 
a rigid-body. It should be noted that one large girth male tested only showed 1 lower belt marker, one female showed 
only the lower belt 4 markers due to a garment fold obscuring the upper belt markers, and another female showed 1 
marker each on the upper and lower belts (reason unknown). As we improved our technique for belt placement and 
became aware of garment folds that could obscure marker viewing, we were successfully monitoring all 8 markers more 
consistently.   
 
2.5 Anthropomorphic phantom acquisition 
    An anthropomorphic phantom experiment was conducted to determine if the 6-DOF motion obtained from SVD of 
the Polaris data could be used to correct for motion. The relative concentrations of Tc-99m in the heart, liver, and 
background were 1.0, 1.0, 0.1, respectively. The phantom was simultaneously SPECT imaged and motion tracked using 
4 rigidly mounted markers for 3 simulated motion steps. The SVD processing produced 6-DOF motion data which was 
used in image reconstruction. 
 
3. RESULTS AND DISCUSSION 
 
3.1 General  
    For reference, Fig. 2 shows the SPECT image coordinate system to which the Polaris marker positions were mapped.  
 
3.2 Volunteer feasibility study 
    An example of the variation in location of the markers for the volunteer who was requested to move slightly during 
motion tracking is shown in Fig. 3. This figure shows the initial and 5 other positional states observed during motion 
tracking displayed in a 3D plot. Note only 7 of the 8 markers were successfully observed in this volunteer. The marker 
positions from this volunteer were used to estimate the 6-DOF rotational and translational motion of this volunteer. Fig. 
4 shows the resulting calculated variation in the 6-DOF position of the volunteer relative to their initial location for the 
selected 5 time points illustrated in Fig. 3. As expected from viewing the 3D plot of the positions in Fig 3. the greatest 
variation was in a y-axis (vertical) translation with the rest of the 6-DOF motion being smaller in magnitude. 
 
3.3 Clinical patient acquisitions 
   Fig. 5 shows a single clinical patient’s non-periodic motion after removal of the respiratory (periodic) component by 
the use of our Neural Network algorithm [11]. The motion plotted is the change from the baseline position. The left side 
3 graphs, from the top down, are for the Upper Chest lateral X axis, vertical Y axis, and axial Z axis showing motion for 
markers 1 through 4 during the approximately 16 minute period of SPECT acquisition. The right side graphs, from the 
top down, are for the Lower Abdomen lateral X axis, vertical Y axis, and axial Z axis motion for markers 5 through 8. 
At a Polaris sample rate of 20 samples per second for the approximately 16 minute (1000 sec) duration of SPECT 
acquisition resulted in about 20,000 recordings of the X, Y, and Z location for each marker. For display purposes in this 
manuscript we have plotted the results at 500 sample (25 second) intervals. 
   What can be seen is that the lateral X axis motion is between 0 to -2 mm for both the upper and lower belts, with all 
the markers on each behaving similarly. The vertical Y axis upper chest shows all 4 markers tending to go downwards, 
between -3 to -7 mm during the course of SPECT acquisition. The vertical Y axis lower abdomen shows more 
downward motion, with all 4 markers drifting downwards between -10 to -11 mm. Thus the abdomen shows a settling 
indicative of what may be a decrease in the magnitude of respiration during SPECT acquisition. This might be an 
indication of what causes “cardiac creep” which is a gradual upward movement of the heart in the chest during 
acquisition and is noted clinically in some patient studies. The axial Z axis shows a general upward change for both the 
upper and lower belt markers of about +2 to + 4 mm and this would be indicative of the patient shifting in a direction 
away from the SPECT gantry towards his own head. The only other interesting observation is the upper chest marker 1 
Z axis motion downwards then back upwards between 175 and 375 seconds, and this could be indicative of the patient 
taking his arm from behind his head and lowering it towards his side and then putting it back behind his head.  
   Fig. 6 shows the 6-DOF calculated motion relative to the initial location of the patient for the clinical patient whose 
marker information was shown in Fig. 5. The data for the remaining 11 patients is not displayed herein due to space 
limitations. The translations shown in Fig. 6a are in millimeters (mm) showing the change from the baseline position, 
and of most interest is the translation in the Y axis of about -8 mm. The rotation matrix information, Fig. 6b, has been 
converted to Euclidian angles showing rotation of the assumed rigid-body about each of the respective X, Y, and Z 
axes. What is of the most interest is the rotation about the X axis, which can be visualized as the patient’s abdomen 
lowering, and this can be seen to be about -2 degrees. 
   The behavior in Fig. 6a and 6b showing downward Y axis abdomen marker movement is consistent with the actual 
marker data shown in Fig. 5c and 5d showing similar downward Y axis motion. This shows the consistency of the 
computed 6-DOF motion information and the actual individual marker motions. 
 
3.4 Anthropomorphic phantom acquisition 
The anthropomorphic phantom experiment tracked the 4 rigidly mounted markers for the 3 motion steps. The 
determined 6-DOF information for each of the steps was used during reconstruction to correct for the observed motion. 
This resulted in virtually identical “no motion” and “corrected” images as shown in Fig. 7.  
 
4.0  CONCLUSIONS 
 
   We have successfully monitored 12 clinical patients while undergoing actual SPECT acquisitions as demonstrated 
herein, and have computed 6-DOF rigid-body motion rotation matrices and centroid translations providing the basis for 
image motion correction. The 6-DOF motion, determined during the anthropomorphic phantom experiment, was 
successfully used to correct the SPECT image for motion artifacts demonstrating the promise of our methodology. A 
comparison of actual marker motion changes from baseline position compared to the calculated rigid-body 6-DOF 
motion shows evidence of residual non rigid-body motion and will be evaluated in further future studies. 
 
 
ACKNOWLEDGEMENTS 
   This work was supported by the National Institute for Biomedical Imaging and Bioengineering (NIBIB), grant R01 
EB001457. The contents are solely the responsibility of the authors and do not necessarily represent the official views 
of the National Institutes of Health.   
REFERENCES 
 
[1] E. H. Botvinick, Y. Y. Zhu, W. J. O'Connell, and M. W. Dae, "A quantitative assessment of patient motion and its 
effect on myocardial perfusion SPECT images," J.Nucl.Med, vol. 34, no. 2, pp. 303-310, Feb.1993. 
[2] F. M. Prigent, M. Hyun, D. S. Berman, and A. Rozanski, "Effect of motion on thallium-201 SPECT studies: a 
simulation and clinical study," J.Nucl.Med, vol. 34, no. 11, pp. 1845-1850, Nov.1993. 
[3] J. A. Cooper, P. H. Neumann, and B. K. McCandless, "Effect of patient motion on tomographic myocardial 
perfusion imaging," J.Nucl.Med, vol. 33, no. 8, pp. 1566-1571, Aug.1992. 
[4] C. Bai, and R. Conwell, “A Systematic Simulation Study of the Effects of Patient Motion on Cardiac Perfusion 
Imaging Using Single Photon Emission Computed Tomography,” [abstract], Society of Nuclear Medicine 52nd Annual 
Meeting, June 18-22, 2005, Toronto, Canada. 
[5] R. R. Fulton, S. Eberl, S. R. Meikle, B. F. Hutton, and M. Braun, "A practical 3D tomographic method for correcting 
patient head motion in clinical SPECT," IEEE Trans Nucl Sci, vol. 46, no. 3, pp. 667-672, 1999. 
[6] B. J. Lopresti, A. Russo, W. F. Jones, T. Fisher, D. G. Crouch, D. E. Altenburger et al., "Implementation and 
performance of an optical motion tracking system for high resolution brain PET imaging," IEEE Trans Nucl Sci, vol. 
46, no. 6, pp. 2059-2067, 1999. 
[7] R. R. Fulton, S. R. Meikle, S. Eberl, J. Pfeiffer, R. T. Constable, and M. J. Fulham, "Correction for head movements 
in positron emission tomography using an optical motion-tracking system.," IEEE Trans Nucl Sci, vol. 49, no. 1, pp. 
116-123, 2002. 
[8] R. D. Beach, P. H. Pretorius, G. Boening, P. P. Bruyant, B. Feng, R. R. Fulton, M. A. Gennert, S. Nadella, M. A. 
King, “Feasibility of stereo-infrared tracking to monitor patient motion during cardiac SPECT imaging,” IEEE Trans 
Nucl Sci, vol. 51, pp. 2693-2698, 2004. 
[9] Boening G, Bruyant PP, Beach RD, Byrne CL, King MA. Motion correction for cardiac SPECT using a RBI-ML 
partial-reconstruction approach. Proceedings of 2004 IEEE Medical Imaging Conference, M4-6, in press. 
[10] Bing Feng
1
, Howard C. Gifford
1
, Richard D. Beach
1
, Guido Boening
1
, Michael A. Gennert
2
, Michael A. 
King
1
,¹Radiology, University of Massachusetts Medical School, Worcester, MA, USA, ²Computer Science, Worcester 
Polytechnic Institute, Worcester, MA, United States, Use of Three-Dimensional Gaussian Interpolation in the 
Projector/Backprojector Pair for Compensation of the Known Rigid-Body Motion in SPECT, IEEE Transactions on 
Medical Imaging, (February 2006, in press)  
[11] R. D. Beach, H. Depold, G. Boening, P. P. Bruyant, B. Feng, H. C. Gifford, M. A. Gennert, S. Nadella, M. A. 
King, “An Adaptive Neural-Network Approach to Decomposing Patient-Motion Tracking Data Acquired During 
Cardiac SPECT Imaging”, In: Conference Record 2004, IEEE Nuclear Science Symposium, Medical Imaging 
Conference (NSS/MIC) October 2004, IEEE, Rome, Italy. 
[12] K. S. Arun, T. S. Huang, S. D. Blostein, Least-Squares Fitting of Two 3-D Point Sets, IEEE Transactions on 
Pattern Analysis and Machine Intelligence, Vol. PAMI-9, No. 5, September 1987. 
[13[ Beach, Richard D., Gifford, Howard C., Shazeeb, Salman, Bruyant, Philippe P., Feng, Bing, Gennert, Michael A., 
“Stereo-Infrared Tracking to Monitor and Characterize Rigid-Body Motion and Respiration During Cardiac SPECT 
Imaging: Progress Towards Robust Clinical Utilization”, In: Conference Record (May 11, 2005) – IEEE Nuclear 
Science Symposium, Medical Imaging Conference (NSS/MIC) October 23-29, 2005, Wyndham El Conquistador Hotel, 
Puerto Rico. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. The Polaris system is seen on the far right mounted on the wall. It views the Infrared (IR) reflecting spheres 
(white spots) on the anterior surface of patients on two elastic belts. The upper chest belt, by our chosen convention, 
contains markers 1 through 4, starting with 1 on the patient’s right. Similarly, the lower abdomen belt has markers 5 
through 8, starting with 5 on the patient’s right.   
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Fig. 2.   (a) SPECT imaging axis convention utilized for mapping of Polaris position data – Right Handed System, (b) 6 
Degree of Freedom (6-DOF) convention for + angular rotations about the 3 Axes (i.e. Counter clockwise (CCW) 
looking inwards towards the origin will be the + angular rotation) 
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Fig. 3.  Marker positions shown in 3D axis of SPECT mapped co-ordinate system showing original 
and 5 later positions. 
Fig. 4.  (a) Euclidian Rotation Degrees (derived from rotation matrix) and (b) centroid 
translation of the 7 marker assumed rigid-body motion at the 5 volunteer positions of Fig. 3 
relative to the starting position.  
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Fig. 5. Clinical patient Non-Periodic or assumed to be rigid-body motion, relative to the baseline position of the 8 individual 
markers. The displayed data for this assumed rigid-body motion were obtained using our Neural Network algorithm 
processing to decompose the combined motion data into respiration (periodic) and remaining patient motion (non-periodic) 
components. Motion data was obtained over an approximately 16 minute SPECT acquisition with Polaris motion data 
gathered at 20 samples per second. Shown is a sample at 500 sample intervals from the approximately 20,000 samples 
recorded showing : (a) Upper Chest Horizontal Lateral (X axis) markers 1 thru 4, (b) Lower Abdomen Horizontal Lateral 
(X axis) markers 5 thru 8, and similarly (c) Upper Chest Vertical (Y axis), (d) Lower Abdomen Vertical (Y Axis), (e) Upper 
Chest Axial (Z Axis), (e) Lower Abdomen Axial (Z Axis), (g) Numbering convention for the Upper Chest and Lower 
Abdomen 4 marker belts.  
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Fig. 6. Clinical patient 6-DOF motion during an actual 16 minute SPECT acquisition with Polaris motion data gathered at 20 samples per 
second. Shown at 500 sample intervals over the approximately 20,000 samples recorded  showing: (a) translation of the 8 marker assumed 
rigid-body centroid from the baseline position, (b) Rotation of the 8 marker assumed rigid-body about its centroid around the horizontal X 
axis (rotX, denoted by angle  in Fig. 2), around the vertical Y axis (rotY, denoted by angle  in Fig. 2), and around the axial Z axis (rotZ, 
denoted by angle  in Fig. 2) from the baseline orientation position. 
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Fig. 7.  Anthropomorphic Phantom: reconstructed slice through heart: (a) no motion, (b) motion no correction, (c) after motion 
correction, (d) count profile from locations indicated by bars in a, b, and c. 
 (a)                                          (b)                                              (c) 
(d) 
       
Abstract— Patient motion during cardiac SPECT imaging can 
cause diagnostic imaging artifacts. Our approach is to monitor 
patient motion during cardiac SPECT imaging using the Polaris 
stereo-IR real-time motion-tracking system. In our earlier work 
[1] we obtained excellent correlation of axial and vertical motion 
as measured by our SPECT system with the Polaris. We also 
showed a good correlation for Polaris tracking of respiration for 
volunteers with data from a pneumatic bellows. Herein, we show 
the successful monitoring of patients during cardiac SPECT 
perfusion imaging. We wrapped elastic belts with four IR 
reflecting spheres on each about the chest and abdomen of the 
patients. The Polaris system reported the 3D location of these 
spheres in a random order intermixed with the location of 
“phantom” spheres. We developed routines to automatically 
recognize and discard the Phantom spheres, consistently order 
the true spheres, and covert Polaris coordinates to SPECT 
coordinates given a calibration. For our 12 analyzed clinical 
patients the data shows that both males and females at rest were 
primarily abdomen breathers with the male peak to peak 
average vertical respiration amplitude larger at 9.2 mm than 
that for the females at 5.6 mm. The male chest average vertical 
amplitude was also a bit larger at 1.6 mm vs. 1.4 mm for 
females. During the 16 minute SPECT acquisition the average 
vertical axis difference between end-expiration levels for the 
abdomen for combined males and females was -4.2 mm, with 
males slightly larger at -4.72 mm vs. females at -3.81 mm. The 
largest vertical end expiration change was -9.0 mm, and was 
observed in the male with the highest Body Mass Index (BMI) of 
44.2. 
  Index Terms— motion, position, SPECT, clinical 
I.   INTRODUCTION 
atient motion can be a major cause of diagnostic imaging 
artifacts, especially in SPECT and PET imaging. Motion 
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information obtained from a six-degree-of-freedom (6-DOF) 
stereo-infrared system can provide input for compensation of 
patient motion as part of iterative reconstruction [1, 2], and 
has also been demonstrated during PET brain imaging [3]. 
We are utilizing the passive version of the Polaris Tracking 
System from Northern Digital Inc., which uses infrared (IR) 
reflection from small spherical targets to provide real-time 
tracking of position and orientation with manufacturer stated 
0.35 mm accuracy and 0.2 mm repeatability. The spheres 
may be grouped into “tools” with fixed geometry that may be 
tracked as one; or the spheres may be individually tracked. 
We have selected the latter mode as being more flexible, and 
better suited to our imaging geometry. As illustrated in Fig. 1, 
Polaris is oriented such that it views the elastic-belt-mounted 
spheres, positioned on the anterior surface of patients, 
through the tunnel of the SPECT gantry. Polaris reports the 
locations of the spheres at approximately 20 samples/second 
enabling the tracking of both respiratory and body motion. 
The choice of tracking individual spheres presented us with a 
number of design issues to be overcome to permit robust 
tracking of patient motion in the clinic. Our goal herein is to 
present our solution to these issues and the results of our first 
clinical usage of the system..   
 
 Fig. 1.  The Polaris system  is seen on the far right mounted on the wall. The 
white spots on the 2 belts are the attached IR reflecting spheres. Volunteer 
and SPECT camera setup was performed by a technologist matching what 
would be employed clinically. 
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 II.   METHODS 
A. Equipment used    
    We utilized the passive version of the Polaris Tracking 
System from Northern Digital Inc. as shown in Fig. 1. As 
employed herein it uses infrared (IR) reflection from small 11 
mm diameter spherical targets to provide real-time tracking 
of the position and orientation in 3 dimensions (3D) of 
individual spheres. The sphere locations as reported in the 
Polaris coordinate system are transformed to that of the 
SPECT system by use of a matrix transformation based on 
calibration studies [1] so that the axes are  X (lateral), Y 
(vertical), and Z (axial). Calibration is performed by 
acquiring the location of 4 spheres by both Polaris and 
SPECT. Thus for calibration mapping purposes, a small 
amount of Tc-99m is deposited in wells at the top of the bases 
to which the spheres are attached. Fig. 2(a) shows a tool with 
3 spheres rigidly attached to the back side of the tunnel of the 
SPECT gantry in a location where it is unlikely to be 
disturbed during patient imaging. We use imaging of this to 
assure the Polaris has not moved thus invalidating a previous 
calibration necessitating a new one. Fig. 2(b) shows chest and 
abdomen belts worn by a volunteer, which were typical of 
those used on the clinical patient. The belts were made of a 
disposable sticky elastic bandage material (cost about $1 
each) and the plastic bases on which the spheres were 
mounted were attached to the belts by eight ½ inch sticky 
back Velcro dots (cost about $0.05 each) for a total cost per 
patient of $2.40. The low cost was important as it allows the 
belts to be disposed of after each use for infection control. 
The spherical markers and mounting bases were reusable 
since they are considerably more expensive. Plastic risers of 
about ½ inch maximum height were used on the upper (chest) 
belt of males if required to facilitate viewing but were not 
needed on females.    
 
Fig. 2.  Showing: (a) The gantry mounted 3 sphere tool used for calibration 
stability monitoring; (b) volunteer with two 4-sphere elastic belts placed 
about the upper (chest) and lower (abdomen) torso.  
B. Can Polaris Reliably View Patients undergoing SPECT    
The first major issue was determining if the system could 
reliably view the chest and upper abdomen of patients being 
imaged by our Philips Medical Systems Irix SPECT system. 
The need to monitor the motion of both the chest and 
abdomen stems from patients generally falling into the 
categories of abdomen breathers (primarily breathe with 
diaphragm) and chest breathers (primarily breathe by rocking 
ribs hinged at back-bone). We therefore place a stretchable 
belt with spheres about both the chest and abdomen. The dual 
belts shown in Fig. 1 and Fig. 2 (b) were successfully tracked 
by Polaris for 11 clinical patients undergoing actual SPECT 
acquisitions, as well as for 9 female and 5 male volunteers of 
different body shapes and sizes. In one additional male 
patient solely a sphere on the abdomen belt was visible. Fig. 
3 is an example of the type of body habitus which presented 
this problem for Polaris in viewing the spheres on the chest 
belt. We recently incorporated a small variable height 
elevation of the spheres on the belts when necessary, to 
overcome viewing limitations due to physique variations. 
Similar issues can arise due to garment cloth folds between 
the upper and lower belts which would have the same effect. 
Fig. 4 shows an example of typical volunteer Polaris 
recorded data after conversion to IRIX coordinates. A 
medially located marker on both the abdomen and chest are 
shown. This volunteer data was gathered over a 2 minute 
time period at about 20 samples per second, thus about 2500 
samples are shown. 
 
Fig. 3. Body habitus potential belt viewing limitations such that upper (chest) 
belt mounted 4 markers may not be seen by Polaris, while lower (abdomen) 
belt mounted 4 markers will be easily seen.   
 
Fig. 4. Plots of recorded Polaris position data (Actual-Average) for a typical 
volunteer taken during a 2 minute duration showing the motion in 3 axes by 
solid line X (lateral), dotted line Y (vertical), and dashed line Z (axial) for: 
(a) an abdomen and; (b) chest spheres. Note the use of finer scale for the 
chest locations plotted in (b). 
C.   How Many Markers are Required to Determine Motion  
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  A second major issue was to determine the optimal number 
and arrangement of spheres based on our desire to track 
respiration, 6-DOF rigid-body motion, and in the future, non-
rigid-body motion. Tradeoff considerations are the minimum 
number of spheres to obtain the required information while 
minimizing the potential number of Polaris “phantom” 
spheres, which potentially number (N)*(N-1) where N is the 
true number of markers. Phantom spheres are false spheres 
which appear to be present when Polaris decodes its stereo-IR 
images, but do not correspond to actual physical spheres. 
Typically, the number of phantoms does not reach its 
maximum, but does vary during data acquisition. Fig. 5 
shows sphere positional data and the typical appearance of 
phantoms reported in the vicinity of the two 4-sphere elastic 
belts. The more varied the geometry of sphere placement, the 
more complex the phantom detection handling algorithm 
becomes. We thus settled on utilizing 2 belts, each with a 
linear arrangement of 4 markers laterally. Fig. 6 is a diagram 
showing how Polaris creates the untrue phantom locations 
which our processing algorithm must deal with. 
 
Fig. 5. An overhead plot of sphere locations for two volunteer worn 4-sphere 
belts with 9 phantom locations also shown. The true 4 sphere vertical 
alignments of the belts can be seen at about -2000 and -2200 on the Polaris Z 
(axial) axis.  
 
 
Fig. 6. Phantom sphere location creation. If Polaris detects 2 true spheres in 
the same plane extending from Polaris, it creates 2 untrue phantoms at the 
intersection of the rays.  
D. Algorithm to Process Raw Polaris Coordinate Data into 
SPECT Image Coordinates  
The third major issue was how Polaris randomly switches 
the reported order of spheres and intermixes the locations of 
phantom spheres. We have successfully implemented a 
processing algorithm which uses gamma-camera geometrical 
constraints, belt-geometry characteristics, and patient 
physical motion rate limitations to remove phantoms and 
reflections and order the valid spheres so motion can be 
tracked. Details of this processing will be given in our 
manuscript to be submitted for peer-review. 
 
 
Fig. 7. Plot of Polaris vertical, lateral, and axial position data for a gantry a 
mounted sphere (marker) shown in Fig 2 (a) used for monitoring calibration 
stability..  
III.   RESULTS AND DISCUSSION 
 Fig. 7 shows Polaris sphere positional information in IRIX 
co-ordinates for one of the three spheres used to monitor the 
stability of the Polaris to SPECT calibration during the time 
clinical patients studies were acquired. Known remounting of 
Polaris on 9/19, brushing into Polaris on 9/21, and bumping 
into Polaris on 9/26 necessitated re-calibrations which can 
clearly be seen. However, from 9/26 through 10/3 nine 
patients were processed with the same calibration since 
Polaris was not disturbed. Closer observation of all 3 sphere 
values showed similar stability justifying the decision. 
A. Can Polaris Reliably View Patients undergoing SPECT  
As mentioned earlier, in one male case only 1 abdomen 
marker was visible. Also, in one female case a garment cloth 
fold resulted in only the 4 abdomen markers being visible. In 
all other cases at least some markers on both belts were seen. 
In the cases where spheres on both belts were not seen,  
spheres on the abdomen belt were seen. The 45 mm 
unstretched spacing between belt spheres stretches to about a 
70 mm spacing when placed on the patients or volunteers. 
The distance from the leftmost sphere to the rightmost marker 
is then about 210 mm on the four marker belts which cover 
the regions of interest on the upper chest and lower abdomen. 
These marker spacings were determined to be optimal 
providing sufficient lateral chest and abdomen coverage for 
useful torso motion information and still be viewable by 
Polaris.  
Fig. 8 shows average peak-to-peak “Vertical” axis 
amplitude of respiratory motion on medially located spheres 
on the chest and abdomen belts. In Fig. 8 (a), 14 volunteers 
were asked to remain motionless and breathe normally. 
Vertical amplitude of respiratory movement of spheres on the 
abdomens was larger than the vertical movement of spheres 
on the chests for all 9 females (avg. 5.8 mm vs 1.8 mm) and 5 
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 males (avg. 10.4 mm vs 1.7 mm). In Fig. 8 (b), 12 clinical 
patients were monitored during rest perfusion SPECT 
imaging with IRB approval, with similar results to the 
volunteers. For the 4 females the abdomen versus chest 
average vertical amplitude was 5.6 mm vs. 1.4 mm, and for 8 
males it was 9.2 mm vs. 1.6 mm. The chest belt was not 
visible for one female and male thus those averages were 
based on 3 and 7 respectively. On average the abdomen 
sphere vertical motion was larger for males than for females. 
In both studies, the abdomen-sphere axial amplitude 
generally remains below 3 mm, with chest-sphere below 2 
mm. Lateral amplitudes are generally the smallest due to the 
medial location of the spheres chosen for reporting. There 
does not appear to be any noticeable correlation between 
Body Mass Index (BMI) and respiration amplitude for males 
or females.  
 
 
 
Fig. 8. Average respiratory peak-to-peak amplitude in mm for motion of 
abdomen and chest spheres located medially on the belts for: (a) 9 female 
(F1-F9), and 5 male (M1-M5) volunteers; (b) 12 clinical patients, 4 females 
(F1RP-F4RP), and 8 males (M1RP-M8RP). 
B. How Many Markers are Required to Determine Motion   
The upper and lower belts have 4 makers on each belt 
which span the torso (about 210 mm), Fig. 2 (b), and are still 
normally viewable by Polaris for most patients. The belts 
were typically centered on the patients or volunteers, and the 
most lateral markers are at 105 mm, with the most medial at 
35 mm considering a 70 mm marker stretched belt spacing. 
Anatomical patient variations sometimes prevent markers 
from being seen, Fig. 3, (e.g. upper belt markers on an obese 
patient), and during respiration and other patient motion 
markers are sometimes not visible by Polaris. Folds of 
hospital garments or other clothing sometimes block a 
marker. 
For these reasons the 4 marker belt was utilized in lieu of a 
3 marker version which was considered. The reasoning being, 
that if some markers were not visible on either the upper or 
lower belt a sufficient number of markers would still be 
visible to allow 6-DOF motion computations. This requires a 
minimum of 3 visible markers, with 1 or more from each belt. 
This would allow rigid-body motion determination for the 
full patient torso. However, if 3 or 4 markers are visible on a 
single belt such as the upper one, 6-DOF motion 
determination for the anatomy in the vicinity of the heart 
could still be very useful as well.. 
 
               M4RP – Low -  R                          M4RP - upper -  R  
 
              M6RP – Low – NR                          M6RP – Up - NR 
 
           M5RP – Low – NR + R                    M5RP – Up – NR + R 
 
      M8RP – Low – NR + R                   M8RP – Low – NR + R 
Fig. 9. Typical patient plots of abdomen and chest sphere position data 
(shown as “actual value”-“average value” for plotting purposes) during the 
full 16 minute clinical SPECT acquisitions. IRIX SPECT image coordinate 
axes are: X (lateral), Y (vertical), Z (axial). “R” indicates potential Rigid-
Body Motion, and “NR” potential Non-Rigid motion.   
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 C. Algorithm to Process Raw Polaris Coordinate Data into 
SPECT Image Coordinates 
Fig. 9 shows examples of typical clinical patient data 
recorded for a single medially located sphere on each of the 
belts during the approximately 16 minute SPECT 
acquisitions. The plots shown are the Polaris data after 
processing to remove phantoms, sort the valid belt markers, 
and map Polaris coordinate system values to IRIX SPECT 
image coordinates. Each of the patient plots are paired left 
and right, showing identifying number first, then Low 
(abdomen) belt or Up (chest belt)), followed by either an R, 
NR, or NR + R. The R indicates cases of suspect rigid-body 
motion since motion in both belts can be seen. NR are cases 
of suspect non-rigid body motion since motion is seen in one 
belt but not the other. NR + R cases are suspect of both 
motion types.   Fig. 10 plots the change (delta) in end 
expiration levels for X (lateral), Y (vertical), and Z (axial) 
axis motions between the beginning and end of the SPECT 
acquisition. This delta data was derived from the plotted 
Polaris data for all 12 clinical patients, examples of which are 
shown in Fig. 9. See Fig. 11 for a detail of how the delta 
values were derived from the plots for each axis. The largest 
Y (vertical) end expiration delta seen was -9.00 mm, and was 
observed in the male with the highest BMI of 44.2. 
Upper / Lower Marker Deltas (0-16 min) at Expiration
-10.00
-8.00
-6.00
-4.00
-2.00
0.00
2.00
4.00
6.00
8.00
F1
R
P
F2
R
P
F3
R
P
F4
R
P
M
1R
P
M
2R
P
M
3R
P
M
4R
P
M
5R
P
M
6R
P
M
7R
P
M
8R
P
Subject
Po
si
tio
n 
D
el
ta
 (m
m
)
Lower X(lateral) axis Upper X(lateral) axis Lower Y(vertical) axis Upper Y(vertical) axis Lower Z(axial) axis Upper Z(axial) axis  
Fig. 10. Plot of X (lateral), Y (vertical), and Z (axial) axis deltas, where 
(delta=end – beginning) position change for abdomen (lower) and chest 
(upper) markers for 12 clinical patients. 
 
Fig. 11. Detail of how expiration delta values were derived for each axis 
from the 12 clinical patient plots, examples of which are shown in Fig. 9. 
Table 1 shows that the average deltas for All (males and 
females) of lower belt Y (vertical) axis are largest at an 
average of -4.42 mm. The Z (axial) axis shows the next 
largest deltas, and X (lateral) axis the smallest changes from 
start to end of the clinical SPECT acquisition. The average 
Male delta of the lower belt Y (vertical) is larger than for 
Females (-4.72 mm vs. -3.81 mm). The average Male delta of 
the upper belt Y (vertical) is also larger than for the Females 
(-2.93 mm vs. -1.93 mm). 
TABLE I 
UPPER (CHEST) AND LOWER (ABDOMEN) MEDIAL MARKER DELTAS  FOR 12 
CLINICAL PATIENTS IN THE X (LATERAL), Y (VERTICAL) AND Z (AXIAL) 
AXES  
 X 
avg. 
(mm) 
X    
SD 
(mm) 
Y  
avg. 
(mm) 
Y   
SD 
(mm) 
Z  
avg. 
(mm) 
Z   
SD 
(mm) 
Lower Female 0.59 1.09 -3.81 2.00 -0.79 2.91 
            Male -0.42 1.54 -4.72 2.65 1.31 2.65 
Upper Female 0.12 0.65 -1.93 2.16 -0.08 0.79 
            Male -1.24 2.31 -2.93 1.18 0.14 2.03 
Lower All -0.08 1.44 -4.42 2.40 0.61 2.80 
Upper All -0.83 2.02 -2.63 1.48 0.07 1.71 
 
IV.   CONCLUSIONS 
We have successfully demonstrated the ability of Polaris to 
monitor 12 clinical patients during actual SPECT 
acquisitions. We have also quantified the X, Y and Z axis 
motion observed using end expiration deltas between the start 
and end of the 16 minute SPECT acquisition, as well as 
determined the average peak to peak respiration amplitudes 
over the same time period.   
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Deconvolution of Compartmental Water Diffusion Coefficients in Stroke Using DW-IR MEMRI 
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Introduction: The apparent diffusion coefficient (ADC) of brain water is known to 
decrease in ischemia.1 Although the mechanism of the decrease is not well understood, it 
is thought to be related to relative changes in the intra- and extra-cellular volume 
fractions during ischemia.2,3 We sought to identify the relative contributions of intra- and 
extracellular water ADC changes during ischemia using Mn2+ as an intracellular MRI 
contrast agent. Intracerebroventricular (ICV) infusion of Mn2+ results in neuronal uptake, 
selectively shortening the T1 and T2 relaxation times of intracellular water. The relative 
differences in T1 or T2 relaxation times between the two compartments can be used to 
selectively null the signal from one of the compartments.4 In the first set of experiments, 
the average T1 and T2 relaxation times of water were measured in the intra- and 
extracellular compartments post-Mn2+ infusion. Secondly, diffusion-weighted inversion-
recovery (DW-IR) images were acquired from each compartment by choosing an 
inversion time (TI) to selectively null the MRI signal from the other compartment.  
 
Methods: All MR imaging was performed on a Bruker Biospin 2T/45 cm horizontal bore 
system equipped with 200mT/m gradients and a surface coil for RF transmit and receive. 
Two groups of rats (SD, 275-300g) were used in this study. The first group (n=5) was 
anesthetized with intraperitoneal injection of chloral hydrate (400 mg/kg) and 
immobilized on a stereotactic frame. Manganese, 50 µl of 25 mM MnCl2 in saline, was 
infused ICV over 2 mins through a burr hole the skull (0.8 mm posterior, 1.2 mm lateral 
to the bregma, and 4mm below the skull). T1 was measured using an IR sequence 
acquired at 2, 12, 24, 48, 72 and 96 hrs time-points post-ICV infusion of Mn2+. A sech 
pulse was used for adiabatic spin-inversion and TI values (21) were spaced 
logarithmically from 14.88-5000 ms. Other imaging parameters were TR = 7.5 s, TE = 7 
ms, FOV = 31 mm, 64 × 64 data matrix with an in-plane resolution of 484 microns and 5 
slices of 1mm thickness. T2 was measured using a CPMG sequence with identical 
resolution (TR = 5 s, TE varied in 24 steps between 4.5 ms and 108 ms). Bi-exponential 
T1 and T2 maps were calculated using Matlab.   
  
In a second group (n=4), Mn2+ was infused (ICV) 72 hrs prior to middle cerebral artery 
occlusion (MCAO). MRI was performed 2 hrs post-MCAO. Eleven DW-IR MRIs were 
acquired with b-values from 5-1080 s/mm2 and TR = 5 s, TE = 27 ms, FOV = 31 mm, 64 
× 64 matrix acquisition (in-plane resolution of 484 microns), 5 1-mm-thick slices, δ = 8 
ms, ∆ = 13 ms and diffusion gradients applied in three directions simultaneously. TI 
values of 100 ms and 450 ms were used to null the intra- and extracellular water signals, 
respectively. Average ADC was calculated from each brain hemisphere and compared 
across all 5 slices. A single-tailed, paired-t-test analysis was used; p<0.05 was considered 
statistically significant. 
 
Results and Discussion: T1-weighted images acquired at various time points showed 
uniform enhancement in the brain at 72 hours post-ICV Mn2+ infusion (the time point 
used for all experiments). The average bi-exponential T1 values were T1a ~ 150 ms; M0a = 
64%; T1b ~ 700 ms; M0b = 34% (Fig 1); the bi-exponential T2 values were T2a ~ 9 ms; M0a 
= 66%; T2b ~ 51 ms; M0b = 34%. Extracellular ADC values calculated from DWIs with TI 
= 100 ms (intracellular water signal nulled) decreased significantly from 1.3 × 10-3 mm2/s 
to 1.1 × 10-3 mm2/s during ischemia (Fig 2). Similarly, intracellular ADC values 
calculated from DWIs with TI = 450 ms (extracellular water signal nulled) showed a 
significant reduction from 0.88 × 10-3 mm2/s to 0.72 × 10-3 mm2/s in the ischemic 
hemisphere (Fig 3). Since Mn2+ distribution was not uniform in all brain regions, there 
may be some signal cross-contamination between compartments if each component is not 
completely nulled at their respective TI values.  
 
Conclusion: ICV infusion of Mn2+ appears to achieve sufficient intracellular concentrations of Mn2+ to move the inter-compartmental equilibrium water exchange into 
the slow-exchange regime5.  When this is the case, it is in principle possible to separate the intra- and extracellular water signals on the basis of differences in their 
respective T1 and T2 relaxation times. The ADCs measured separately from intra- and extracellular water in ischemic rat brain showed a significant reduction during 
cerebral ischemia.  However, the absolute values of both the intra- and extracellular ADCs are somewhat higher than the combined rat-brain ADCs measured from both 
compartments (~0.8 × 10-3 mm2/s).  Furthermore, the percent-ADC reduction following ischemia is not as large in these studies (~15-18%) as that observed from the 
combined compartments (~30-35%) under similar ischemic conditions.  However, the effect of inter-compartmental equilibrium water exchange is not accounted for in 
either of these cases and this issue may be responsible for some of these differences. 
 
Reference: 1) Moseley et al MRM 1990;14:330 2) Neil JJ et al MRM 1996;35:329 3) Duong TQ et al MRM 1998;40:1 4) Silva et al MRM 2002;48:826 5) Labadie et 
al JMR Ser B 1994;105:99 
Figure 1: Evaluation of MR-compatibility in varying configurations under two imaging protocols. 
Large markers represent mean normalized SNR and smaller points represent individual SNR values 
for each of the ten images in the set. In the final filtered and shielded configuration, mean SNR loss 
was limited to only 3% at the worst case under the more sensitive T2 imaging. 
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Introduction: MR provides the ability to perform closed loop image-guided surgery. However, the inability to use conventional sensors and actuators in high-
field MR limits the availability of assistive technologies for interventional procedures. MR-compatible robotic systems have been investigated by several groups and 
a review can be found in [1]. The field of MR-compatible robots has yet to come to maturity, with many groups reinventing the wheel when it comes to actuator 
selection and evaluation. A side by side comparison of actuation techniques with the intent of a fair comparison between technologies is presented in [2]. Inherently 
MR-compatible actuation techniques include those that require no electrical connection to their controller; thus pneumatic and hydraulic actuation schemes, as well 
as remote actuation through mechanical means are suitable. Although pneumatics have been successfully used for control of robots in MRI, they either require a 
complex control scheme to generate the required accuracy for servo control [3] or a complex mechanism and controller design with an inherently limited accuracy 
for open loop stepping control [4]. A technology that shows significant promise as an actuator for MR-compatible interventional devices is the piezoelectric motor. 
In their “out of the box” configuration, the Nanomotion piezoelectric linear motor has shown to be adequate for many applications, but far from ideal with SNR 
losses reported at 20% when running in the scanner [2]. A closed-loop controller based on the PiezoMotor piezoelectric linear motor is independently evaluated in 
[5] with SNR loss reported at 14%. We present our development of a technique to optimize the PiezoMotor actuator and controller such that the effects on image 
quality are negligible. 
Materials/Methods: The motor used in this study is the nonmagnetic version of the Piezo LEGS (PiezoMotor, Uppsala, Sweden). These motors are available in 
both linear and rotary versions. The motor is powered through a 5m shielded, 24G 6-conductor cable. To ensure adequate shielding, the ground strap on the cable 
shield is physically attached to the motor housing and the exposed shield and leads extending to the motor are wrapped in aluminum tape with conductive adhesive. 
The cable runs to a controller (PiezoMotor driver) situated in an RF shielded aluminum enclosure with the cable shield fully grounded to the enclosure at the 
entrance point with aluminum tape. Inside of the enclosure, a filter bank is placed between the motor leads on the amplifier outputs. The filter is an L-C filter in a Pi 
configuration with a cutoff frequency of 65 kHz (L = 12uH, C/2 = 1uF). This cutoff frequency allows the drive signal that reaches a maximum of 3KHz to pass 
through unaffected while filtering out any residual noise in frequencies near the Larmor frequency (63.9MHz for 1.5T to 127.8MHz for 3T) that would affect image 
quality. A clean power supply was provided to the amplifier board using 12VDC power from two 6V lantern-type batteries placed inside of the enclosure. The 
enclosure is fully sealed with conductive aluminum tape and connected to the scanner room ground. The experiments were performed in a Bruker Biospin 2T/45 cm 
horizontal bore system equipped with 200mT/m gradients. The phantom used in the imaging study was a 25mm ID  tube filled with 0.25mM MnCl2.The motor and 
phantom were placed inside of a custom-made 50mm diameter birdcage coil for RF transmit and receive. The configuration used provides for a very sensitive 
instrument for measuring degradation of image quality. In the experiments, the controller was placed approximately 3m from the scanner bore.  
Experiments and Results: The configurations evaluated include: baseline of phantom only, motor with no shielding or filtering (powered and unpowered), 
motor with exposed inline filters (powered and unpowered), and fully shielded, grounded and filtered motor (powered and unpowered). Ten images were acquired 
for each configuration under each of two imaging protocols. The two image protocols used in this study were: 1) T1-weighted images, 256X256, TR=400ms, 
TE=15ms, SW=45.4kHz, st/is=2/2.2mm, FOV=8cm, 10slices, Gain = 1200, NEX=2 and 2) T2-weighted images, 256X256, TR=2252ms, TE=150ms, SW=20kHz, 
st/is=2/2.2mm, FOV=8cm, 10slices, Gain = 7000, NEX=1. The SNR of the acquired images was used as the metric of image quality. SNR was calculated as the 
mean signal in a 25pixel (~8mm) square ROI inside of the phantom divided by the standard deviation of the noise in a 25pixel (~8mm) square ROI in the periphery 
of the image outside of the phantom and nearby ringing 
artifacts. The SNR for each configuration was normalized 
by the average SNR of the 10 baseline images for each 
imaging protocol. The results are shown in Fig. 1, where 
the large symbol represents the mean normalized SNR for 
each configuration and imaging protocol and the smaller 
points represent the normalized SNR for each of the 
individual images in the set. The SNR degradation of the 
final configuration proved to be visually unidentifiable and 
resulted in a mean SNR loss of 3% in the worst case. 
Discussion: We have optized the usage of the 
PiezoMotor PiezoLEG actuator such that the effect on 
image quality is negligible. As such, it now appears that if 
appropriate shielding and filtering is utilized, these motors 
may serve as viable candidates for high accuracy MRI-
compatible manipulators. We are currently developing a 
custom mult-axis driver and power distirbution boards for 
thse motors with incorporated filtering and shielding. The 
initial application for these motors will be a robotic device 
for neurosurgery where high precision without loss of 
image quality is essential. 
References: 
[1] Tsekos, N.V., Khanicheh, A., Christoforou, E., 
Mavroidis, C. Magnetic resonance-compatible robotic and mechatronics systems for image-guided interventions and rehabilitation. An Rev BME. Aug 2007; 
9:351-387 
[2] Fischer G.S., Krieger A., Iordachita I., Csoma C., Whitcomb L., Fichtinger G., Mri compatibility of robot actuation techniques – a comparative study. MICCAI. 
Sep 2008; 5242: 509-517. 
[3] Fischer G.S., Iordachita I., Csoma C., Tokuda J., DiMaio S.P., Tempany C.M., Hata N., Fichtinger G., Mri-compatible pneumatic robot for transperineal prostate 
needle placement. Trans Mech. Jun 2008; 13(3):295-305. 
[4] Stoianovici, D., Patriciu, A., Petrisor, D., Mazilu, D., Kavoussi, L. A new type of motor: pneumatic step motor. Trans Mech. Feb 2007; 12(1): 98-106. 
[5] Elhawary, H., Zivanovic, A., Rea, M., Davies, B., Besant, C., McRobbie, D., de Souza, N., Young, I., Lamprth, M.: The feasibility of mr-image guided prostate 
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Introduction: Overexpression of wtEGFR (170kD epidermal growth factor receptor) due to gene amplification is implicated in the development of aggressive gliomas. 
Receptor imaging in vivo could potentially provide more accurate tumor detection, typing, and staging. The goal of this study was to image EGFR-overexpressing 
orthotopic human glioma tumors using local retention of a paramagnetic molecular substrate di(tyramido)-DTPA(Gd) (diTyr-DTPA(Gd), Fig. 1A) as a strategy of 
targeted MR signal enhancement. EGF receptor was targeted by using monoclonal antibody (humanized mAb EMD72000, Merck KGaA) conjugates with peroxidase 
(HRP) and glucose oxidase (GO) as a self-complementing enzymatic signal amplification system 
(Bogdanov et al. 2007). The substrate (hydrogen peroxide) for the key enzymatic reaction, catalyzed by 
a HRP conjugate was generated by a conjugate of mAb with glucose oxidase (GO) as depicted in Fig. 
1B. MR signal was generated at the EGFR expression sites due to a binding of reactive intermediate 
products of diTyr-DTPA(Gd) oxidation by HRP. 
 
Methods: Paramagnetic substrate diTyr-DTPA(Gd) was synthesized as shown in Fig. 1A (Querol et al. 
2007). MAb conjugates were synthesized by linking HRP or GO to mAB via bisaromatic hydrazone 
bonds. Size-exclusion HPLC purified conjugates were characterized in human glioma Gli36 cell culture 
and the ratios of HRP and GO conjugates were selected to provide the maximum signal at the lowest 
toxicity. Gli36ΔEGFR tumor xenografts were stereotaxically implanted in the brains of athymic rats. 
MR images were acquired in a Philips Achieva 3.0T/60 cm equipped with 80mT/m actively shielded 
gradients. T1-weighted (T1wt) spin-echo (SE) MRI was performed with the following parameters: 
TR/TE = 700ms/8.2ms, FOV = 2.56 cm X 2.56 cm, matrix = 256x128, NEX = 4. Two weeks after 
tumor implantation, each animal was anesthetized with isofluorane and imaged on two occasions. 1) 
Day 1 – a pre-contrast image was acquired followed by IV injection of 0.1 mmol/kg diTyr-DTPA(Gd). 
Twenty T1wt images were then acquired over a 2-h period. 2) Day 2 – targeted mAb conjugates (100 
µg mAb/animal) were injected IV. Three hours later, a pre-contrast image was acquired followed by IV 
injection of 0.1 mmol/kg diTyr-DTPA(Gd). Thirty T1wt images were then acquired over a 
3-h period. Pre-contrast T2wt SE images were acquired on both days to corroborate the 
presence of tumor observed in the T1wt slices. Animals were sacrificed and the frozen brain 
sections were stained for peroxidase activity and EGFR expression. 
 
Results and Discussion: T1wt images showed strong initial enhancement of the tumor 
within minutes after IV contrast injection – either with (Day 2) or without (Day 1) the 
preinjection of mAb conjugates (Fig. 2). However, the initial enhancement of the tumor 
following IV injection of diTyr-DTPA(Gd) with the conjugates (Fig 2B – 8 min) was 
significantly higher than that on Day 1 in the same animal (Fig. 2A – 9 min). Furthermore, 
contrast agent retention was higher on Day 2 (Fig. 2B) – as compared to Day 1 (Fig. 2A) – 
particularly in the tumor rim region over the same time period. Spatial deconvolution of the 
tumor signal showed different rates of contrast agent washout for the rim and the core 
regions. Bioelimination of diTyr-DTPA(Gd) was quantified by fitting the temporal signal-
intensity decay for each tumor region.  For Day 1, a monoexponential [Eq. 1] best modeled 
the data. For Day 2, a biexponential [Eq. 2] was a more appropriate model. 
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For the contrast agent without conjugates (Day 1), the washout time constant (τ0) for the rim (54±20 ms) 
was significantly higher (P < 0.02) than that of the core region (35±9 ms) (Fig. 3A). This difference was 
attributed to the higher vascular density in the periphery of the tumor. For the Day 1 data, the single 
component – with time constant τ0 – was attributed to unbound contrast agent. For the contrast agent with 
conjugates (Day 2), the biexponential model yielded a long and a short signal-decay time constant (τ1 and τ2, 
respectively) for both the tumor rim and core regions (Fig. 3B). The component with the short time constant 
(τ2) was attributed to unbound contrast agent while the component with the long time constant (τ1) was 
attributed to contrast agent bound to the conjugate.  The time constant associated with the bound contrast 
agent (τ1) was not significantly different between the rim and the core regions.  However, for the component 
associated with the unbound contrast agent, the time constant (τ2) for the rim (22±9 ms) was significantly 
higher (P < 0.03) than that of the core region (9±4 ms) (Fig. 3B). Furthermore, for the Day 2 data, the time 
constants associated with the unbound contrast agent (τ2) in the tumor rim and core regions were 
significantly less than the corresponding washout time constants (τ0) in the same regions on Day 1 (22±9 ms 
vs. 54±20 ms in the rim (P < 0.002); 9±4 ms vs. 35±9 ms in the core (P < 0.00003), respectively). Although 
the contrast agent is considered to be unbound in each case, the reduced washout times on Day 2 may arise 
from a decrease in vascular permeability due to the perivascular accumulation of high-affinity antibody-conjugates (Thurber et al. 2008) and associated cytotoxicity. 
The presence of extravasated and bound conjugates in tumor tissue was proven by using anti-HRP and anti-GO histochemical staining of the frozen brain sections. 
 
Conclusions: Following conjugate administration (Day 2), the increase in contrast agent retention was attributed to a second contrast-agent component (with the long 
time constant, τ1) that was not present when diTyr-DTPA(Gd) alone was administered (Day 1).  This long-retained component is consistent with enzyme-mediated 
coupling of the paramagnetic agent to EGFR-overexpressing cells in the tumor; allowing effective MRI visualization of conjugate co-localization at the targeted site. 
 
References: Bogdanov, A., et al. (2007). Bioconjug Chem 18: 1123-30. Querol, M., et al. (2007). Chembiochem 8: 1637-41. Thurber, GM, et al. (2008). Adv Drug Del 
Revs 60: 1421-1434.  
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Fig. 2 – Sequential T1wt rat brain images showing Gli36 tumor
xenografts. A) Day 1 – after IV injection of diTyr-DTPA(Gd) with no
conjugates. B) Day 2 – after IV injection of di-(tyramido)-DTPA (Gd)
with conjugates in the same animal. 
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Fig. 3 – A) Day 1 –
washout time
constants τ0 for
diTyr-DTPA(Gd)  in
the absence of
conjugates in tumor
rim and core regions
(n=8).  
B) Day 2 – long τ1
and short τ2 washout
time constants for
diTyr-DTPA(Gd) in
the presence of
conjugates in tumor
rim and core regions
(n=4).
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Fig. 1 A – Chemical synthesis diTyr-DTPA(Gd); B –
Reaction of peroxidase substrate diTyr-DTPA(Gd) with the
enzyme pair (glucose oxidase/peroxidase) conjugated to
anti-EGFR mAb. 
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Novel hydroxytryptophan-based Gd chelating substrate for imaging myeloperoxidase activity. 
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Introduction:   Myeloperoxidase (MPO) is one of the crucial imaging targets that has clear outcome- predictive value in several diseases, including myocardial 
infarction and stroke [1]. MPO has also been implicated in the progression of cancer, several CNS pathologies, and in the development of unstable atheroma. Because 
the catalytic activity of MPO is preserved in live tissue, the enzymatic activity of MPO can be used as a marker of inflammation sites in vivo. We previously synthesized 
and tested several paramagnetic complexes of mono- and bis- amides of macrocyclic and linear chelates that “sense” MPO activity [2-4]. As a result of MPO-mediated 
catalysis, the above sensors oligomerize and/or form covalent bonds with proteins resulting in increased molar relaxivity (r1 and r2). This enables MR imaging of MPO 
activity in vivo. Although the existing paramagnetic MPO sensors have very high kinetic stability [5], the thermodynamic stability of bisamides is usually compromised 
and the solubility of substituted tryptamides in water is limited. The goal of the current study was to synthesize and characterize a novel bifunctional MPO sensor with 
the same number of donor atoms as in DTPA (i.e. N3O5) in anticipation of improved thermodynamic stability and better solubility. 
 
Methods: An octadentate ligand (bis-amide of DTPA) was synthesized by reacting hydroxytryptophan, a 
naturally occurring amino acid, with DTPA dianhydride in the presence of pyridine. Gadolinium was trans-
chelated from Gd citrate. The resultant chelate was purified by acetone precipitation and purified by C18-
HPLC using a gradient of acetonitrile. The obtained product (bis-HTrp-DTPA(Gd), substrate I) was 
characterized by using 1H, 13C NMR and TI-MS. The control substrate (bis-5-hydroxytryptamide) of Gd 
DTPA (substrate II) was synthesized as described in [4]. The comparative substrate activation studies were 
performed using glucose oxidase GOX/MPO or GOX/horseradish peroxidase (HRP, positive control) as 
complementing activity-coupled enzymatic pairs (3 iU GOX : 1.5 iU MPO or HRP) in the presence of 0.1-5 
mM of paramagnetic MPO substrate and 5 mM glucose. The reaction was terminated by sodium azide (5 
mg/ml) after 0.5 h (HRP) or 2 h (MPO). Gradient SDS-PAGE (5-15%) was performed using samples 
incubated in the presence or the absence of the substrates to account for potential protein cross-linking using 
silver staining.  
 
Results and Discussion: The structure of the purified chelate was proven by 1H NMR spectrometry and 
MALDI-ITMS (m/z 796.4 (C36H43N7O14 - H+)). The gadolinium complex of the above chelate  (m/z 951.3, 
Fig. 1), i.e. substrate I ,  was further tested in the presence of peroxide-generating GOX and either MPO, or 
HRP.  The additional substrate in vitro efficacy testing involved comparing the MPO and HRP-mediated 
relaxivity increase in the presence of a hydrogen peroxide source (glucose/glucose oxidase) to that of a 
previously described and in vivo tested substrate II 
[2,5].   
 We observed an MPO-dependent increase 
of molar relaxivity of Gd in the reaction mixture 
from 4.9 to 8.3 [mM.s]-1  (1.7 fold at 0.47T) at 2 h 
(Fig. 2). HRP, which has a higher effective kinetic 
constant, showed a similar 1.8-fold increase of 
relaxivity under identical conditions.  In the case of 
bis-5HT-DTPA(Gd), we observed very similar 
changes of relaxivity (1.7 vs. 1.8 times, 
respectively), suggesting that both Gd chelates I and 
II were used by peroxidases as reducing substrates. 
However, there were notable differences in terms of 
the type of reaction products: substrate II and HRP 
gave insoluble cross-linked final products if the 
reaction proceeded for several hours while the 
products of substrate I were soluble.  Gradient SDS-
PAGE analysis of enzymatic activation of substrate I 
showed the formation of 10-20 kDa oligomerized 
products (Fig. 3, arrow) in the case of HRP, while in 
the reaction mixture containing MPO we observed 
the formation of a new band of cross-linked proteins. 
This result suggested covalent binding to proteins as 
a potential mechanism of relaxivity increase as a consequence of an MPO-catalyzed reaction.  No apparent 
cross-linking of proteins was observed in the case of substrate II. Imaging of phantoms at 3T (Fig. 3, spin-echo 
sequence, TR/TE=200/30ms, NEX=1), as expected, showed smaller increase of r1 (20%) at this field strength 
than at 0.47T. HRP resulted in a strong 1.9-fold increase of r2 in the case of substrate II but no such changes 
were observed with substrate I proving a lack of product aggregation.  
 
Conclusions: Bis-HTrp-DTPA(Gd) is a novel paramagnetic reducing substrate of MPO. It results in MPO-
mediated increase of Gd relaxivity similar to that of bis-5HT-DTPA(Gd). However, Bis-HTrp-DTPA(Gd) has 
high water solubility and undergoes MPO-specific conversion into protein cross-linking reactive intermediates.  
We anticipate it to be an efficient sensor for in vivo imaging of MPO activity due to potential binding to tissue 
proteins in inflammatory lesions.  
 
References: 1. Brennan ML et al. NE J Med 349: 1595, 2003; 2. Ronald JA et al. Circulation 120:592, 2009; 3. Chen JW et al. MRM 52:1021, 2004; 4. Querol M et 
al., Org Lett. 17, 1719, 2005; 5. Rodriguez E et al. JACS 132:168, 2009,  
 
 
 
 
 
Fig. 1. Structures of MPO substrates I and II 
 
Fig. 2. Relaxivities of chelated Gd in substrate I 
and substrate II and relaxivities of reaction 
mixtures containing MPO/GOX or HRP/GOX 
enzyme pairs. 
 
Fig. 3. Top: Gel electrophoresis of MPO and HRP-
containing reaction mixtures. Cross-linked product 
is marked with X. Bottom: T1W SE images of 
reaction mixtures containing MPO/GOX or 
HRP/GOX enzyme pairs at 3T. 
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Introduction: Divalent manganese ion (Mn2+) is a widely used T1 contrast agent in manganese-enhanced MRI (MEMRI) studies to visualize 
functional neural tracts and anatomy in the brain in vivo. In animal studies, the goal is to use a dose of Mn2+ that will maximize the contrast while 
minimizing its toxic effects. In rodents, systemic administration of Mn2+ via intravenous (IV) injection has been shown to create unique MRI contrast 
in the brain at a maximum dose of 175 mg/kg [1, 2]. The subcutaneous (SC) route can deliver Mn2+ at a maximum dose of 320 mg/kg (LD50 value). 
However, IV administration of Mn2+ results in faster bioelimination of excess Mn2+ from the plasma due to a steep concentration gradient between 
plasma and bile. By contrast, following SC injection, Mn2+ is released more slowly into the bloodstream, thus avoiding immediate hepatic 
elimination [3]. Therefore, SC administration of Mn2+ will result in prolonged accumulation of Mn2+ in the brain via the choroid plexus than that 
obtained via IV administration of Mn2+. The goal of this study was to investigate the MRI dose response of Mn2+ in rat brain following SC 
administration of Mn2+. 
 
Methods: Experiments were carried out using 12 male Sprague Dawley rats weighing 200-450 g. MnCl2 was administered using SC injection at 
three different doses: 75 (n=3), 150 (n=3), and 300 (n=6) mg/kg. All MR imaging was performed at 2.0T. Multi-slice T1-weighted (T1-WT) MR 
images (TR/TE = 700/15 ms) were acquired pre-injection and 6, 24, 72, and 168 h following the SC injection of Mn2+. T1 relaxation times were 
measured using an inversion recovery sequence (TR/TE = 10,000/4.8 ms, 16 inversion time (TI) points ranging from 15 ms to 3300 ms) acquired at 
the same time points as the T1-WT images. Three different brain regions of interests (ROIs) were selected (cortex, sub-cortical region, and caudate 
nucleus) from three acquired slices. A mean ROI value from each TI point was used to calculate the respective tissue T1 values.       
  
 
Results and Discussion: T1-WT signal enhancement (SE) was apparent in the 
rat brain at 6 h which expanded from the ventricles to the sub-cortical and 
cortex regions. Uniform enhancement was achieved throughout the brain by 
the 72 h time-point at all administered Mn2+ doses which persisted up to 168 
h. The T1-WT SE was proportional to the dose of Mn2+ administered. Greater 
Mn2+ uptake occurred in the sub-cortical region than the cortex for all the SC 
Mn2+ doses administered causing greater shortening of the T1 relaxation time 
in the sub-cortical region ROI than the cortex ROI (Fig. 2). ANOVA test for 
mixed models showed a significant effect of Mn2+ dose (P < 0.01) and time 
point after Mn2+ injection (P < 0.0001) on the reduction of T1 relaxation times 
in the cortex (Fig. 2A) and sub-cortical (Fig. 2B) regions. Similar dose-
dependent behavior of T1 relaxation times has been observed in different 
regions of the mouse brain following IV injection of Mn2+ [2]; however, the 
prolonged enhancement obtained with SC Mn2+ injection (up to at least 168 h) 
is contrary to the short-term enhancement observed when Mn2+ was 
administered via IV [1] or even intrathecal injection [4]. 
 
Conclusion: This study is the first to demonstrate a dose-dependent response of Mn2+ on T1 relaxation times in the rat brain following SC injection of 
Mn2+. SC administration of Mn2+ leads to a more prolonged enhancement in the brain than IV Mn2+ administration which can be useful for 
longitudinal in vivo studies that require brain enhancement to persist for a long period of time to visualize neuroarchitecture like in Alzheimer’s 
disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases. 
 
References: [1] Aoki et al. (2004). NeuroImage 22: 1046-59; [2] Lee et al. (2005). Magn Reson Med 53(3): 640-648; [3] Bertinchamps et al. (1966). 
Am J Physiol 211(1): 217-224; [4] Liu et al. (2004). Magn Reson Med 51(5): 978-987. 
Fig. 2 – Plots of in vivo mean T1 relaxation times (–1 SD) as a 
function of time after subcutaneous injection of MnCl2 at three 
different doses in the A) cortex ROI, and B) sub-cortical region 
Fig. 1 – Dose dependence and time course of MEMRI contrast. T1-
weighted axial MR image sets are shown as a function of varying 
doses of MnCl2 and as a function of time after subcutaneous injection 
of MnCl2.   
6642 
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Introduction: The goal of this study was to image EGFR- and EGFRvIII-overexpressing aggressive 
orthotopic human glioma tumors using local retention of peroxidase-generated products of a 
paramagnetic molecular substrate di(tyramido)-DTPA(Gd) (diTyr-DTPA(Gd), Fig. 1). EGF receptor 
variants were targeted by using specific humanized anti-EGFR EMD72000 and non-specific anti-
EpCAM mAb monoclonal antibody (mAb) conjugates. The conjugates were synthesized using 
peroxidase (HRP) and glucose oxidase (GO) as a self-complementing enzymatic signal amplification 
system [1] as depicted in Fig. 1. MR signal was generated at the EGFR expression sites due to co-
localization of targeted conjugates which resulted in specific binding of reactive intermediate products of 
diTyr-DTPA(Gd) oxidation by HRP-mAb conjugate. 
 
Methods: The paramagnetic substrate diTyr-DTPA(Gd) was synthesized as described in [2]; mAb 
conjugates were synthesized by linking HRP or GO to mAb via bisaromatic hydrazone bonds. Size-
exclusion HPLC purified conjugates were characterized in human glioma Gli36ΔEGFR cell culture and 
the ratios of HRP and GO conjugates were selected to provide the maximum signal with low 
cytotoxicity. Gli36ΔEGFR tumor xenografts were stereotaxically implanted in the brains of athymic rats. MR images were acquired at 3T. T1-weighted (T1-WT) spin-
echo MRI was performed with the following parameters: TR/TE = 700ms/8.2ms, FOV = 2.56 cm X 2.56 cm, matrix = 256x256, NEX = 4. Two weeks after tumor 
implantation, each animal was anesthetized with isofluorane and imaged on two occasions. 1) Day 1 – a pre-contrast image was acquired followed by IV injection of 
0.1 mmol/kg diTyr-DTPA(Gd). Twenty T1-WT images were then acquired over a 2-h period. 2) Day 2 – either specific anti-EGFR or non-specific EpCAM conjugates 
(100 µg mAb/animal) were injected IV. Four hours later, a pre-contrast image was acquired followed by IV injection of 0.1 mmol/kg diTyr-DTPA(Gd). Thirty T1-WT 
images were then acquired over a 3-h period. Animals were sacrificed and frozen brain sections were stained for peroxidase activity and EGFR expression. 
 
 
Results and Discussion: T1-WT images showed enhancement of the tumor within minutes after IV contrast injection – 
either without (Day 1) or with (Day 2) the preinjection of either mAb conjugates (Fig. 2). However, the initial 
enhancement of the tumor with pre-injected anti-EGFR conjugates (Fig. 2A, Day 2 – 8 min) was significantly higher than 
that observed on Day 1 in the same animal (Fig. 2A, Day 1 – 9 min) and on both days in a different animal without and 
with pre-injected anti-EpCAM conjugates (Fig. 2B, – 7 min). Furthermore, contrast agent retention was also higher in the 
tumor pre-injected with anti-EGFR conjugates (Fig. 2A – Day 2) compared to all the other cases – particularly in the tumor 
interface region over the same time period. Spatial deconvolution of the tumor signal showed different rates of contrast 
washout for the interface and the core regions of the tumor.  
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Bioelimination of diTyr-DTPA(Gd) was quantified by fitting the temporal signal-intensity decay (SID) for each tumor 
region. On Day 1, without any anti-EGFR or anti-EpCAM conjugate pre-treatment, a monoexponential [Eq. 1] best 
modeled the data for both the tumor interface and core regions (Fig. 3A, curves 1-4). Animals pre-injected with anti-EGFR 
conjugates (Fig. 3B, curves 1,2) exhibited biexponential signal decay both in the tumor interface and core regions; 
however, after the pre-injection of non-specific anti-EpCAM conjugates (Fig. 3B, curves 3,4), the SID showed only a 
single decay component. The single component of monoexponential decay – decay time constant (DTC) τ0 – was attributed 
to unbound contrast agent. The two components of the biexponential model yielded a long and a short DTC (τ1 and τ2, 
respectively). The component with the short DTC (τ2) was attributed to unbound contrast agent while the component with 
the long DTC (τ1) was attributed to contrast agent bound to the cells.  
 
Conclusions: Following anti-EpCAM conjugate pre-treatment or no conjugate administration, a monoexponential SID of 
the contrast agent indicates the absence of specific mAb conjugates binding to the tumor. This is expected since anti-
EpCAM conjugates do not bind to glioma cells and diTyr-DTPA(Gd) does not bind to tumor cells in the absence of 
conjugates. With anti-EGFR conjugate administration, a biexponential mode of contrast SID indicates specific binding of 
paramagnetic products to cells, which led to long-term enhancement of MR signal (Fig. 2A – Day 2). This long-lasting MR 
signal component is consistent with enzyme-mediated coupling of the paramagnetic agent to EGFR-overexpressing cells in 
the tumor allowing effective MRI visualization of conjugate co-localization at the specific targeted site. 
 
References: [1] Bogdanov, A., et al. (2007). Bioconjug Chem 18: 1123-30; [2] Querol, M., et al. (2007). Chembiochem 8: 1637-41.  
 
Fig. 2 A – T1-WT sequential rat brain images depicting enhancement of human glioma xenografts as a function of time 
post injection of diTyr-GdDTPA; Top row - temporal washout of diTyr-GdDTPA with no conjugate pre-injection (Day 
1); Bottom row - washout of diTyr-GdDTPA following IV injection with anti-EGFR conjugates (Day 2) in the same 
animal slice (time shown in mins); B – human glioma xenografts without and with pre-injection of EpCAM-targeted 
conjugates. The images correspond to the same pattern as shown in Panel A. 
Fig. 3 – Normalized T1-WT signal 
intensities (derived from the same tumors
shown in Fig. 2) measured in the
interface or core regions of Gli36ΔEGFR
tumors prior to injection of conjugates
(A), and after the pre-injection of either 
specific anti-EGFR (“EGFR”) or non-
specific EpCAM (“EpCAM”) conjugates 
(B) as a function of time post-diTyr-
DTPA(Gd) injection. 
 
Fig. 1 – Reaction of peroxidase substrate diTyr-DTPA(Gd)
with the enzyme pair (glucose oxidase/peroxidase)
conjugated to either anti-EGFR or anti-EpCAM mAb. 
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